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ABSTRACT 
 
Fetal chromosomes are examined conventionally by G-band karyotyping. More 
recently Prenatal Chromosomal Microarray (CMA) has been used to look for fetal 
chromosomal abnormalities. Advantages of CMA include its higher detection rate. 
Disadvantages include its detection of Variants of Unknown Significance (VOUS).   
 
I recruited a prospective cohort of 243 women with structural abnormalities on fetal 
ultrasound scan. A 1Mb targeted BAC array was performed in addition to G-band 
karyotyping. In 62 cases from this cohort an additional higher resolution 60K 
oligonucleotide array was used. A health economic analysis, by use of a decision 
tree, was performed. Finally qualitative work determined women’s feelings about 
testing.  
 
The 1Mb BAC cohort found a 4.1% increase in fetal chromosomal abnormalities over 
karyotyping, with a low detection rate of VOUS (0.4%). The 60K sub-cohort noted an 
extra 4.8% pathogenic chromosomal anomalies but, in addition, a 13% increase in 
VOUS. The health economic analysis indicated that when CMA is £360 (per test) and 
the Willingness To Pay (WTP) for a “positive diagnosis” is £9768; then CMA is cost 
effective over karyotyping. Qualitative analysis showed that couples were keen for as 
much information as possible. They struggled to recall and retain information 
conveyed at the time of the testing.  
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CHAPTER 1 INTRODUCTION AND AIMS 
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INTRODUCTION 
During the 1860s both Charles Darwin and Gregor Mendel proposed their 
hypotheses of heritability . By the middle of the nineteenth century it was largely 
agreed that hereditary information was located within the nucleus of a cell, but the 
nature of this hereditary material was unknown. German anatomist Walter Flemming 
was the first to discover “stainable material” or chromatin using innovative staining 
techniques. The term chromosome was later coined by Heinrich Waldeyer. It was not 
until 1956 that the correct numbers of human chromosomes were estimated by Joe 
Hin Tjio and Albert Levan as 46. 
 
Chromosomes are “packages” of DNA tightly coiled around proteins called histones, 
supporting the chromosomes structure. It is during cell division that chromosomes 
have a key role in ensuring DNA is copied and distributed accurately. During cell 
division and the metaphase stage of the cell cycle, chromatin condenses and 
chromosomes become visible as two sister chromatids joined by a centromere with a 
short p arm (for petit) and long q arm (for queue).  
 
Chromosomal anomalies are a major cause of perinatal morbidity and mortality (1-3). 
Since the late 1960’s full conventional G-band karyotyping has been the mainstay of 
excluding and diagnosing structural karyotypic abnormality. In order for 
chromosomes to become visible under a light microscope chemical dyes need to be 
applied. G-banding is the most commonly used and involves treating chromosomes 
with trypsin (to degrade proteins, relax the chromatin and allow access of the 
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Giemsa stain) and then staining with Giemsa. Heterochromatic regions (which are 
adenine and thymine rich DNA and relatively gene poor) stain more darkly.  Less 
condensed regions (guanine-cytosine rich and gene rich DNA) incorporate less stain 
and appear as light bands.  Chromosome preparation and G-band quality can be 
affected by many factors relating to quality include the sample type (blood often 
yields a better preparation than amniotic fluid or a Chorionic Villus Sample) and 
whether the sample has clotted or has been delayed in transit. Laboratory factors 
include a change in temperature, a problem with reagents, and analysis is 
dependent on the skill of the operator. Despite significant improvements in 
cytogenetic resolution over the last 25 years, conventional full karyotyping can only 
detect anomalies down to a resolution of 5-10 Mb (4).  
 
In the 1990’s the use of QFPCR (Quantitative Fluorescence Polymerase Chain 
Reaction) to target specific whole chromosomal anomalies (typically Trisomy 13, 18, 
21, and sex chromosome anomalies X and Y) provided a relatively cheap and rapid 
result (within 48-76 hours) when a prenatal screening test was reported as “high risk” 
(5).   
 
QFPCR analysis is performed by amplifying and detecting small tandem repeats 
(genetic markers). Fluorescently labelled primers are used for PCR amplification and 
the copy number of the marker is representative of the copy number of the 
chromosome.  A normal diploid sample has a contribution from each of the two 
chromosomes. Two alleles of a specific marker are represented by two peaks at a 
1:1 ratio if heterozygous and one large peak double the size if homozygous. The 
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detection of 3 peaks 1:1:1 ratio or 2:1/1:2 indicates an additional chromosome (as in 
Trisomy).  
 
Many laboratories are now providing this test alone for karyotyping after a high risk 
screening result and only performing further conventional full karyotyping using G-
banding when the risk of more complex chromosome anomalies is high (i.e. 
structural differences on fetal ultrasound scan).  
 
Fluorescence In Situ Hybridisation (FISH) is a useful adjunct to full conventional 
karyotyping when a high degree of suspicion of a specific chromosome anomaly is 
present (e.g. Di George syndrome and a cardiac anomaly) or when clarification of a 
difference seen on karyotype is sought. This technique may be used to identify 
interstitial submicroscopic microdeletions and microduplications or subtelomeric 
deletions and duplications (6). FISH uses fluorescent probes that bind to 
complementary parts of the chromosomes.  Microscopy is then used to find out 
where the probe is bound to the chromosomes. Probes are constructed and tagged 
with fluorophores. An interphase or metaphase preparation of chromosomes is 
produced and repetitive sequences of DNA blocked (usually by adding short DNA 
fragments to the sample). The probe is then added and the sample hybridised. 
Results are visualised using a microscope that can excite the dye and record the 
images.  
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FISH and QFPCR are ‘targeted’ approaches capable only of assessing a limited 
number of loci and so require the referring clinician to suspect a specific 
chromosomal aberration from the fetal phenotype. 
 
From FISH analysis comparative genomic hybridisation (CGH) was derived, 
providing a way of looking for chromosomal changes genome-wide. CGH used a test 
and a control genome and labelled with fluorescent dyes hybridized them to 
metaphase chromosomes (7). Unlike its precursors which relied on examination of a 
single target and prior knowledge of a chromosome region that should be studied, 
CGH could search the whole genome for imbalances. However its resolution was still 
often limited to 5-10Mb (8).  
 
The next development was array Comparative Genomic Hybridisation (aCGH) or as 
it will be referred to hereafter Chromosomal Microarray (CMA).  CMA combined the 
CGH technique with the use of microarray (9). Originally designed for use in 
oncology studies, CMA was (and is still) used to develop molecular classification of 
different tumour types, look at tumour progression and identify therapeutic targets 
(7;10). Later it was used to identify submicroscopic deletions or duplications in 
children with undiagnosed learning difficulties and mental retardation (11-14) before 
being used in the prenatal setting.  
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Chromosomal microarray involves hybridisation of patient DNA onto predetermined 
targets representative of the whole genome; BAC clones, or synthetic 
oligonucleotide probes spotted onto glass slides.  The patient or ‘test’ DNA (in a 
prenatal context obtained by amniocentesis, chorionic villus sampling (CVS) or 
cordocentesis) is extracted from the relevant sample, labelled with a fluorochrome, 
mixed with a reference DNA pool (labelled with a different fluorochrome) and then 
hybridized on the microarray slide in the presence of cot-1 DNA to suppress 
repetitive sequences. After hybridisation and laser scanning, fluorescent ratios on 
each array spot are calculated and normalized so that the median log 2 ratio is 0 (15-
17). User defined thresholds are then set for calling copy number changes as loss or 
gain (Figure 1) (18).  
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Figure 1 The Basic Principle of chromosomal microarray (18) 
 
  
Legend Figure 1 (18): The basic principle of chromosomal microarray. Differentially labelled test and reference 
DNA are co-hybridised to the microarray, spotted with genomic clone or oligonucleotide probes, in the presence 
of cot-1 DNA which suppresses repetitive sequences. After hybridisation and laser scanning, fluorescent ratios 
on each array spot are calculated and normalized so that the median log 2 ratio is 0. User defined thresholds are 
set for calling copy number changes as loss or gain. 
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Advantages of CMA 
CMA has many advantages when compared with the chromosome testing strategy 
described above. CMA utilises uncultured cells reducing the “turnaround time of the 
results” (in our laboratory to 5 days, presently) and is amenable to automation and 
high throughput analysis that provide the potential for positive health economic 
effects.  Microarrays will become quicker to analyse as chromosomal variants 
detected will be compared to local (within the laboratory), national and international 
databases. Most importantly it is of “high resolution” allowing detection of 
submicroscopic deletions or duplications though the specific choice of CMA platform 
determines the resolution of the test (15-17). 
 
Earlier CMA technology used BAC (Bacterial Artificial Clones 100-200kb in size) and 
these are targeted to known regions of microdeletion or duplication syndromes. More 
recently, mostly in the postnatal setting, synthetic oligonucleotide probes of 25-75bp 
are used. These typically are higher resolution but also allow flexibility in the 
selection of probes and can therefore be customised by the user i.e. using a lower 
resolution in the prenatal setting to minimise any results of unknown clinical 
significance. Single Nucleotide Polymorphism or SNP based arrays have the 
advantage of detecting Long Continuous Stretches of Homozygosity (LCSH) that can 
enable the detection of some forms of Uniparental Disomy (Uniparental isodisomy 
but uniparental heterodisomy is not detected unless the parents are also tested) or 
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consanguinity1 (17;19).  Such ‘high resolution’ CMA is increasingly utilised in 
prenatal diagnosis. 
 
Disadvantages of CMA 
CMA technology does have limitations. CMA is only able to potentially detect 
unbalanced chromosomal changes. De-novo (non-inherited) balanced chromosomal 
rearrangements (such as reciprocal translocations or insertions) may disrupt genes 
and lead to phenotypic disease without detectable gains or losses at breakpoints 
(20). However, in practice, many apparently balanced rearrangements detected by 
G-banding are not truly balanced at a DNA level, and microarray testing can be used 
to detect small regions of DNA loss or gain and so clarify the exact nature of the 
rearrangement (21). Furthermore, array CGH may not detect triploidy, unless SNP 
based arrays are used. However, this limitation, certainly in the UK, is avoided as 
QFPCR is likely to continue to be used prior to array analysis as a rapid and cost 
effective screen for common aneuploidy and triploidy. In addition, low level 
mosaicism may not be detected by CMA technology (15;17).  
 
The most significant current potential disadvantage of CMA is the identification of 
novel, previously unreported, variants of unknown significance (VOUS) that, 
particularly in the prenatal setting, can cause difficulties in clinical management 
because of the uncertainty of the relationship between the VOUS and likely clinical 
                                            
1
 UPD occurs when a fetus inherits both two copies of a chromosome, or part of a chromosome, from one parent (e.g. both chromosome 15 are 
inherited from the mother and no chromosome 15 is inherited from the father). In isodisomy there are two copies of the same chromosome and in 
heterodisomy the two chromosomes are different. UPD may cause developmental defects if the chromosome involved contains imprinted genes 
or, in the case of isodomy, the involved chromosome carries a mutation for an autosomal recesively inherited disorder). 
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effect. In order to facilitate more accurate assessment and interpretation of VOUS 
there is an ongoing major effort to catalogue and collate genomic and clinical 
information. The development of copy number variation (CNV) databases, such as 
the International Standards for Cytogenomic Array Consortium (ISCA) from within 
the dbGaP (Database of Genotype and Phenotype at NCBI 
www.ncbi.nlm.nih.gov/gap) and the Database of Genomic Variants (DGV 
http://projects.tcag.ca/variation) will facilitate the resolution of VOUS into benign or 
pathogenic variants. Postnatally detected pathogenic cases are also recorded in 
DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using 
Ensembl Resources www.ensembl.org/index.html) (15-17). The detection of VOUS 
may increase the emotional burden on the parents. If prenatal diagnostic tests have 
been utilised in the presence of a suspected congenital malformation there is the 
possibility that such information, however ‘non-informative’, may increase the 
possibility of termination of pregnancy. Hence the aim when using such technology 
in prenatal diagnosis is to identify known pathogenic variants but not to increase 
parental anxiety by identifying variants of uncertain or no clinical significance in a 
prenatal diagnostic situation. In addition, the identification of copy number variations 
(CNVs) of uncertain significance that then require the analysis of parental DNA for 
further interpretation has financial consequences and delays the availability of 
definitive results. 
 
Copy number variation (CNVs) and Classification of CNVs 
Development and application of these microarrays led to the emergence of multiple 
whole genome CNV studies in normal populations. Until this point single nucleotide 
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polymorphisms or SNPs were thought to be the predominant form of genetic 
variation (A SNP is a base substitution involving a single nucleotide). The publication 
of two cohorts reporting widespread copy number variation in normal individuals 
(22;23) began to change this thinking and it is now recognised that CNVs accounts 
for more (estimate range from 4Mb-24Mb of variation between individuals) 
nucleotide variation than SNPs (approximately 2.5Mb) (24). CNVs are segments of 
DNA of 1 kb or larger present at a variable copy number in comparison with a 
reference genome (25).  
 
CNVs lead to disease or alter phenotype through different mechanisms involving 
influencing gene dosage and expression. Figure 2 below (Feuk et al) shows these 
different mechanisms (25).  
 
Redon et al determined that approximately 12% of the human genome exhibits copy 
number variation (27). With such widespread benign CNV density application and 
interpretation in a clinical setting can be challenging in terms of classifying variants 
as pathogenic, benign or novel variants of uncertain clinical significance 
(VOUS)(15;17).  
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Figure 2 How CNVs affect gene expression and phenotypic traits (25) 
 
 
Figure 2 Legend (25): A) Involves the deletion or duplication of a region resulting in loss or gain of multiple genes 
and a direct correlation between genotype and phenotype, resulting in a microdeletion or duplication syndrome. 
B) Shows that when a gene is located within a region that varies in copy number there can be increased gene 
dosage leading to increased gene expression. C) Shows a CNV involving a deletion or duplication that can lead 
to an unmasking of a recessive risk allele. The subsequent decreased gene dosage of the wild-type allele can 
lead to disease. The opposite can occur with increased numbers of copies harbouring a risk allele, which may 
result in increased disease susceptibility. D and F) Show how a CNV can lead to inhibition of a DNA enhancer 
interaction, the chromatin structure or access to transcription factors to their binding sites as in E). 
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There are general principles that can be applied to the analysis of CNVs in order to 
establish their pathogenicity (Table 1) (28). In general terms a CNV is more likely to 
be pathogenic if (a) it is inherited from an affected parent or affected relative, if it 
overlaps an imbalance in the database of affected individuals, DECIPHER, (b) it is 
particularly gene “rich” and these genes are classified as causing morbidity by OMIM 
(online Mendelian Inheritance in Man http://www.ncbi.nlm.nih.gov/omim). Minor 
criteria for a pathogenic CNV is that a deletion is more likely to be pathogenic than 
duplication and the larger it is the more likely it is to be pathogenic. A CNV is more 
likely to be benign if inherited from an unaffected parent or relative, overlaps with the 
database of health individuals (database of genomic variation), be gene “poor” and 
that genes in the region are not known to cause morbidity. CNVs are also more likely 
to be benign if small in size, a duplication and devoid of regulatory elements(15-17).  
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Table 1 Factors influencing the risk assessment of a CNVa (28) 
 
Major criteria Characteristic of 
pathogenic CNVs 
Characteristic of 
benign CNVs 
1. a. CNV is inherited from a healthy parent    
  b. CNV is inherited from an affected parent    
2. a. CNV is similar to a CNV in a healthy relative    
  b. CNV is similar to a CNV in an affected 
relative 
   
3. a. CNV overlaps a genomic imbalance in a CNV 
database for healthy individuals (for example, 
Database of Genomic Variants) 
   
  b. CNV overlaps a genomic imbalance in a CNV 
database for affected individuals (for example, 
DECIPHER) 
   
4. CNV contains morbid OMIM genes    
5. a. CNV is gene rich    
  b. CNV is gene poor    
Minor criteria Characteristic of 
pathogenic CNVs 
Characteristic of 
benign CNVs 
1. a. CNV is a deletion    
  b. CNV is a homozygous deletion    
2. a. CNV is a duplication    
  b. CNV is an amplification (gain of more than 
one copy) 
   
3. CNV is >3 Mb in size    
4. CNV is devoid of known regulatory elements    
 
The resolution of arrays 
The sensitivity of CMA is determined by the number and density of the probes and 
their resolution. In the clinical setting, in order that CMA has an improved detection 
over G-band karyotyping, it must accurately detect imbalances smaller than 5Mb (the 
smallest resolution visible by light microscopy with G-band preparations) (15-17). 
Array platforms in common clinical use have a typical resolution of 10kb in targeted 
disease specific regions of the genome and 200kb in the genome backbone. 
Although most known pathogenic CNVs are 400kb or larger, as array resolution 
increases smaller recurrent imbalances will be detected.  More recent information 
available using high resolution arrays show that 95% of benign CNVs may be less 
than 100kb in size (29).  A table contrasting and comparing commonly used CMA 
platforms and their resolution is presented below (Table 2) (30). 
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Table 2 Comparison of array design strategies.  
Adapted from a table taken from the National Genetic Reference Laboratory technology assessment “Comparison for cytogenetics array platforms hardware and 
software for use in identifying copy number aberration in constitutional disorders.” 
 Affymetrix 2.7M ISCA 4x180K (Agilent) ISCA 8x60K 
(OGT/Agilent) 
NGRL 4x44K 
(Agilent) 
1Mb constitutional 
targeted array 
(Bluegnome) 
Backbone 
coverage 
1kb/probe 25kb/probe 60kb/probe 75kb/probe 1Mb/probe 
Target 
region 
coverage 
690bp/probe 5kb/probe or 20 probes 
per targeted 
region(average 50 
probes per targeted 
region) 
Average 40 probes per 
targeted region 
2 to 5 extra probes 
per targeted region 
1Mb/probe but in 
triplicate 
Backbone 
resolution 
Depend on markers, size and 
confidence 
100kb (4 probes to 
make a call) 
240kb (4 probes to 
make a call) 
225 kb (3 probes to 
make a call) 
2Mb (2 probes to 
make a call) 
Target 
region 
resolution 
If set as 20 markers resolution 
will be 20x690bp for the targeted 
region 
20kb (4 probes to make 
a call) 
48kb (4 probes to make 
a call) 
60kb (3 probes to 
make  call) 
200kb (2 probes to 
make  a call) 
Probe 
types 
2.3million non polymorphic 
markers for CNV, 400,000 SNP 
markers for LOH and UPD 
Non-polymorphic 
markers 
Non-polymorphic 
markers 
Non-polymorphic 
markers 
Non-polymorphic 
markers 
Probe size 49mer 60mer 60mer 60mer 150-200kb 
Number of 
included 
targeted 
regions 
Coverage (%) using filter 20 
markers minimum size 50kb 
cancer genes (318)(100%) 
HPI (548)(98%) 
X chromosome genes 
(786)(98.1%) 
OMIM genes (12,242)(99.2%) 
501 targeted regions 498 targeted regions 155 targeted regions 143 targeted regions 
CNV= Copy Number Variant   LOH=Loss Of Heterozygosity  OMIM=Online Mendelian Inheritance in Man  UPD=Uniparental Disomy 
HPI= Haploinsufficiency   OGT= Oxford Gene Technology SNP= Single Nucleotide Polymorphism  
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THE USE OF CMA TESTING PRENATALLY AND THE LITERATURE UP UNTIL 
THE END OF 2009 
Prenatal fetal karyotyping can be offered during a pregnancy because a screening 
test has indicated a ‘high’ risk that the fetus may have aneuploidy; because of a 
structural anomaly on ultrasound examination; a family history of chromosomal 
abnormality; or because of parental choice.  Although I aimed to answer the question 
of prenatal CMA testing when a structural anomaly was seen on scan much of the 
literature from other parts of Europe and the USA include other referral indications.  
 
In 2009 when this research was in its infancy the literature looking at CMA use in a 
prenatal context was limited, but I took the decision to review it comprehensively by 
way of a systematic review and meta analysis (31). My aim was to look at the 
amount of extra information provided by CMA over conventional G–band karyotyping 
in the existing literature for any referral indication for testing, and when the indication 
for testing was structural abnormalities on ultrasound scan.  
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Methods 
My systematic review followed a prospective protocol developed using widely 
recommended and comprehensive methodology(32). 
 
Data sources 
The search focused only on prenatal studies using microarray technology.  A search 
strategy was developed based on existing advice for prevalence searches(33;34). 
MEDLINE (1970–Dec 2009), EMBASE (1980–Dec 2009), and CINAHL (1982–Dec 
2009) were searched electronically. The search of MEDLINE and EMBASE captured 
citations containing the relevant MeSH keywords and word variants for “microarray” 
and “prenatal”. The following terms were used to describe CMA; array, Comparative 
Genomic Hybridisation, microarray and oligonucleotide array. Similarly, antenatal 
diagnostics, fetal diagnostics, prenatal and fetal were used to capture “prenatal”. 
Bibliographies of relevant articles were manually searched to identify papers not 
captured by the electronic searches. Web of science (1996-2009) was used to 
capture any grey literature. Experts were also contacted for completeness of the 
search (the authors of the papers by Coppinger J et al (35) and Van den Veyver et al 
(36)).  There were no language restrictions in the search or selection of papers.  
 
 
 
 
18 
 
Eligibility criteria for selecting studies 
Studies were selected in a two-stage process. Initially, all abstracts or titles in the 
electronic searches were scrutinised by two reviewers (SH and SP-a fetal medicine 
Consultant) and full manuscripts of potentially eligible citations were obtained. 
Differences were resolved by discussion. Unresolved disagreements were resolved 
by a third reviewer (AC Professor of Gynaecology). Studies were selected if 
chromosomal microarray or microarray had been used on prenatal specimens (either 
analysed during pregnancy or after delivery). I also selected reports if the same 
technology had been used on postnatal specimens following termination of 
pregnancy for structural abnormalities detected on ultrasound scan. Papers were 
excluded if the testing was performed postnatally and the indication for running the 
CMA had not been determined prenatally. Papers were also excluded if the array 
was performed on children, or adults, or it was used for pre-implantation genetic 
diagnosis, or the diagnostic investigation of recurrent miscarriages.  Finally papers 
were excluded if they used comparative genomic hybridisation technique and not 
array-comparative genomic hybridisation/chromosomal microarray. Non-English 
studies were assessed by people with the command of the relevant language if the 
title or abstract appeared to fit the criteria. Only papers that allowed generation of a 
2x2 table (comparing karyotyping to array) were included. In two instances in order 
to construct a 2x2 table the authors were contacted. In the case of Coppinger J et al 
(35) direct discussion/correspondence allowed  extra information to be obtained and 
us to include the paper. In the second case (Van den Veyver et al (36)), I was still 
unable to include the paper as the authors were unable to provide us with enough 
information to complete a 2x2 table. 
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Data extraction 
Data were extracted by two reviewers (myself and SP-a fetal medicine consultant). 
For each of the outcomes, data were extracted into tables, giving descriptive and 
numerical information for each study. Data were extracted on study characteristics 
and data quality. Data were used to construct 2x2 tables of test accuracy comparing 
normal and abnormal karyotype results against normal and abnormal microarray 
results. Case studies <5 cases were excluded from the meta- analysis.  
 
Quality assessment 
All articles meeting the selection criteria were assessed for quality using the 
validated tool STROBE (37) (Figure 3). A study was considered to be of good quality 
if it used a prospective design, if it used a representative population (it used array 
technology on all samples not just those with that demonstrated array in exclusively 
normal or abnormal conventional karyotype), it performed array testing on parents to 
aid interpretation of CNVs and it used a validated assessment tool (i.e. an 
identifiable, reproducible array). Expert opinion from cytogeneticists at the West 
Midlands Regional Genetics Department was sought to determine the validity of the 
array used (DM-Head of Cytogenetics at the WMGL). 
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Figure 3 Quality assessment using STROBE 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100%
Source of funding
Generalisability (normal and abnormal karyotypes)
Interpretation of results
Limitations of study
Summarises key results
Reports all results and precision
Reports number of outcome events
Participant characteristics and follow-up time
Reports number of individuals in flow diagram
Describes all statistical methods
Explanation of quantitative variables and their analysis
Explanation of study size
Efforts to address bias
Data sources and methods of assessment
Defines all variables
Eligibility and matching criteria
Describe setting and recruitment period
Study design prospective
Introduction states background and objectives
Title and abstract appropriate
Yes
No
 
Legend: STROBE is used to assess the quality of the publications included within the systematic 
review (37). Many publications were retrospective and did not have a set period of recruitment and did 
not account for the cohort size.  
Data synthesis 
The analysis was performed in two steps depending on the way in which the CNVs 
were grouped. The first analysis grouped pathogenic, unknown and benign CNVs as 
array detectable variants.  The second analysis moved benign CNVs into the normal 
group leaving the abnormal CNVs being those that were pathogenic plus those that 
were of unknown significance and potentially pathogenic. Analysis was performed for 
samples undergoing both karyotyping and array regardless of the clinical indication 
(maternal anxiety, high risk on serum Downs screening, structural abnormality on 
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ultrasound scan). Analysis was then performed for those undergoing chromosomal 
analysis for structural abnormality on scan. 
I explored the possibility of separating the data further by attempting to compare 
different samples types (amniocentesis and chorionic villous samples) and the effect 
that this may have on the CMA results. However this was not possible as the studies 
did not record which sample type the DNA was extracted from when an abnormal 
chromosomal result was found (with the exception of one paper) (35). 
Using 2x2 tables, I computed and pooled the percentage agreement between the 
two technologies (with 95% confidence intervals) for the articles overall. The 
calculated percentage of extra cases identified by array in those with a normal 
karyotype (both overall and by referral indication) with 95% confidence intervals was 
calculated and pooled (Appendix J). Finally, I calculated and pooled the percentage 
of cases in which a result of “unknown significance” was reported (Appendix J). 
Heterogeneity in rates was examined graphically and statistically.  Statistical 
heterogeneity manifests itself in the observed intervention effects being more 
different from each other than one would expect due to random error (chance) alone. 
The Chi-Squared test was performed for a statistical assessment of heterogeneity 
(Appendix J). For graphical assessment, “Forest plots” of point estimate of rates and 
their 95% CIs were used. For exploration of reasons for heterogeneity, stratified 
analysis was performed according to the features of the population (indication for 
referral). For the meta-analysis log rates were pooled, weighting each study by the 
inverse of its variance and the summary estimates exponentiated (Appendix J). A 
random effects model was used in the light of heterogeneity. All statistical analyses 
were performed using Stata 8.0 statistical software (Stata Corp., College Station, 
Texas, USA).  
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Results  
Literature identification and selection 
 
I summarised the process of literature identification and selection in Figure 4. There 
were 10 primary articles identified as meeting the selection criteria (21;35;38-45).  
 
Of the original articles, 97 were excluded as they did not meet the selection criteria. 
The remaining 38 articles were obtained and reviewed and a further 8 articles were 
requested after review of the reference lists. Of these 46 articles, 36 were then 
excluded as they did not meet selection criteria. The ten primary studies, containing 
798 participants met the inclusion criteria to be included in the systematic review 
(21;35;38-45). Eight of these studies were included in the meta-analysis (35;38-
40;42-45), two were excluded from the meta-analysis as array CGH was only 
performed when an abnormal karyotype had been detected (21;41). 
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Figure 4 Study selection algorithm 
 
Total Citations from electronic searches  
Medline n=34 
Cinhal  n=22 
Embase n= 74 
Given n=5    Total n=135 
 
     
 
 
Studies retrieved for detailed evaluation 
n=38 
 
                                 
 
 
                   
           
 
  
 
 
 
 
Legend: The flow diagram above accounts for all the papers reviewed during the process of a 
systematic review. 
Number excluded after screening abstract  n=97 
Pre-implantation genetics n=11 
children/postnatal n=3  
non-invasive testing maternal n=14 
recurrent miscarriages n=5  
none relevant n=64 
Searching of relevant lists:  
Hand n=8 
Studies excluded: n=36 
Used cell lines n=6  
Not able to  distinguish if prenatal or abortion material n=1  
Not able to  construct 2x2 tables n=3  
Postnatal/child n=4  
Only assessing  trisomy , 13, 18 and 21  n=3 
Detecting mosacism only n=1 
No microarray used n=13  
No data n=2 
Not relevant n=3 
Studies included in systematic review: 10 
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Table 3 Characteristics of 10 included studies 
 Author 
Year 
Design Array type Probes 
 
Whole 
genome 
(WG) 
/targeted 
genome 
(TG) 
Sample Type Indication for array Sample 
Size 
1 Tyreman 
M et 
al.(43) 
2009 
retrospective Genechip SNP 
6.0 array 
(Affymetrrix) 
 
Commercial 
946,000 
probes 
(CNVs) 
 
 
WG Amniotic fluid 
=87 
Chorionic 
Villus 
Sampling =15 
Placenta 
biopsy 
following  
termination of 
pregnancy =4 
 
 
Ultrasound 
anomaly: 
(Cardiac = 34 
Multisystem = 24 
Large 
NT/hydrops/CH = 
18 
CNS 16 
Skeletal = 6 
Abdominal wall = 2 
Others = 6) 
106 
2 Bi W et 
al.(39) 
2008 
prospective BCM V6 
oligonucleotide 
array (V6 
Oligo) 
(Agilent) 
 
Commercial 
 
44,000 
oligo 
probes 
 
 
WG and 
TG 
Amniotic fluid Maternal age =6 
Anomaly on US= 5 
Family History 
abnormality =2 
multiple 
miscarriages=1 
 
14 
pregnancies 
15 fetuses 
3 Shaffer 
LG et al. 
(40)2008 
prospective Prenatal  BAC 
array version  
(signature) 
 
Commercial 
 
 
2,100 
BAC 
probes 
 
 
TG Prenatal 
cultured 
Amniotic Fluid  
or  Chorionic 
Villus 
Sampling 
Postnatal 
blood 
Family history = 19 
Maternal age = 2 
Parental anxiety = 
20 
Anomaly US = 110: 
(Abnormal 
genitalia=6 
CNS = 19 
CH/NF/NT/hydrops
=22 
GI = 9 
Dysmorphic = 4 
Cardiac = 17 
GD = 2 
Multiple = 3 
Micrognathia = 2 
Midline defect = 8 
Renal = 2 
Skeletal = 11 
SUA = 1 
Others= 4) 
 
151 prenatal 
 
4 De 
Gregori   
M et.al. 
(21) 2007 
retrospective 60-mer 
oligonucleotide 
microarray 
 
Commercial 
 
60 mer 
oligo 
probes 
 
 
WG Does not state Reciprocal 
translocations=14 
Maternal age =3 
17 
5 Rickman 
L et 
al.(41) 
2006 
retrospective BAC/PAC 
resolution 
10Mb   
common 
microdeletion 
syndrome  
 
own array 
 
 
600 
BAC 
probes 
 
 
TG Cultured 
amniocytes or 
Chorionic 
Villus 
Sampling  
 
Previously known 
karyotypes 
All known 
unbalanced 
rearrangements 
30 
 
6 Sahoo T 
et al.(38) 
2006 
prospective BCM v4.0  
 
Baylor 
 
Commercial 
 
 
366 
BAC 
probes 
 
 
TG Amniotic Fluid 
=56 (26 
uncultured) 
Chorionic 
Villus 
Sampling =42 
(32uncultured) 
Increase maternal 
age 
Increased serum 
screen 
Family history 
Abnormality on US 
 
98 samples 
total 
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BAC=Bacterial Artificial Clone  SUA=Single Umbilical artery 
BCM=Baylor College of Medicine TG= Targeted Array 
CNS=Central Nervous System  WG=Whole Genome array 
CNV=Copy Number Variant 
GI=Gastrointestinal 
IUGR=Intrauterine growth retardation 
NT=Nuchal Translucency 
SNP= Single nucleotide Polymorphism 
7 Le 
Caignec  
C et al. 
(42)2005 
retrospective Genosensor 
BAC array 300 
(Vysis/Abbott) 
 
commercial  
287 
BAC 
probes 
 
 
TG Frozen fetal  
tissue 
All normal karyotype 
All had 
malformations 
All had at least 3 
anomalies in 
CVS/urogenital/ 
digestive/CNS 
49 
8 Vialard F 
et al. 
(45)2009 
prospective Genosensor 
BAC/PAC 
array 300 
(Vysis/Abbott) 
 
commercial 
287 
BAC 
probes 
 
 
TG Muscle biopsy 
=15 
Lung 
biopsy=13 
thymus = 4 
skin = 3  
liver = 3 
bladder = 1 
2 or more 
abnormalities 
cardiovascual/uroge
nital/skeletal/digesti
ve/CNS 
39 
9 Coppinger 
J et 
al.(35) 
2009 
prospective Signature 
prenatal chip V 
4.0 
 
Commercial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature Chip 
Whole 
Genome 
 
commercial 
>2100 
BACs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4670 
BACS 
TG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WG 
Amniotic fluid 
= 40 
CVS = 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amniotic 
fluid=149 
CVS=30 
Unspecified 
prenatal cell 
type =3 
Anxiety= 6 
Family history= 19 
Advanced maternal 
age= 3 
Abnormal maternal 
serum screen =1 
Abnormal 
ultrasound =33: 
(CNS= 3 
Skeletal =1 
CH/NT/hydrops =18 
GI =1 
IUGR= 1 
MCA =7 
Unspecified =7) 
All normal 
Karyotype 
 
 
Anxiety =3 
Family history =17 
Advanced maternal 
age=5 
Abnormal maternal 
serum screen =2 
Abnormal 
ultrasound =155: 
(CNS= 16 
Musculoskeletal =8 
Cleft lip =6 
CH/NT/hydrops =24 
GI= 4 
Renal/ambiguous 
genitalia =4 
Cardiac =13 
IUGR =7 
Multiple =63 
Unspecified =10) 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
10 Kleeman 
L et al. 
(44) 
2009 
prospective Signature 
prenatal chip V 
4.0 26 patients 
 
Signature 
whole genome 
chip 
 
commercial 
 
 
1887 
BACs 
 
 
4685 
BACs 
TG 
 
 
 
WG 
Amniotic fluid 
= 47 
CVS = 3 
Abnormal 
ultrasound scan and 
normal karyotyping: 
(Cardiac =24 
CNS = 6 
Skeletal = 6 
Urogenital = 4 
Cleft lip/palate = 2 
CH/NT/hydrops = 3 
GI = 2 
Multiple = 17 
Growth disorder =3) 
50 
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Study Characteristics 
Table 3 summarises the characteristics of the publications used including the design 
of the study (retrospective or prospective), the array type, sample type, if the array 
was targeted or covered the whole genome, the indication for the array (divided into 
different structural abnormalities where known) and the sample size. Study quality 
assessment showed deficiencies in many areas of methods (Figure 3). Only 3 
papers meet all four quality criteria; being prospective in design, using array and 
karyotyping on a representative population (i.e. population did not have all known 
abnormal/normal karyotype), investigating parents to aid interpretation of CNVs and 
using a validated assessment tool (38;39;45).  
 
Agreement between Tests 
The overall agreement between karyotype and array results was 88.2% (95% CI 
79.2-98.2-100%). When benign CNVs were removed from the abnormal array group 
and treated as normal array results (as described above in the second analysis) the 
agreement was increased; 95.6% (95% CI 86-100%). The data were homogeneous 
(Chi2 p=0.99, p=0.97 respectively). Four out of ten papers were used to review the 
overall agreement between karyotype results and array results (n=333). Six out of 
ten papers could not be included as the data set was not complete (i.e. sample 
population was skewed by only using CMA on those samples with all normal or all 
abnormal karyotypes, papers (21; 40-44)). 
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Results: in cases where testing was performed for any referral indication 
CMA detected overall 12% (95% CI 8.8 -16.4%) more chromosomal imbalances 
when karyotyping was “normal” (Figure 5a) when the array was performed for any 
clinical indication. When benign CNVs were recognised, removed and treated as 
normal results, the detection rate decreased to 3.6% (95% CI 1.5 - 8.5%) (Figure 
6a). This 3.6% included all CNVs known to be pathogenic and those of unknown 
significance with the potential to be pathogenic. I therefore calculated how often a 
result of unknown significance would be found when CMA was performed prenatally 
for any clinical indication. Results of “unknown significance” were found in 1.1% (0.4 
- 2.7%) of cases. Eight out of ten papers were used for these meta-analyses (35;38-
40;42-45) (n=751). Two were excluded as they did not contain data for chromosomal 
anomaly detection rate by array when a normal karyotype was reported ((21;41). 
These data were heterogeneous (Chi2 p=0.00).  
 
One of the papers appeared to contribute disproportionately to the heterogeneity of 
the data (Tyreman et al (43)). This paper used a higher resolution array (Affymetrix 
SNP 6) and did not use parental testing for clarification of CNVs of unknown 
significance. It therefore had a high detection rate of all CNVs; pathogenic, unknown 
significance and benign. Because of this I performed a sensitivity analysis by 
excluding the results from this paper. With this paper excluded array detected 10.7% 
(95% CI 9.1-12.6%) more chromosomal imbalances when karyotyping was normal 
compared with 12% (95% CI 8.8 -16.4%) with the paper included. With exclusion of 
the paper by Tyreman et al and when benign CNVs were removed and treated as 
normal results, the detection rate of chromosomal imbalances by CMA decreased 
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from 3.6% to 2.9% (95% CI 1.3-6.3%) when karyotyping was normal. Exclusion of 
this paper did not significantly reduce the CMA detection rate; in addition the data 
were still heterogeneous. Taking this into account, and given that the paper by 
Tyreman et al is an important paper with one of the largest cohorts of patients, it was 
decided that the inclusion of this paper was important to present the totality of 
evidence.  
 
Conventional karyotyping did not detect any chromosomal imbalances that were not 
detected by array CGH in the same 8 papers used in the above meta-analysis. Two 
papers included in the systematic review (21;41) but not in the meta-analysis used 
CMA only when an abnormal karyotype had been found.  They did find that CMA 
was not able to detect one case of triploidy and 14 cases of balanced translocation.  
These two papers were not included in the meta-analysis as they only looked at 
cases with abnormal karyotype results and therefore a 2x2 table of their results could 
not be constructed.  
 
Results: in cases when a structural abnormality was noted on ultrasound scan 
Array technology detected overall 11.2% (95% CI 5.7 - 22.1%) more chromosomal 
imbalances above that of conventional karyotyping (Figure 5b).  When “benign 
CNVs” were removed from the analysis and placed with the normal array results, the 
detection rate of chromosomal abnormalities decreased to 5.2% (95% CI 1.9 -
13.9%). This included results that are known to be pathogenic and those of unknown 
significance with the potential to be pathogenic (Figure 6b). Six papers were used 
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(39;40;42-45). These papers all contained results on patients that had undergone 
karyotyping, and array tests as they had pregnancies where a structural fetal 
malformation was suspected on ultrasound scan (n=359). The size of these 
chromosomal imbalances ranged depending on the resolution of the CMA used from 
60kb(18) to 60Mb(17). In 1.9% (0.4 - 9.5%) of cases where the patient was referred 
with a fetal anomaly on ultrasound and conventional karyotyping was “normal”, a 
result of “unknown significance” was reported.  These data were heterogeneous (Chi 
2 p=0.000).  
 
The actual numbers of different structural abnormalities were recorded in 4 out of the 
6 papers (35;40;43;44). Where possible the different structural abnormalities are 
recorded in table 3. The pooled data from the 4 papers show that the largest 
numbers of patients had cardiac abnormalities (n=88), increased nuchal 
translucencies, cystic hygromata or hydrops (n=82) or central nervous system 
abnormalities (n=60). It is not possible to divide the structural abnormalities into 
groups to perform separate analysis for CMA testing as all four papers include 
groups with either “multiple congenital abnormalities”, which was not broken down 
further, or “other” groups where the abnormality is not specified. None of the papers 
include single “soft” markers although the paper by Tyreman et al includes multiple 
soft markers (43). The vast majority are major abnormalities. The papers also do not 
always provide data post delivery/post mortem so it is not possible in most cases to 
say if the abnormality was confirmed or, in the case of increased nuchal 
translucency, if it was linked to other structural abnormalities.  
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Conventional karyotyping did not detect any chromosomal imbalances that were not 
detected also by CMA.  
 
Figure 5 Detection of chromosomal imbalances by CMA when Karyotype is 
normal (including benign CNVs) 
 
Legend Figure 5: Forest Plot showing the percentage of chromosomal imbalances 
detected by CMA over conventional G-band karyotyping when the analysis is 
performed including pathogenic CNVs, VOUS and benign CNVs. 5a) Results when 
testing is performed for any clinical indication, 5b) Results when testing performed 
for abnormal fetal ultrasound findings. 
5b 
5a 
 
% (95% CI) 
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Figure 6 Detection of chromosomal imbalances by CMA when Karyotype is 
normal (excluding benign CNVs) 
 
 
 
Legend Figure 6: Forest Plot showing the percentage of chromosomal imbalances 
detected by CMA over conventional G-band karyotyping when the analysis is 
performed including pathogenic CNVs, VOUS but excluding benign CNVs. 6a) 
Results when testing is performed for any clinical indication, 6b) Results when 
testing performed for abnormal fetal ultrasound findings. 
 
6a  
6b  
% (95% CI) 
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Publication Bias 
Publication Bias was assessed by performing Eggers Test (based on a linear 
regression method where the standard normal deviate is plotted against precision 
Appendix J) and by use of funnel plots. When array detection over karyotype was 
meta-analysed there was no significant publication bias for either analysis (Eggers 
testing performed for any indication p=0.667 when testing performed for abnormal 
scan findings p=0.9406). This can be shown in the funnel plots below (Figure 7 and 
8). 
Figure 7 funnel plot of publication bias when testing performed for all 
indications 
Bias assessment plot
-0.5 0.5 1.5 2.5 3.5
0.3
0.2
0.1
0.0
Log(odds ratio)
Standard error
 
Legend Figure 7: Funnel plots graphically represent the papers precision (or number 
of participants in the study) against the treatment effect (from a negative effect on 
the far left to a positive effect on the right). We can see graphically if there is any 
publication bias if small negative studies (those on the bottom left) have been 
excluded. The funnel plot above does not show evidence of publication bias.  
Treatment effect (Log (odds ratio)) 
Precision 
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Figure 8 Funnel plot of Publication bias when testing performed for abnormal 
ultrasound findings.  
Bias assessment plot
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Discussion  
Overall agreement between prenatal array technology results and conventional 
cytogenetic karyotyping from data in the literature until 2009 was good. This 
increased further with removal of “benign” CNVs. It is to be expected that the 
percentage agreement between technologies would increase with removal of 
“benign” CNVs as the remaining microarray results are more likely to be pathogenic.   
 
CMA detected notably more chromosomal imbalances over conventional karyotyping 
both when it was performed prenatally for any clinical indication and when it was 
performed for a structural abnormality on scan. As well as results of a known 
pathogenic nature this does, however, include results of unknown pathogenic 
significance. 
 
The frequency of CNV of unknown significance is increased if parental samples are 
not available, as analysis will reveal whether the variant detected in the fetus is 
Precision 
Treatment effect (Log (odds ratio)) 
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familial or de novo. However, because of incomplete/variable penetrance, familial 
variants are not always benign (28). Variants of unknown significance (or VOUS) 
results are of concern as they may both increase parental anxiety and lead to 
problems in prenatal counselling.  I was aware that it would be important to define 
the VOUS rate in my work going forward, but in addition to the rate it would also be 
important to ask women and their partners how they thought or felt about these 
results.  
Karyotype did not detect any chromosomal imbalances when CMA was reported as 
normal in those papers used in the meta-analysis (35;38-40;42-45). This was 
reassuring to us as it suggested that CMA alone will not miss many significant 
results, and that areas in which microarray technology is weak are not common in a 
typical referral population (balanced translocations, inversions and a lower sensitivity 
for triploidy).  
 
The strength of the study lies in the rigor of the methodology. It met quality criteria 
laid down in the MOOSE(46) statement. But the meta-analysis contained a relatively 
small sample size of 751 participants for overall analysis and 409 participants with 
fetal anomalies identified using ultrasound. Many cohorts were retrospective with 
case selection rather than consecutive cases. Papers were heterogeneous with both 
prospective and retrospective methodology, different indication for referral and 
different CMA used. This accounts for the large confidence intervals in my analysis.  
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The inclusion of some published studies that include participants with a known 
abnormal karyotype may have influenced the results as they are not necessarily a 
representative population. This was particularly so when they were being used to 
illuminate the weaknesses with CMA technology such as detection of mosaicism, or 
when cases of known inversions or translocations were tested by CMA to see if the 
rearrangement was balanced.  
 
Array technologies have increased in resolution over the time these studies were 
conducted, but they have also become more commercially available allowing greater 
validation of results between different published studies. I could not allow for 
ascertainment bias towards cases that clinicians may have felt would have yielded 
an abnormal result from array and therefore included them in their results (i.e. 
choosing a case with multiple structural abnormalities).  
 
In 2009 this systematic review provided evidence of the relative advantage of using 
array testing in prenatal diagnosis even when karyotype is normal. But many of the 
cohorts were small and retrospective using custom designed arrays, and cases were 
selected by clinicians/scientists. Many questions at this point in time were still left 
unanswered. What would be the added information provided by CMA over 
convention G-band karyotyping in a prospective large cohort where consecutive 
women were recruited? The indication for referral with the largest detection rate by 
CMA appeared to be fetuses with abnormal scan findings. What would be the true 
detection rate by CMA in this cohort? Would it be reasonable to suggest CMA as 
frontline testing in this group? Would CMA represent a cost effective option in the 
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NHS? Would variants of unknown significance be commonly encountered and how 
would women and their partners view results that had an element of uncertainty? 
 
Up to 12% of any individual’s genome is likely to exhibit normal copy number 
variation (CNV) and there is emerging evidence of a huge degree of structural 
complexity within these chromosomal regions (27). In addition, limited data exists on 
the prevalence of CNVs between different ethnic populations (47). In 2009 These 
concerns led to recommendations from the ACOG that conventional G-band 
karyotyping should remain the principal cytogenetic tool in prenatal diagnosis. They 
also suggested that targeted arrays can be offered as an adjunct in prenatal cases 
with abnormal anatomical findings and a normal conventional karyotype (48). 
 
This systematic review and meta-analysis (prior to the undertaking of my own cohort) 
revealed an increased detection rate of chromosomal abnormalities with CMA, both 
for prenatal indications overall and when congenital malformations were noted on 
ultrasound scan. But large confidence intervals included in the analysis show that 
more work must be done before I could answer the question of absolute detection 
rate over conventional karyotyping. Prospective research was needed in this area 
with a large cohort that undergo both karyotyping and a commercially reproducible 
array. The optimum resolution array to be used in a prenatal setting had not yet been 
decided, and a targeted array would be suitable in its ability to identify CNVs in 
known disease specific loci of the human genome, but risks missing a pathogenic 
CNV not in these particular genomic regions. A high resolution array will have the 
ability to detect more CNVs but risks having more results of unknown certainty which 
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need additional time for interpretation and provoke additional uncertainty. I 
concluded that perhaps while this technology was being investigated targeted arrays 
were more suitable when they were to be used in the clinical setting and results fed 
back to patients.  
 
 
 It was concluded that a Health Economic assessment of microarrays was of 
importance when evaluating the implementation of this prenatal diagnostic test into 
routine practice.  Within the UK NHS setting almost all prenatally obtained samples 
are screened using QFPCR to exclude common trisomies.  A proportion of centres 
also continue to offer full karyotyping and depending upon the type of structural 
malformation noted, target testing for specific chromosome anomalies are performed 
(such as FISH for Di-George syndrome when a cardiac anomaly is detected).  
 
Finally it was concluded that there was an urgent requirement for patient satisfaction 
and qualitative research into the emotional response in parents with the 
implementation of such prenatal diagnostic tests. 
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AIMS  
1) To define the detection rate by CMA over conventional G-band karyotyping 
when there is a structural anomaly on ultrasound scan using my chosen CMA 
platform. I would define this by recruiting a prospective consecutive cohort of 
women that had accepted chromosomal testing because of structural 
abnormalities on fetal ultrasound scan. 
 
2) In a subset of the cohort to run (postnatally) a higher resolution (60K) array to 
evaluate the effect of pathogenic chromosomal detection rates and also 
variant of unknown significant detection rate. 
 
3) To perform a health economic analysis looking at the amount the NHS would 
have to be willing to pay for a case to be detected by CMA. 
 
4) To perform qualitative work to evaluate how women and their partners feel 
about the use of CMA testing, particularly when a result has uncertainty 
attached. 
 
5) To define the ethical dilemmas presented by prenatal CMA testing and 
suggest potential solutions. 
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CHAPTER 2 PROSPECTIVE PRENATAL MICROARRAY COHORT 
 “THE BIRMINGHAM BAC ARRAY COHORT” 
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Introduction 
The introduction to CMA testing and the literature until 2009 have been outlined in 
Chapter 1. In order to attempt to answer aim 1 (To define the detection rate by CMA 
over conventional G-band karyotyping when a congenital structural anomaly is 
detected on ultrasound scan using my chosen CMA platform.) a prospective cohort  
study was designed (49).   Pregnant women whose babies were noted to have a 
congenital malformation on ultrasound examination were offered fetal karyotyping 
and after consent would undergo both full, “conventional” G-band karyotyping and 
CMA testing. Other “sub aims of this study” included: 
 
 1) to define the Variant of Unknown Significance (VOUS) rate in this case cohort as 
this would be of extreme importance when and if translated into routine clinical care.  
2) to determine if the tissue sample type (amniocentesis, Chorionic Villus Sampling, 
fetal blood sampling) made a difference to quality of DNA extracted and the failure 
rate of the CMA technique.  
 
I decided, after initial discussion, that a “targeted”, relatively conservative, 
constitutional Bacterial Artificial Chromosome (BAC) array should be used for my 
study. Although of lower resolution (and therefore potentially would miss pathogenic 
CNVs) there were advantages to using this array: 
a) The West Midlands Genetics laboratory (WMGL) that would be performing the 
microarray testing were experienced with the use of the array in postnatal 
testing and preliminary analysis indicated that it worked with prenatal DNA 
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(which is often of lower quality and quantity when compared with postnatal) 
samples.  
b) The “turnaround time” for results was <14 days which would be important in a 
prenatal cohort.  
c) I felt that using this BAC array would limit the CNVs that were judged to be of 
unknown significance. 
 
Limiting Variants of Unknown Significance (VOUS) is of the upmost importance in 
the prenatal period, particularly if the VOUS is unrelated to the phenotype seen on 
scan, as a more detailed phenotype is unavailable prenatally (i.e. autism). There is 
currently no national or international guidance on the reporting of VOUS and I felt 
that I should consider each case on a “case-by-case” basis but if a VOUS did arise 
that had potential clinical significance it would be discussed with a consultant clinical 
geneticist who would feed back the information to the patient alongside a fetal 
medicine consultant.  
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Methods 
Recruitment 
A protocol was written (Appendix a) after discussion with the fetal medicine 
consultant lead at Birmingham Women’s Foundation Trust, a consultant clinical 
geneticist of the West Midlands Regional Clinical Genetics Service and also the 
Head of Cytogenetics in the West Midlands Genetics Laboratory (WMGL). Patient 
information sheets were also written after discussion with Dr Peter Farndon, Director 
of the National Genetics Education and Development Centre in Birmingham 
(Appendix b). Two information sheets were created; one for on-going pregnancies 
and one for when a decision had been made to terminate the pregnancy. Consent 
forms were produced in line with guidance from the National Research and Ethics 
Service (Appendix c).  
 
Pregnant women were approached at Birmingham Women’s Foundation Trust within 
the tertiary referral centre for Fetal Medicine, as a fetal anomaly was suspected. 
After a detailed ultrasound scan had confirmed the fetal anomaly (or redefined the 
fetal anomaly they had been referred with) women were counselled by a fetal 
medicine consultant (and if appropriate other specialists). Part of this counselling 
involved discussion relating to the possibility of a chromosomal anomaly being 
associated with the abnormal ultrasound scan findings.  Prenatal testing for common 
autosomal aneuploidies in the form of QFPCR (for Trisomy 13, 18 and 21) as well as 
sex chromosome aneuploidy was offered. In our centre, all fetal karyotypes are 
routinely further investigated using conventional G-band karyotyping. If accepted, 
women were approached to have CMA testing, within the Birmingham BAC Array 
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study. Women were formally counselled regarding the increased resolution of the 
test over G-banding but were also informed of the disadvantages, namely detection 
of VOUS. The fact that CMA would miss balanced rearrangements was not 
discussed as G-band karyotyping was being performed in parallel which would 
detect this. Written information was given to the patient. 
 
Inclusion and exclusion criteria 
Inclusion criteria for the study included if a congenital malformation on ultrasound 
scan or a nuchal translucency measuring over 3.5mm (between 11-13+6 weeks) was 
noted. Single, so-called “soft markers” (echogenic bowel, choroid plexus cyst, 
echogenic cardiac foci, and single umbilical artery) were not indications for inclusion, 
although “multiple ultrasound markers” were included. Women were also excluded 
from consent if they were under 18 years old or it was felt by the counselling 
consultant that the patient lacked the capacity for providing informed consent of the 
test.  
 
Details of the Cohort 
I prospectively recruited 317 (97%) prenatal women seen at the Fetal Medicine 
Centre at Birmingham Women’s Foundation Trust. Six women (1.5%) were recruited 
by University Hospital Coventry and Warwickshire NHS trust and five (1.5%) were 
recruited from City and Sandwell NHS trust. Recruitment took place between 
November 2009 and April 2012. Ethical approval for the study was granted by the 
Staffordshire Research and Ethics Committee (reference no. 09/H1203/74).  The 
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fetal sample that was taken was either amniotic fluid by amniocentesis (typically 
20mls) n=154 (63.5%), Chorionic Villus Sampling (typically 15-25mgs) n=53 (21.5%), 
fetal blood (typically 1-1.5mls) n=29 (12%), fetal tissue taken at post-mortem (n=6; 
2.5%) and in one case (0.5%) a pulmonary effusion sample (containing a high 
density of fetal lymphocytes).  
 
Parental (maternal and paternal) venous blood samples were obtained at the same 
time as the invasive fetal sample to exclude maternal cell contamination and to 
establish inheritance of CNVs where necessary. Samples types and the need for 
culturing to increase the DNA quantity are described in detail in Table 4. 
 
Table 4 Sample type used in Birmingham BAC cohort 
Sample type Sample number and percentage 
Uncultured amniocentesis 146 (60%) 
Cultured amniocentesis 8 (3.5%) 
Uncultured Chorionic Villus Sampling 50 (20.5%) 
Cultured Chorionic Villus Sampling 3 (1%) 
Fetal Blood Sample 29 (12%) 
Fetal Tissue 6 (2.5%) 
Pulmonary effusion sample 1 (0.5%) 
 .  
CMA testing was not initiated until the results of the quantitative fluorescent 
polymerase chain reaction (QFPCR) were available and not processed further if 
Trisomy 13, 18, 21 or Monosomy X were detected. If QFPCR was normal then 
karyotyping and microarray testing were run in parallel.  
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Laboratory methodology 
Differently fluorescently labelled test and reference DNAs of the same gender were 
competitively hybridised to whole genome BAC (Bacterial Artificial Chromosome) 
microarrays, (CytoChip Focus constitutional, BlueGnome Cambridge, UK®). The 
methods for which are outlined in appendix D. These arrays have BAC data points at 
every 1Mb in the genome as a whole and tiled, overlapping BACs in regions 
associated with recurrent constitutional syndromes and within subtelomeric and 
centromeric regions. Each data point is replicated within the array design (triplicate in 
the genome backbone and quadruplicate in targeted regions) negating the need for a 
dye-swap experiment. This relatively “focused” microarray was chosen to minimise 
detection of VOUS. In essence I used a >2 x BAC threshold for calling which 
equates to a working resolution of >2Mb genomic backbone and >200kb in targeted 
regions. The laboratory methods were performed by staff in the WMGL due to the 
number of samples processed and the rapid turnaround time required. 
 
CMA Analysis 
Detected copy number gains or losses were compared with known CNVs in publicly 
available databases (Database of Genomic Variants 
http://www.ncbi.nlm.nih.gov/dbvar/, Decipher, http://decipher.sanger.ac.uk/, 
International Standards for Cytogenomic Arrays Consortium database, 
https://www.iscaconsortium.org/index.php/search) and against our own internal 
database to ascertain the clinical significance of the variation. Those CNVs of clinical 
significance or unknown significance were confirmed by fluorescence in situ 
hybridisation (FISH) on metaphase spreads using one or more BAC clones within 
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the abnormal region and in some cases were repeated on higher resolution 
microarray (Affymetrix 2.7M Cytogenetics Research array or ISCA 60K CytoChip 
oligonucleotide array). The same BAC microarray was also performed on parental 
samples to evaluate if the CNV was inherited or had occurred de novo.  
 
Classification of CNVs and blinding 
CNVs were classified as benign, VOUS or pathogenic in accordance with the 
American College of Medical Genetics (ACMG) guidelines (50). Pathogenic CNV are 
documented as clinically significant in multiple peer-reviewed publications. 
Penetrance and expressivity of the CNV is well defined, even if known to be variable. 
They may include large CNVs not described in the medical literature at the size 
observed in the fetus, but overlap a smaller interval with clearly established clinical 
significance.  
 
A benign CNV will have been reported in multiple peer-reviewed publications or 
curated databases as being a benign variant, particularly if the nature of the copy 
number variation has been well characterised, and will typically represent a common 
polymorphism (documented in greater than 1% of the population). 
 
VOUS will have included findings that are later demonstrated to be either clearly 
pathogenic or clearly benign, but insufficient evidence was available for unequivocal 
determination of clinical significance at the time of reporting (50).  
48 
 
Results were fed back to patients when they were pathogenic or a VOUS. On 
average the turnaround time for CMA was 10 days. When a potentially pathogenic 
difference was detected on CMA I was contacted by the WMGL and I then made an 
appointment for the patient and her family to be seen by a consultant clinical 
geneticist, normally the next working day.  
 
Analysis of the CMA took place at the WMGL where conventional G-band 
karyotyping results for the sample were also being interpreted. The analysts were 
not strictly blinded from one another and therefore it was a possibility that a positive 
result by CMA could alter how the conventional G-banding karyotyping was 
interpreted. Therefore, to exclude that possibility, slides were sent to a second 
laboratory for G band karyotyping (where the results of the microarray were 
unknown) for prospective and independent interpretation (South East Scotland 
Cytogenetics Service, Western General Hospital, Edinburgh).  Analysis was included 
into the workflow of this second laboratory to ensure that the analysis was blinded. 
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Results  
328 women were prospectively recruited to have both CMA and full, conventional G-
band karyotyping performed. Uptake was 90% of those approached. One patient 
was excluded, as at recruitment, there was only a single soft marker visualised on 
ultrasound scan. Eleven subjects were excluded as there was insufficient DNA to 
perform both tests. One was only performed on a very high resolution Affymetrix 
2.7M array and was therefore excluded. 66 samples were excluded as QFPCR 
demonstrated either Trisomy 21,13,18 or Monosomy X (20%). The BAC microarray 
failed in 5 cases (1.5%), two of which were due to maternal cell contamination and 
three due to failure of the DNA quality. Two cases were fetal blood samples, two 
were amniocentesis samples and one was a CVS sample. There was no association 
between different invasive sample types and failure of the CMA test. One case of 
conventional G-band karyotyping failed (0.3%). Therefore BAC CMA was performed 
on 243 samples (from 243 patients) and compared to G-band karyotyping in the 
same samples (Figure 9). 
 
A total of 228 (94%) samples from fetuses with congenital abnormalities in a single 
‘anatomical’ system were included and 15 (6%) samples from fetuses with 
abnormalities within two or more systems as seen on scan. The range and type of 
fetal anomalies are described in Table 5 and were classified according to the Human 
Phenotype Ontology Website (www.human-phenotype-ontology.org/).  
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Figure 9 Flow diagram of samples for the Birmingham BAC chromosomal 
microarray Cohort 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
QF-PCR = Quantitative Fluorescent PCR 
MCC = Maternal cell contamination 
CU = clean up 
*Blinded results 
^Including 9 pathological and 1 VOUS reported to patients 
 
N= 328 recruited with fetal 
anomaly on USS 
Excluded N= 85 (26%) 
1 soft marker only 
11 insufficient DNA for both tests 
1 performed on 2.7M array only 
66 trisomy 21,13,18 or monosomy 
X on QF-PCR 
5 microarray failed (1.5%) (MCC 2 
failed CU 3) 
1 karyotyping failed (0.3%) 
 
N=243 (74%) 
Both microarray and 
karyotype performed 
 
 
Abnormal on both 
microarray and 
karyotype N= 12 
(4.9%)* 
Abnormal on 
microarray only N=10 
(4.1%)^ 
Abnormal on karyotype 
only N= 4 (1.6%) 
Normal on both 
N=217 (89.4%) 
 
 
Legend: The flow diagram above account for all cases that were included in the BAC 
array cohort 
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Table 5 Structural anomaly classified using the Human Phenotype Ontology 
(HPO) System 
 
Structural anomaly N= Percentage 
Single 228 94% 
Central nervous 
system 
51 21% 
Cardiovascular 
system 
41 17% 
Increased Nuchal 
Translucency>3.5mm 
/Cystic hygroma 
40 16.5% 
Musculoskeletal 
system 
25 10.5% 
Genitourinary system 20 8.5% 
Congenital 
diaphragmatic hernia 
15 6% 
Abdominal wall 
defect 
11 4.5% 
Head/face/neck 7 3% 
Respiratory system 5 2% 
Spina Bifida/ 
encephalocele 
5 2% 
Hydrops 4 1.5% 
Gastrointestinal tract 3 1% 
Tracheal/oesophageal 
fistulae 
1 0.5% 
Multiple systems 15 6% 
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In 2 fetal samples the original chromosomal abnormality seen at the WMRGL was 
not noted on the ‘blinded’ review at a second laboratory where the cyto-geneticists 
were unaware of the microarray findings (Table 6 fetal samples 16-17). These 
included a mosaic duplication of 12p13.33-p11.1 consistent with Pallister Killian 
syndrome (case 16) and a de novo 1.7-3 Mb deletion between 1p36.33 and 1p36.32 
consistent with 1p36 microdeletion syndrome. Both would have been causative of 
the findings on scan (case 17). The results presented are those of the “blinded” data 
series. 
 
243 BAC microarrays were processed; 156 (64%) had no CNVs and 87 had at least 
one CNV (36%). In total 121 CNVs were found within these 87 samples and these 
were divided into benign, VOUS and pathogenic CNVs. 90/121 (74%) were common 
benign CNVs, 2 (1.6%) were uncommon benign CNVs requiring further testing with 
FISH (in 2 separate samples) and these results were not fed-back to patients.  
 
Three VOUS were detected in 3 separate samples (2%) (Table 6 fetal samples 1-3) 
although this was reduced to just n=1 (fetal sample 1) (0.8%) after further testing 
using higher resolution microarray (two VOUS were reclassified as either artefact or 
uncommon benign CNV). The single “true VOUS” result (case 1) was fed back to the 
patient and presented a difficult counselling scenario. A 0.5-1Mb duplication between 
Xp22.32 and Xp22.31 was detected in a male fetus with a cardiac anomaly (truncus 
arteriosis). This had led to partial duplication and possible disruption of the gene 
NLGN4. The gene has no known cardiac link but has been linked to 
neurodevelopmental delay and autism. This duplication was maternally inherited (the 
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mother having no learning difficulties). Only one, phenotypically normal, male relative 
was available for testing, but he did not have the CNV.  X-inactivation studies carried 
out on maternal DNA were inconclusive.  
 
Seventeen CNVs (14% of the CNVs) were classified as pathogenic and were also 
seen by karyotyping (in 12 separate fetal samples, 4.9% of the cohort Table 6; 4-15). 
These included 4 cases of aneuploidy (2 cases of Triple X also detected by QFPCR 
and 2 cases of Trisomy 9). In seven cases there was a large structural chromosome 
anomaly present visible on both G-band and microarray (cases 8-14). In one case 
the structural chromosome abnormality (a de novo ~3.5Mb deletion within 17p11.2 
consistent resulting in Smith-Magenis syndrome) was at the limit of cytogenetic 
resolution and was only visible due to high quality chromosome preparation. 
 
Nine CNVs (7.4%) in 9 fetuses were considered pathogenic and were not detectable 
by karyotyping (Table 6; 16-24). These included a finding of a mosaic 
isochromosome 12p (consistent with Pallister Killian syndrome), 1p36 microdeletion, 
4 cases of 22q11.2 microdeletion (Di George syndrome) and deletion of PMP22 
(associated with hereditary neuropathy with liability to pressure palsies). One fetus 
(Table 6 Fetal sample 17) had a de novo 6-8Mb duplication between 11q24.2 and 
11q25 including ~50 HGNC genes and 17 OMIM genes. Finally one fetus (Table 6 
fetal sample 24) had a ~3.2 Mb deletion at 5q35.3. More detailed analysis using an 
ISCA 60K oligoarray further defined the deletion as being ~1.9Mb in size with 
additional ~1.1Mb duplication at 17q25.3, both of which had been inherited from the 
mother who had an unbalanced translocation between 5q and 17q. The mother has 
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dyspraxia and mild facial dysmorphia. The unbalanced translocation was inherited 
from the proband’s maternal grandmother who had the translocation in a balanced 
form and does not have any learning difficulties. Prenatal ultrasound findings 
demonstrated absent corpus callosum and a meningocele.  As the mother shows a 
phenotype consistent with the chromosomal abnormality it was deemed likely to be 
pathogenic.  
 
In five fetal samples (2% of the cohort) karyotyping detected a chromosomal 
anomaly when microarray was reported as normal; one was a false positive due to 
maternal cell contamination, and three were balanced inherited inversions unlikely to 
have a phenotypic effect on the fetus. The fifth fetus was mosaic for monosomy X on 
an amniocentesis sample and triple X on CVS (undetected by QFPCR), in a fetus 
with a univentricular heart and hydrops fetalis. Postnatal blood taken from the baby 
after birth showed mosaicism for Monosomy X and triple X (47,XXX[45]/45,X[15]). 
This chromosomal anomaly is consistent with the phenotype on scan (Table 6 25-
28).  
 
In the cohort those samples showing Trisomy 13,18 and 21 and monosomy X did not 
go on to have CMA testing (n=66 had Trisomy 13,18, 21 and monosomy X and n=46 
(70%) had an increased nuchal translucency over 3.5mm). Of the 22 pathogenic 
chromosomal and one true VOUS identified by either CMA and/or conventional 
karyotyping it is worth noting that 7 cases (30% of pathogenic findings) had an 
increased nuchal translucency >3.5mm as either part or the sole reason for testing. 
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Table 6 Positive chromosomal abnormalities detected by CMA and/or G-band karyotyping  
N
o. 
Ultrasound 
scan findings 
G-banding 
results centre 
1 
G-banding 
results 
centre 2 
Chromosomal 
Microarray 
Classification Pregnancy outcome 
1 Truncus 
Arteriosis 
Normal Agree centre 
1 
arr cgh 
Xp22.32p22.31(RP11
-60N3->RP11-
769N24)x2, Xp22.3 
(RP11-44F2)x2 mat 
possible disruption 
NLGN4 
VOUS 
Confirmed on 
2.7M array 
LB 
Had cardiac surgery 
postnatally. Normal 
development at 7 months of 
age 
2 Arms and hand 
in fixed flexion 
Feet severe 
equinous 
deformity 
Hydrothorax 
Possible 
micrognathia 
Small 
cerebellum 
Normal Agree centre 
1 
arr cgh 
9q34.11(RP11-
339B21-RP11-
409K20)x3 dn  
VOUS BAC 
array. 
Repeated on fetal 
tissue 2.7M array 
most likely 
artefact report 
amended 
TOP 
PM confirmed micrognathia 
abnormal posture and 
pleural effusions 
Cerebellum appeared 
normal 
3 Increased 
nuchal 
translucency 
>3.5mm and 
bladder 
outflow 
obstruction 
Normal Agree centre 
1 
arr cgh 6q27 (RP1-
19N21-RP11-114B3) 
x1 mat 
VOUS BAC 
array; FISH and 
60k  ISCA array 
likely uncommon 
benign 
LB no follow up data 
available 
56 
 
4 Increased 
nuchal 
translucency 
>3.5mm 
Trisomy 9 Agree centre 
1 
Agree Pathogenic TOP PM report 
demonstrated hydrocephaly. 
Severe dysmorphism 
abnormal lung lobation. 
Abnormal GI tract. Bilateral 
renal cystic disease 
5 Increased 
nuchal 
translucency 
>3.5mm 
Trisomy 9 Agree centre 
1 
Agree Pathogenic TOP No Pm report available 
6 Scoliosis 
hemivertebrae 
small kidney 
Trisomy X Agree centre 
1 
Agree Pathogenic LB absent left kidney and 
hemi-vertebral anomalies. 
Seen at 4 months old. Also 
noted flattened occiput with 
abnormal epicanthic folds 
and inverted nipples.  
7 Ventriculomeg-
aly 
Trisomy X Agree centre 
1 
Agree Pathogenic LB no follow up data 
available 
8 Holoprosencep
-haly 
46,XX,der(2)del(
2)(p16.2p22.3)d
el(2)(q14.1q22.1
)dn,t(5;6)(q22;p
11)dn 
Agree centre 
1
1 
arr cgh 
2p22.1p21(RP11-
173C1->RP11-
110G2)x1, 
2q14.2q22.1(RP11-
6906->RP11-
279M2)x1 dn 
 
 
 
 
 
Pathogenic TOP PM confirmed alobar 
holoprosencephaly. 
Unilateral cleft lip and 
palate. Interrupted aortic 
arch and abnormal lung 
lobation 
57 
 
9 Short long 
bones, skeletal 
dysplasia, 
IUGR, enlarged 
heart 
45,X,idic(Y)(q11
.2)[27]/45,X[7] 
Agree centre 
1 
agree Pathogenic SB PM confirmed skeletal 
dysplasia. IUGR. Dilated 
heart and small thymus 
10 
 
Increased 
Nuchal 
translucency 
>3.5mm 
46,XX,del(6)(q1
1.1q16.1)dn 
Agree centre 
1 
arr cgh 
6q11.1q16.1(RP1-
91N13->RP11-
538A16)x1 dn 
Pathogenic TOP No Pm report available 
11 Increased 
nuchal 
translucency 
>3.5mm 
47,XX,+r(8)(p10
p21.2)[12]/46,X
X[8] 
Agree centre 
1 
arr cgh 
8p21.2p12(RP11-
138J2-RP11-
>197P20)x2~3 dn, 
8p12p11.1(RP11-
479P21-RP11-
>65O11)x1~2 dn 
Pathogenic TOP No Pm report available 
12 Holoprosencep
-haly 
46,XX,del(7)(q3
2)dn 
Agree centre 
1 
arr cgh 
7q32q36.3(RP11-
36B6->RP11-867L5) 
x1 dn 
Pathogenic TOP No Pm report available 
13 Dandy-Walker 
malformation 
46,XX,del(6)(q2
5.1)dn 
Agree centre 
1 
arr cgh 
6q25.1q27(RP1-
297M16->RP11-
114B3)x1 dn 
Pathogenic TOP No Pm report available 
14 Hypoplastic 
left heart, 
borderline 
ventriculomeg
aly 
46,XX,der(8)del(
8)(p23)inv 
dup(8)(p23.1p1
1.2)dn 
Agree centre 
1 
arr cgh 8p23.3 
(RP11-1029B10-
>RP11-479M8)x1 dn 
8p22 (RP11-145015-
>RP11-65011)x3 dn 
 
Pathogenic TOP PM report confirmed 
Hypoplastic left heart 
syndrome and bilateral mild 
ventriculomegaly. Also 
hypoplastic aortic arch, 
ventricular septal defect and 
agenesis of corpus callosum  
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15 Nuchal 
translucency > 
3.5mm 
46,XY,del(17)(p
11.2p11.2)dn 
 
Agree centre 
1 
arr cgh 
17p11.2(RP11-
219A15-RP11-
121A13)x1 dn  
Smith Magenis 
syndrome 
Pathogenic TOP No Pm report available 
16 Increased 
Nuchal 
translucency 
>3.5mm, 
diaphragmatic 
hernia, short 
femur 
47,XX,+der(12)(
pter-p11::p13.3-
p11::pter)dn[10]/
46,XX[5]Palliste
r Killian 
syndrome  
Disagree 
centre 1
2 
arr cgh 
12p13.33p11.1(RP11
-519B13->RP11-
460N10)x3 dn 
Pallister Killian 
syndrome 
Pathogenic 
Confirmed using 
FISH analysis 
NND 
 
17 Bilateral 
ventriculomeg-
aly 
46,XY,del(1)(p3
6.3)dn 
Disagree 
centre 1 
arr cgh 
1p36.33p36.32(RP5-
857k21->RP11-
333E3)x1 dn 
1p36 microdeletion 
syndrome 
Pathogenic TOP No Pm report available 
18 Nuchal 
translucency > 
3.5mm 
developed 
cardiac defect 
Normal Agree Centre 
1 
arr cgh 
11q24.2q25(RP11-
10N17->RP11-
358H4)x3 dn 
 
Pathogenic TOP No Pm report available 
19 VSD aortic 
coarctation 
Normal Agree centre 
1 
arr cgh 
22q11.2(RP11-
800B02->RP11-
330P17)x1 dn  
Di George syndrome 
Pathogenic Miscarriage. No PM. 
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20 Double outlet 
right ventricle 
Normal Agree centre 
1 
arr cgh 
22q11.21(RP11-
800B02->RP11-
330P17)x1 dn 
Di George syndrome 
Pathogenic TOP No Pm report available 
21 Tetralogy of 
fallot 
 
Normal Agree centre 
1 
arr cgh 
22q11.21(RP11-
800B02->RP11-
330P17)x1 dn 
Di George syndrome 
Pathogenic TOP No Pm report available 
22 Truncus 
arteriosis 
Normal Agree centre 
1 
arr cgh 
22q11.21(RP11-
800B02->RP11-
330P17)x1 mat 
Di George syndrome 
Pathogenic TOP PM confirmed truncus 
arteriosus type 1 
23 Bladder 
outflow 
obstruction 
Normal Agree centre 
1 
arr cgh17p12(RP1-
27J12-RP11-
385D13)x1 pat 
Including gene 
PMP22: hereditary 
neuropathy with 
liability to pressure 
palsies (HNPP) 
Pathogenic 
Likely incidental 
finding 
TOP 
Before result of microarray 
known. No PM. 
24 Absent corpus 
callosum and 
meningocele 
Normal Agree centre 
1 
arr cgh 5q35.3(RP11-
281O15->RP11-
99H18) x1 mat 
Pathogenic LB 
Admitted to SCBU following 
delivery. Anomalies 
confirmed.  
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IUGR= intrauterine growth retardation 
1
 Blind laboratory :Deletion 2q and translocation detected but missed 2p deletion 
LB = live birth    
2
Abnormality not present on the 6 cells examined 
NND= neonatal death   
3
Postnatal blood sample 47XXX[45]/45X[15] 
PM = post-mortem 
SB = still birth 
SCBU special care baby unit     
SHH= sonic hedge hog 
TOP = Termination of pregnancy 
Legend: The table represents positive findings by either CMA and/or G-band karyotyping in my prospective cohort. It also shows 
the concordance between the two centres performing G-band karyotyping (centre 1 is the West midlands Genetics Laboratory, 
centre 2 is South East Scotland Cytogenetics Service). The classification of the chromosomal variant and the pregnancy outcome 
are also represented.  
25 Univentricular 
heart, hydrops 
45,X 
Amniocentesis 
47,XXX CVS
3
 
 
Agree centre 
1 
Normal Pathogenic LB admitted to SCBU 
following delivery. 
Anomalies confirmed. 
26 Lower limb 
abnormality 
46,Y,inv(X)(p11
q13)mat 
Agree centre 
1 
Normal Benign TOP PM confirmed absent 
fibulae and short angular 
tibiae with three toes on 
each foot 
27 Borderline 
ventriculomeg
aly 
46,XX,inv(10)(q
22q23)pat 
 
Agree centre 
1 
Normal Benign LB no follow up data 
available 
28 Transposition 
great arteries 
Double outlet 
right ventricle 
Ventricular 
septal defect  
46,XY,inv(19)(p
13.1p13.3)mat 
Agree centre 
1 
Normal Benign LB 
Admitted to SCBU following 
delivery. Anomalies 
confirmed. 
61 
 
Discussion 
In my cohort I found that chromosomal microarray had an increased detection rate 
over conventional karyotyping in 4.1% of cases (10/243). Compared with other 
cohorts this seems appears a conservative increase over karyotyping (51;52). 
However the reason for this is that the choice of CMA was targeted and purposefully 
conservative to limit the amount of parental follow up required and VOUS detected.  I 
found CMA to be a robust and accurate method and (in the vast majority of samples) 
without culturing cells. The turnaround time in the WMGL is 10 days, longer than 
previously reported (52). The main reason for this was that samples were kept on 
hold and then analysed in one “batch” at the beginning of the week. With more 
dedicated staff this could be reduced to 5 days, significantly reducing the wait for 
couples.  
 
The VOUS rate was just 0.4% and with sensitive but accurate counselling by a 
clinical genetics consultant the patient did not find the result concerning, was grateful 
for the information and continued the pregnancy. However had the result not been 
managed well this may have led to increased anxiety both in the antenatal period 
and postnatally if the pregnancy continued. More qualitative work on the effect of 
VOUS on women and the partners is available in chapter 5. 
 
When the G-banding analysts were blinded from the microarray results they did not 
detect three of the chromosomal differences that were detected when analysis was 
taking place in the same laboratory. The blind results are probably more 
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representative of what is routinely seen or missed by conventional cytogenetics if 
CMA was not to be performed.  However the blinded analysts did not have as much 
clinical information regarding the pregnancy and problems seen on scan which may 
have affected their analysis of particular chromosomal regions.  
 
In my cohort increased nuchal translucency >3.5mm had a high rate of pathogenic 
chromosomal differences even when common autosomal or sex aneuplodies were 
excluded.  
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Published work from chapter 2 
This work has been published: 
S.C.Hillman, D.J.McMullan, G. Hall, F.S. Togneri, N. James, E.J Maher, C.H. Meller, 
D. Williams,   R.J. Wapner,  E.R. Maher and M.D.Kilby. Use of Prenatal chromosomal 
microarray use: a prospective cohort of fetuses and a systematic review and meta-
analysis. USOG 2013 Jun;41(6):610-20 
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CHAPTER 3 HIGH RESOLUTION OLIGONUCLEOTIDE 60K MICROARRAY 
PLATFORM 
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Introduction 
The potential advantages and disadvantages of CMA testing in the prenatal setting 
have been discussed in previous chapters. However the correct resolution of the 
CMA platform to use is debatable. As the resolution of the microarray platform 
increases, generally the number of detectable VOUS will increase in addition to an 
increase in pathogenic findings (see chapter 4) Spearman's rank correlation 
coefficient (Rho) = 0.809108 (P = 0.0012) (49). If VOUS are to be reported to women 
and their partners this would mean additional counselling, and depending on how the 
information is viewed/handled additional anxiety and emotional stress. This anxiety 
has the potential in some instances to cause women to consider termination of the 
pregnancy, for a “CNV” that may in time be redefined as uncommon but benign.   
 
Few studies have used different resolutions of CMA (35;44;53) and none have 
directly compared differing resolutions on the same prenatal samples.  I sought to 
examine a sub-set of cases where a 1Mb targeted BAC array had been performed 
prenatally and, in addition, perform a whole genome cytochip oligonucleotide 60K 
CMA (BlueGnome Cambridge) once the pregnancy was complete (54). The aim 
would be to determine the “extra” CNV pathogenic information gained from the 
higher resolution array and the amount of uncertainty obtained from the raised 
resolution of the CMA. 
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Methods 
At the time of written consent for the 1Mb BAC array study, parents were asked if 
they would give consent for a higher resolution array test to be performed when the 
pregnancy was complete (either after a live birth, miscarriage or termination of 
pregnancy). As the VOUS rate had not been determined when using the higher 
resolution array, women were told that they would only be informed of the 60K CMA 
outcome if it showed a “pathogenic CNV”.  
 
In total, 243 fetal cases underwent a 1Mb BAC array test (49).  Of these there was 
enough DNA available to process 71 cases for an additional 60K oligonucelotide 
array postnatally (see Figure 10). In the main this was because the prenatal sample 
was cultured or an additional sample was taken, prior to termination of pregnancy at 
feticide (Table 8). In 172 cases, all available DNA had been utilised following 
QFPCR, conventional karyotyping and 1Mb BAC array. The 60K oligonucleotide 
microarray used was the International Standard for Cytogenomic Array (ISCA) 
design v2.0 (https://iscaconsortium.org/) and data was analysed using BlueFuse 
Multi v3.0 such that theoretically the majority of CNVs  >15kb in 500 disease 
gene/telomeric regions (including all well characterized microdeletion and 
microduplication syndromes) and CNVs >180kb in the genomic backbone would be 
detectable. The laboratory methodology for the CMAs was conducted by me in ~50% 
of cases and by WMRGL staff in ~50% of cases.  
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The majority of the fetuses had a single structural anomaly (n=66/93%). Of these the 
most commonly represented malformations were; central nervous system anomalies 
(22.5%), cardiovascular system (predominantly heart anomalies) (18%), 
musculoskeletal (14%), and genitourinary system (12.5%) abnormalities (see Table 
7). Of the 71 cases (where sufficient DNA was available) to process the 60K array, 
the majority were umbilical cord blood samples at delivery (n=14/20%); fetal blood 
samples (at late termination of pregnancy) (n=18/25%) or fetal tissue following 
miscarriage or termination of pregnancy (n=22/31%) (see Table 8). Few were taken 
from CVS or amniocentesis samples (cultured or uncultured) and in all 3 cases 
where CVS samples were used the 60K array failed.  The reason for few cases 
being taken from CVS and amniocentesis samples is the low quantity of DNA 
remaining after preceding primary tests (full karyotype, QFPCR and BAC array).  
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Figure 10 Flow diagram of cases available for high resolution 60K CMA testing  
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
N=243  
Both BAC Microarray and 
karyotype 
Sufficient fetal DNA  
N= 71 samples 
 
 
Abnormal on both 
60KCMA and 
karyotype N=2(3.2%) 
Both seen by BAC 
array but extra 
information in 1 case 
 
Pathological on 60K 
CMA normal karyotype 
N=6 (9.6%) 
2 cases not seen by 
BAC 
1 case partly seen by 
BAC 
Extra Info 60K N=3 
(4.8%) 
 
 
VOUS on 60K Array. 
Normal on BAC 
Array and karyotype 
N=13(21%) 
Likely benign N=5 
VOUS potentially 
reportable 
N=8(13%) 
Normal on BAC and 
60K array and 
karyotype N=41 
(66%) 
Insufficient DNA in N=172 (after 
performing BAC array and 
Karyotype 
 Microarray Failed 
N=9 due to DNA 
quality 
60K performed (in 
addition to information 
from the BAC array) 
N=62 samples 
 
Legend: The above flow diagram account for all participants included in the 60K CMA cohort 
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Table 7 Structural anomaly using the Human Phenotype Ontology system 
 
Structural anomaly N= Percentage 
Single 66 93% 
Central nervous 
system 
16 22.5% 
Cardiovascular 
system 
13 18% 
Increased Nuchal 
Translucency>3.5mm 
 Or Cystic hygroma 
7 10% 
Musculoskeletal 
system 
10 14% 
Genitourinary system 9 12.5% 
Abdominal wall 
defect 
5 7% 
Head/face/neck 2 3% 
Respiratory system 1 2% 
Spina Bifida &/or 
encephalocele 
3 4% 
Multiple systems 5 7% 
 
Table 8 Sample type of those cases that had 60K CMA performed 
 
Sample type Sample number and 
percentage (n=71) 
Samples where CMA 
failed (%of those that 
failed n=9) 
Uncultured amniocentesis 6 (8.5%) - 
Cultured amniocentesis 7(10%) 1(11%) 
Uncultured Chorionic 
Villus Sampling 
3 (4%) 3 (34%) 
Cultured Chorionic Villus 
Sampling 
1 (1.5%) - 
Fetal Blood Sample (Pre-N) 18 (25%) 2 (22%) 
Fetal Tissue 22 (31%) 2 (22%) 
Umbilical Cord blood 
(Post-N) 
14 (20%) 1 (11%) 
Pre-N=Prenatal. 
Post-N=Postnatal. 
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Of the 71 prenatal samples obtained, in 9 the microarray failed due to the quality of 
the DNA remaining following the fore-mentioned tests. 62 samples therefore had 
both a postnatal 60K Oligonucleotide array as well as a the prenatal1Mb BAC array.  
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Figure 11 Tools to assess the pathogenicity of a copy number variant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copy number variant region:  
1) Seen in normal populations (DGV/ISCA/Local laboratory 
cohort) 
2) Common polymorphism >1% of population 
yes 
No 
OMIM morbid gene  
Decipher                                  CNV related to                           
ISCA 
 Pubmed                                   phenotype? 
* 
                                          
Yes 
Obviously 
related 
No Not 
Obviously 
related 
De Novo?  
De Novo?  
Likely 
pathogenic 
Yes1 
No but 
parent 
affected 
Likely 
pathogenic 
No 
Unaffected 
parent 
More detailed analysis 
yes 
More detailed analysis 
Benign 
No 
VOUS 
Likely 
Benign 
Phenexplorer 
http://compbio.charite.de/phenexplorer/ 
Top gene 
http://toppgene.cchmc.org/ 
STRING 
http://string-db.org/ 
Functional work 
VOUS no subclassification2,5,6,7 VOUS likely benign2,8,9,10 VOUS likely pathogenic2,3,4 
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Legend: The above figure is a flow diagram showing the process and tools available to assess the pathogenicity of a CNV.  If seen in normal populations or is 
a common variant with no phenotypic effect the CNV is defined as benign. If not it needs more detailed evaluation including Decipher, ISCA, OMIM and 
PubMed and may require parental evaluation. Further analysis uses the online tools Phenexplorer, Topgene and STRING to link phenotypes and genes 
included in the CNV.  
1
Penetrance and Expressivity of CNV is documented and well understood 
2
Each CNV will have unique considerations requiring clinical judgment 
3
CNV is described in a single case report but phenotype relevant to scan findings 
4
Gene within the CNV has compelling gene function relevant to the phenotype 
5
CNV contains genes, but genes are dosage sensitive or Haploinsufficiency scores <30% 
6
CNV genes with some evidence for biological links to phenotype 
7
CNV is contradictory in publications/databases, conclusions regarding significance are not established 
8
CNV is described in a small number databases of variation but is not a common polymorphism 
9
CNV contains genes but no firm biological links to phenotype 
10
The CNV is a duplication and contains unremarkable genes which have Haploinsufficiency scores of>30% 
*
X chromosome imbalances should
 
be treated as a separate entity because of differing dosage tolerance. X chromosome imbalances are also 
underrepresented in the database of genomic variation and internal data maybe more useful. Smaller imbalances are expected to have a more significant 
effect than their autosomal counterparts, and may be tolerated in female carriers due to X inactivation. 
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Results 
This chapter summarises a case-cohort of 62 “fetal” DNA samples that underwent 
both prenatal targeted BAC array and postnatal 60K array. My study noted that the 
higher resolution 60K array was able to detect all pathogenic CNVs detected by the 
targeted BAC array. This included three previously published resultsm(49)  including 
a case of 22q11.2 deletion (Di George syndrome), a deletion of 6q25.1q27 
(46,XX,del(6)(q25.1)dn) visible on both the BAC array and conventional G-band 
karyotyping and a rearrangement of chromosome 2 (46,XX,der(2)del(2) (p16.2p22.3) 
del(2)(q14.1q22.1)dn,t(5;6)(q22;p11)dn) again large enough to be seen by 
conventional G-band karyotyping. All three of these findings were pathogenic CNVs 
(pCNVs) and associated with the findings on fetal ultrasound scan.  
 
In addition to the chromosomal anomalies detectable by the Birmingham BAC array 
study (prenatally), the 60K array performed after the end of the pregnancy, also 
detected CNVs defined as either pathogenic or VOUS in a further 16 cases. Five of 
these were re-defined as VOUS (likely benign) (Table 9 cases 1,2,3,4,5).  The 
decision was made not to report these findings by a multidisciplinary discussion and 
review of the cases (between senior cytogeneticists, clinical geneticists and fetal 
medicine subspecialists). 
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In three cases pathogenic CNVs were detected by the 60K array (not previously 
noted with the prenatal microarray).   These included: 
 
i) Case 6: A de novo 47kb deletion of Xp22.2 in a female fetus with ventriculomegaly 
and agenesis of the corpus callosum. This deletion included the gene OFD1 
(orofaciodigital syndrome). Cases have been described with central nervous system 
abnormality and agenesis of the corpus callosum (which was also noted on post-
mortem examination of this case (55) (Table 9; case 6).  
 
ii) Case 7: A de novo 118kb duplication of Xp22.33 including the PQBP1 region 
causing Renpenning syndrome(56;57). This syndrome is linked to 
neurodevelopmental morbidity (mental retardation) and cardiac anomalies (Table 9; 
Case 7).  
 
iii) Case 8:  A 1.1Mb duplication on chromosome 17q25.3, found in addition to the 
deletion on 5q35.3 detected by the prenatal BAC array (and confirmed and further 
delineated by 60K array). This was from a maternally inherited unbalanced 
translocation. Given the size and gene content of this deletion/duplication and the 
fact that the mother suffered from dyspraxia and had mild facial dysmorphism, it was 
determined that this was a pathogenic finding, associative of the findings on scan 
(Table 9; Case 8).   
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A one sided Fisher’s exact test showed a non-significant difference in detection rate 
of pCNVs detected by the 60K platform compared with the BAC array 
(p=0.0605)(Appendix J). There is a chance this may be attributed to a small cohort 
undergoing the higher resolution array. 
 
However, the 60K array detected a further 8 cases in which the CNVs were 
classified as a VOUS and could not be redefined as either probable benign or 
pathogenic (Table 9; Cases 9-16). This represents 13% of the 60K cohort and there 
was a significantly increased frequency of VOUS detection with the 60K platform 
compared with the BAC array (One sided Fisher’s exact test p=0.0001)(Appendix J).  
 
VOUS detected included: 
 
i. Case 9).  A maternally inherited duplication 15q25.2 in a fetus with USS 
findings of exomphalos. No obvious link to the phenotype could be found but it 
could be a reciprocal variant of the 15q25.2 deletion cases with links to 
congenital diaphragmatic hernia and cognitive defects (58). 
 
ii. Case 10). A paternally inherited deletion 9q22.32 in a fetus with an absent 
femur on USS. Possible disruption of the homeobox gene BARX1 (expressed 
in proximal fore and hindlimbs) may have been implicated in the phenotype 
findings (59). 
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iii. Case 11). This case shows of the difficulty in interpretation when parental 
DNA is not available to interpret the CNV. This duplication on 22q11.22 in a 
fetus with USS findings of Dandy Walker syndrome is a VOUS without 
knowledge of parental inheritance. 
 
iv. Case 12).  Shows a paternally inherited duplication of 3q21.1 in a fetus with 
findings of fetal akinesia syndrome. Here there were no clear cut gene 
associations but the gene ADCY5 is associated with fetal growth 
abnormalities (60). 
 
v. Case 13). Here a 20Mb deletion 6q25.1-6q27 had been detected by 
conventional cytogenetics, the BAC array and the 60K array, and was 
interpreted to be pathogenic and causal of the Dandy Walker syndrome found 
on USS. In addition the 60K array found a 2Mb deletion at 8p21.1-p12 
containing many genes and may have contributed to the USS findings. 
 
vi. Case 14). A maternally inherited duplication at 1q21.1 in a fetus with USS 
findings of LUTO was found. This duplication covered the Thrombocytopenia 
and absent radius susceptibility region.  Although this fetus did not have any 
skeletal anomalies on postmortem examination and the CNV is not likely to 
have been causative of the phenotype. 
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vii. Case 15). A de novo duplication at Xq21.1 in a male fetus that had USS 
findings of an enlarged thickened bladder and lower urethral tract obstruction. 
This duplication included the gene ATRX (Alpha-thalassemia/MR syndrome) 
(61). This is an example of an X linked imbalance with disease associated 
gene but not related to the phenotype. 
 
viii. Case 16). A maternally inherited duplication of Xq13.3 in a male fetus with a 
lower limb abnormality. This duplication involved the gene KIAA2022 (linked 
to MR)(62) and again shows the difficulty in interpretation  of an X linked 
imbalance with disease associated gene but unrelated to the phenotype. 
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Table 9 Results of the 60K CMA cohort 
 
ID Chromosome Del 
/dup 
Phenotype on 
ultrasound 
Sampl
e type 
Inheritance Outcome of pregnancy Comments VOUS 
Class. 
1 arr 
11q25(133,244,
652-
133,842,923)x3 
pat 
Dup 
 
VSD 
Hypoplastic left 
heart 
CB Paternal Live Birth No obvious genes related 
to phenotype; may disrupt 
OPCML (Ovarian Cancer  
gene)(63) 
bCNV 
2 arr 
Xq21.31(89,444,
893-89,517,088) 
x1 mat 
male fetus 
Del Exomphalos 
Increased NT 
Enlarged lateral 
ventricles 
Hypoplastic 
cerebellum 
Enlarged cistern 
magna 
Tissue Maternal TOP 
PM available: 
Bilateral talipes 
Large omphalocele 
Thoracic hemivertebrae 
Anus atresia 
Cardiac hypoplasia 
Small bowel atresia 
Bent femur/tibia and 
humerus 
Renal agenesis 
No significant genes; 
inherited and seen in local 
cohort of postnatal cases 
 
bCNV 
3 arr  
6p22.3(20,740,9
83-21,162,532) 
x1 mat 
Del Skeletal 
dysplasia 
Tissue Maternal TOP 
PM available: 
Lethal skeletal dysplasia, 
short stature , large head 
and severe rhizomelic 
shortening of the limbs. 
Consistent with 
thanatophoric dysplasia 
type 1 
Deletion in CDKAL1; 
associated with diabetes. 
No evidence for 
association with structural 
anomalies (64) 
bCNV 
4 arr  15q11.1 
(20,787,768-
23,146,102)x1p
at 
Del Increased NT CB Paternal 
Note code 
Live Birth Common CNV associated 
with susceptibility to 
neurological conditions 
 
bCNV 
 
5 
arr 4q35.1 
(186,826,674-
187,139,541)x3 
mat 
 
 
 
 
Dup 
 
Truncus 
arteriosis 
FBS Maternal TOP 
PM unavailable 
Seen in low levels in DGV 
but also in local cohort. 
bCNV 
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6 arr  Xp22.2 
(13,769,563-
13,817,279)x1 
dn 
female fetus 
Del Ventriculomegal
y 
FBS De novo TOP 
PM available 
Confirmed hydrocephalus. 
Absent corpus callosum 
Absence of left uterine 
horn and fallopian tube 
OFD1 and GPM6B Female 
fetus 
OFD1 (Orofaciodigital 
syndrome) related to 
phenotype cases described 
with CNS abnormalities 
including agenesis of 
corpus callosum.(55)  
 
pCNV 
7 1)Xp11.23 
2)Xp22.33 
 
arr 
Xp11.23(48,699,
033-
48,818,269)x3 
mat 
 
arr 
Xp22.33(492,27
8-877,581)x3 dn 
Male fetus 
Dup 
And 
Dup 
Univentricular 
heart 
FBS Maternal TOP 
PM unavailable 
1)SHOX duplication 
2)PQBP1 region 
(TIMM17B, PQBP1, 
SLC35A2). Inherited but 
not a common CNV. 
Mutation of PQBP1 causes 
Renpenning 
syndrome(56;57)  Linked to 
MR and sometimes cardiac 
anomalies 
1) bCNV 
 
2)  pCNV 
8 1)arr 
5q35.3(178,791
009-
180696,777)x1 
mat and  
2)arr 
17q25.3(79,953
997-
81,044,524)x3m
at 
Del 
and 
dup 
EncephaloceleA
bsent corpus 
callosum 
Amnio Maternal  Live Birth 17q contains 32 genes 
(missed by BAC array) 
5q contains 41 genes 
(seen by BAC array) 
Gene list attached 
 
pCNV 
9 arr 
15q25.2(83,597,
474-
84,946,159)x3 
mat 
 
Dup Exomphalos CA Maternal Live Birth No Obvious link to 
phenotype found. Maybe a 
reciprocal variant of the 
15q25.2 deletion cases 
with links to congenital 
diaphragmatic hernia and 
cognitive defects 
VOUS: Uncertain(58) 
 
 
  
uCNV 
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10 arr 
9q22.32(96,698,
759-
96,946,777)x1 
pat 
Del 
 
Absent femur CB Paternal Live Birth Deletion of PTPDC1 no 
known interactions or 
associations. Possible 
disruption of BARX1 
(homeobox gene). Mouse 
Barx 1 is strongly 
expressed in areas of head 
and neck mesenchyme 
and in the wall of the 
developing stomach and  is 
expressed at weaker levels 
in the proximal fore- and 
hindlimbs.(59) 
uCNV 
11 arr 22q11.22 
(22,905,038-
23,720,200)x3 
?dn 
Dup 
 
Dandy Walker 
Agenesis corpus 
callosum 
meningeocoele 
FBS ? de novo 
(maternal 
sample failed 
QC) 
TOP 
PM available: 
Posterior fossa Dandy 
Walker Cyst 
Hydrocephalus 
Corpus callosum present 
Small defect in upper 
cervical spine 
22q11.22: ~50% overlap 
with benign CNV in DGV 
~50% more unique 
(includes BCR gene and 
little DGV here).  
 
uCNV 
without 
parental 
samples 
12 arr 
3q21.1(122,505,
327-
123,152,363)x3 
pat 
Dup Micrognathia 
Hemivertebrae 
Hydrothorax 
Clindodactyl 
 
Tissue Paternal TOP 
PM available 
Fetal hydrops 
Findings consistent with 
fetal akinesia most likely 
muscle in origin 
Not a common variant; no 
clear cut gene 
associations.  
ADCY5 associated with 
fetal growth (60) 
uCNV 
13 arr 
8p21.1p12(27,5
79,264-
29,765,976)x3 
?dn?pat 
Del Dandy Walker FBS ? de novo 
No paternal 
samples 
TOP 
PM unavailable 
~2Mb deletion including 
many genes 
Phenotype likely caused by 
concurrent 20Mb deletion 
6q25.1-6q27 detected also 
by BAC array 
 
 
 
 
 
 
 
 
 
uCNV 
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bCNV= likely benign VOUS  pCNV= likely pathogenic VOUS    uCNV=uncertain VOUS 
Del=deletion    PM = Post Mortem    
Dup=Duplication   TAR = Thrombocytopenia with absent radius     
MR = mental retardation  TOP = Termination of pregnancy 
NT= nuchal translucency
14 arr 1q21.1 
(143,700,200-
146,507,547)x3
mat 
Dup 
 
LUTO 
Dilated renal 
pelvis 
Anyhydramnios 
Fluid in 
abdominal cavity 
Tissue Maternal TOP 
PM Available: 
Findings of Wenstrup 
syndrome-
cloacamembrane 
abnormality 
Rectum agenesis, recto-
vesicular fistula, bicornate 
uterus 
Indifferent external 
genitalia 
Oesophagus atresia and 
trachea-oesophageal  
fistule 
No skeletal anomalies.  
Dup of the 1q21.2/TAR 
susceptibility region.  
Not likely causative of 
phenotype though.  
 
uCNV 
15 arr 
Xq21.1(76,921,0
53-
76,934,913)x3 
dn 
Male fetus 
Dup Enlarged thicken 
bladder ? lower 
urethral tract 
obstruction 
Amnio De novo Live Birth Including gene ATRX 
(Alpha-thalassemia/MR 
syndrome)(61) Example of 
X imbalance with disease 
associated gene but not 
related to phenotype 
uCNV 
16 arr 
Xq13.3(73,802,2
02-
73,878,653)x3 
mat 
Male fetus 
Dup Lower limb 
abnormality 
Amnio Maternal  TOP 
PM available: 
Missing fibula 
Short bowed tibia 
Three toes bialterally 
Partial duplication involving 
gene KIAA2022 (linked to 
MR) (62) 
uCNV 
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Discussion 
 
To summarise, this prenatal cohort of 62 samples are the only reported series to 
have undergone two different platform of arrays of different resolutions on the same 
proband. This has allowed us to directly compare the effects of increasing array 
resolution on both the pathogenic detection rates but also the rate of VOUS.  
 
It is conceded that a degree of non-specific selection bias occurred as cases were 
selected because of the availability of fetal DNA (26% of total prenatal cohort).  
However, this sub-cohort of babies with congenital malformations appeared 
representative of the whole cohort.  My study noted that the higher resolution 60K 
array was able to detect all pathogenic CNVs detected by the targeted BAC array. 
The BAC cohort study (Chapter 2) suggests that using this “targeted” array platform 
in a prenatal population of fetuses with congenital malformations on USS would give 
a pathogenic CNV rate over and above conventional G-band karyotyping of 4.1% 
(95%CI 2.1-7.6)% (n=10 cohort size 243). However this array would only give a 
VOUS rate of 0.4% (95% CI 0.07-2.2) (n=1 cohort size 243) (49).  Other studies in 
the literature, most notably the NICHD study (65), using a 44K array platform, noted 
that CMA analysis revealed clinically relevant deletions or duplications in 6.0% with a 
structural anomaly noted, higher than the prospective Birmingham BAC array cohort. 
However, VOUS rates were also correspondingly high. 
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In this comparative cohort study, when I used the higher resolution 60K array 
platform on 62 of the same fetal samples, a higher detection rate of additional 
pathogenic CNVs (4.8%(95% CI 1.6-13.3 n=3) was detected over and above BAC 
array and 9.6%(95%CI 4.5-19.5% n=6) over and above conventional G-band 
karyotyping. This was, however, not a significant increase (One-sided Fisher’s exact 
test p=0.06). However, in line with previous literature, VOUS rates were significantly 
higher at 21% (95%CI 12.7-32.6) (n=13 cohort size 62) (49). When systematic 
analysis of the VOUS occurred, this was lowered to 13% (95%CI 6.7-23.4) (n=8 
cohort size 62), with 5 of the VOUS being reclassified as VOUS  “likely benign”, but 
still showed a highly significant increase in VOUS from the BAC array (One-sided 
Fisher’s exact test p=0.0001). 
 
These observations demonstrate that higher resolution microarray platforms are 
associated with higher detection rates of true pathologic CNVs, but also the higher 
the rate of VOUS. These observations are relevant as qualitative evidence from the 
NICHD study has shown that reporting of VOUS in the antenatal period can be 
considered “toxic knowledge”, and that it raises women’s anxiety levels and 
potentially psychological morbidity in pregnancy, and that this continues  after their 
child is born (66). 
 
Currently there is no guidance either nationally or internationally regarding the 
reporting of VOUS to women and their partners in the antenatal period. One may 
have the view that the  reporting of VOUS in the antenatal period should be at the 
very least ‘guarded’ and many would argue that this information should not be 
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divulged. This is further complicated as classification of CNVs is often not 
straightforward and a spectrum of “uncertainty” can be attributed to particular CNVs. 
There will therefore be likely disagreements between clinicians, scientists and 
patients themselves as to what constitutes enough evidence to make reporting of the 
CNV in the best interests of the woman and her partner. The decision as to report 
should ideally be taken by multidisciplinary consensus rather than decision being 
made by one group alone. 
 
 
 
 
 
 
Submitted manuscript from Chapter 3 
The following manuscript from chapter 3 has been published: 
Hillman SC, McMullan DJ, Silcock L, Maher ER, Kilby MD. 
How does altering the resolution of chromosomal microarray analysis in the prenatal 
setting affect the rates of pathological and uncertain findings? 
J Matern Fetal Neonatal Med 2013; Aug 19. 
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CHAPTER 4 UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS 
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Introduction 
In Chapter 1 the literature up until 2009 was systematically reviewed and meta-
analysed where possible. Between December 2009 and December 2012, and over 
the period of the Birmingham BAC and 60 K cohorts, other large prospective cohorts 
have been published adding to the literature. In this chapter I sought to bring the 
literature at the end of the study up to date and to also include data taken from my 
own Birmingham BAC Cohort and then more contemporary cohorts using a 60k or 
high resolution ‘platform’, as recent additions to the literature. This provides the most 
complete and up to date critical appraisal of the literature looking at the use of 
prenatal CMA use firstly for any indication and secondly when the indication is an 
abnormal scan finding (with a congenital malformation). It also provides the most 
complete analysis on VOUS rates and how they vary between indications and types 
of ‘platform’ for CMA (49).  
 
Method 
The systematic review followed a prospective protocol developed using widely 
recommended and comprehensive methodology (32). This was done by framing the 
question for review in this case “In the prenatal setting how much extra information, 
regarding chromosomal anomalies, does CMA provide over traditional karyotyping in 
cases where both tests are performed?”.  And in addition to this question “In a 
prenatal setting what is the detection rate of Variants of Unknown Significance when 
CMA is performed?”.  Secondly the relevant literature was identified as described 
below, thirdly that the quality of the literature was assessed using recognised tools 
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as described below. Fourthly that the evidence was summarised and meta-analysed 
if appropriate. Finally that the findings were interpreted and discussed.  
 
Data sources 
The search focused on prenatal studies using microarray technology. A research 
strategy was developed based on existing advice for prevalence searches (67). 
Medline (January 1970 to December 2012), Embase (January 1980 to December 
2012) Cinhal (January 1982 to December 2012) and clinicaltrials.gov databases 
were searched electronically. The search of MEDLINE and EMBASE captured 
citations containing the relevant MeSH keywords and word variants for “microarray” 
and “prenatal”. The following terms were used to describe microarrays: microarray, 
DNA microarrays, array comparative genomic hybridisation, array CGH. Similarly, 
antenatal diagnosis, prenatal and fetal, were used to capture “prenatal”. 
Bibliographies of relevant articles were manually searched to identify papers not 
captured by electronic searches. Experts were also contacted for completeness 
(36;51;68). There were no language restrictions in the search or selection of papers.  
 
Eligibility criteria for selecting studies 
Studies were selected in a two-stage process. Initially all abstracts or titles were 
scrutinised by two reviewers (myself and Dr César Meller, a visiting Fetal Medicine 
Sub-speciality Fellow) and full manuscripts of potentially eligible citations were 
obtained. Studies were included if chromosomal microarray had been used on 
prenatal specimens (analysed during pregnancy or after delivery). The CMA may 
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have been performed for any referral indication not just because there were 
abnormal findings on fetal ultrasound scan. Papers were excluded if microarray was 
not performed on prenatal acquired samples, if they were performed for pre 
implantation diagnostics or if they were performed for recurrent miscarriage. Finally 
papers were excluded if they used the CGH technique (the precursor to CMA) and 
not array CGH/chromosomal microarray. Non-English studies were assessed by 
someone with a command of the relevant language if the title or abstract appeared to 
fit the criteria. Only papers that allowed generation of a 2x2 table comparing the 
outcomes of CMA against the outcomes of conventional karyotyping were included.  
 
Data was extracted by two reviewers (myself and Dr César Meller). Differences were 
resolved by discussion with a third reviewer (Professor Mark Kilby). The author Dr 
Ron Wapner (RJW) also gave us information on the National Institute of Health’s 
(NIH) cohort study prior to the data being published in the public domain, and also 
gave an accompanying explanation (65). For each of the outcomes data were 
extracted into tables giving descriptive and numerical information for each study. 
Data were extracted on study characteristics and data quality. Data were used to 
construct 2x2 tables of test accuracy comparing normal and abnormal microarray 
results. Case studies of fewer than 10 cases were excluded from the meta-analysis. 
 
Quality assessment and data synthesis 
Study quality was assessed using STrengthening the Reporting of OBservational 
studies in Epidemiology (STROBE) (37). Microarray results were considered to be 
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“positive” if they had VOUS (and therefore potentially pathogenic) or pathogenic 
results. Benign results were included in the CMA “negative” group as they are not 
clinically relevant and would not be reported to clinicians or patients.  
 
These data were further broken down to repeat the same analysis but when the 
clinical indication for CMA was a structural abnormality seen on ultrasound scan. 
Using 2x2 tables, I computed and pooled the percentage agreement between the 
two technologies (both for any clinical indication and for abnormal ultrasound scan) 
with 95% confidence intervals. The calculated percentage of extra cases identified 
by microarray in those with a negative karyotype (both for any clinical indication and 
for abnormal ultrasound scan) with 95% confidence intervals was calculated and 
pooled (Appendix J). Conversely, I then calculated and pooled the percentage of 
extra cases identified by karyotyping in those with a negative microarray result (both 
for any clinical indication and for abnormal ultrasound scan) with 95% confidence 
intervals. Finally I calculated and pooled the percentage of cases in which a result of 
VOUS was reported. Heterogeneity in rates was examined graphically and 
statistically (Chi-squared test) (Appendix J).  For graphical assessment, “Forest 
plots” of point estimate of rates and their 95% CI’s were used. For exploration of 
reasons for heterogeneity, stratified analysis was performed according to the year of 
publication. A random effects model was used in the light of heterogeneity. All 
statistical analyses were performed using Stata 11.0 statistical software (Stata Corp., 
College Station, Texas, USA). 
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Results  
Literature identification and selection 
The process of literature identification and selection is summarised in Figure 12. In 
addition to these data from my cohort, there were 25 primary articles that met the 
selection criteria (21;38;39;41-45;51-53;65;68-80) (16 not included in my previous 
2009 meta-analysis, prior to embarking upon my Birmingham BAC study (51-
53;65;68-80)). 22 cohorts (including my own cohort study) were included in the meta-
analysis and four were excluded as either microarray was only performed when an 
abnormal karyotype had been detected (21;41) or because I could not extract data 
required for a 2x2 table (36,70). In all 25 cohorts the collective number of samples 
analysed was 17,113. The meta-analysis was then performed using the same 
cohorts but additionally adding data taken from my 60K cohort (26 cohorts in total, 
collective number of samples analysed is 17,175). In the case of Fiorentino et al the 
paper published in 2012 (69) contains data from their publication in 2011(52). I was 
able to extract data from the 2012 paper to look at CMA detection over full 
karyotype. However the 2011 publication is used to look at overall agreement 
between the two tests, VOUS rate and karyotype over CMA rate as this was not 
extractable from the 2012 publication. 
 
Study Characteristics  
Table 10 summarises the study characteristics including the study design, 
microarray type, sample type, indication for sampling and sample size. Figure 13 
shows the quality assessment of papers included. 
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Figure 12 study selection process for updated systematic review 
Total Citations from electronic searches  
Medline n=116 
Cinhal  n=32 
Embase n= 404 
Clinical trials.gov n=1 
Experts n=6 
Own study n=1 
Total n=560 
 
     
 
 
 
                                 
 
 
                   
           
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Legend: The above flow diagram accounts for all journal articles reviewed during the process of the 
systematic review
Number excluded after screening abstract   
n=460 
Duplications removed n=14 
Studies retrieved for detailed evaluation 
n=86 
Searching of relevant lists:  
Hand n=8 
Studies excluded: n=69 
Used cell lines n=6  
Not able to  distinguish if prenatal or 
abortion material n=1  
Not able to  construct 2x2 tables n=7  
postnatal/child n=4  
Only assessing  trisomy , 13, 18 and 21  
n=3 
Detecting mosacism only n=1 
No microarray used n=13  
No data n=9 
Not relevant n=10 
Presented conference full data not 
available n=15 
 
Studies included in systematic review: 25 
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Table 10  Study Characteristics of studies included in the systematic review 
 Author Year Design Array type Whole 
genome 
(WG) 
/targeted 
genome 
(TG) 
Sample Type Indication for 
array 
Sample 
Size 
1 Le 
Caignec  
C et al 
(42) 
2005 Retrospective Genosensor 
BAC/PAC array 
300 
(Vysis/Abbott) 
 
 
TG Frozen fetal  
tissue 
All normal 
karyotype 
All had 
malformations 
All had at least 3 
anomalies in 
CVS/urogenital/ 
digestive/CNS 
49 
2 Rickman L 
et al (41) 
2006 Retrospective BAC/PAC 
resolution 10Mb   
common 
microdeletion 
syndrome  
 
TG Cultured 
amniocytes or 
Chorionic 
Villus 
Sampling  
 
Previously known 
karyotypes 
All known 
unbalanced 
rearrangements 
30 
 
3 Sahoo T 
et al (38) 
2006 Prospective BCM v4.0  
 
Baylor 
 
 
 
TG Amniotic Fluid 
=56 (26 
uncultured) 
Chorionic 
Villus 
Sampling =42 
(32 
uncultured) 
Increase maternal 
age 
Increased serum 
screen 
Family history 
Abnormality on US 
 
98 samples 
total 
 
93 
 
4 De 
Gregori   
M et al 
(21) 
2007 Retrospective 60-mer 
oligonucleotide 
microarray 
WG Does not state Reciprocal 
translocations=14 
Maternal age =3 
17 
5 Bi W et al  
(39) 
2008 Prospective BCM V6 
Oligonucleotide 
array (V6 Oligo) 
(Agilent) 
 
 
WG and 
TG 
Amniotic fluid Maternal age =6 
Anomaly on US= 5 
Family History 
abnormality =2 
multiple 
miscarriages=1 
14 
pregnancies 
15 fetuses 
 
6 Vialard F 
et al (45) 
2009 Prospective Genosensor 
BAC/PAC array 
300 
(Vysis/Abbott) 
 
 
TG Muscle biopsy 
=15 
Lung 
Biopsy=13 
Thymus = 4 
Skin = 3  
Liver = 3 
Bladder = 1 
2 or more 
abnormalities 
cardiovascular/urog
enital/skeletal/diges
tive/CNS 
39 
7 Tyreman 
M et al  
(43) 
2009 Retrospective Genechip SNP 
6.0 array 
(Affymetrrix) 
 
WG Amniotic fluid 
=87 
Chorionic 
Villus 
Sampling =15 
Placenta 
biopsy 
following  
termination of 
pregnancy =4 
 
 
Ultrasound 
anomaly: 
(Cardiac = 34 
Multisystem = 24 
Large 
NT/hydrops/CH = 
18 
CNS 16 
Skeletal = 6 
Abdominal wall = 2 
Others = 6) 
106 
94 
 
8 Kleeman L 
et al (44) 
2009 Prospective Signature 
prenatal chip V 
4.0 26 patients 
 
Signature whole 
genome chip 
 
 
 
TG 
 
 
 
WG 
Amniotic fluid 
= 47 
CVS = 3 
Abnormal 
ultrasound scan 
and normal 
karyotyping: 
(Cardiac =24 
CNS = 6 
Skeletal = 6 
Urogenital = 4 
Cleft lip/palate = 2 
CH/NT/hydrops = 3 
GI = 2 
Multiple = 17 
Growth disorder=3) 
50 
9 Maya I et 
al (72) 
2010 Retrospective 236 used 
signature chip 
whole genome 
V1.0-2.0/BCM 
BAC 
chromosomal 
microarray V5 or 
6 
19 samples used 
oligo 105K whole 
genome array or 
BAC V5.0-6.0 
WG Amniocentesis 
= 243 
CVS = 16 
Unknown=10 
AMA=61 
AUS=102 
FIS=43 
AFK=15 
PA=46 
MSS=2 
269 
10 Faas BH 
et al (73) 
2010 Retrospective Affymetrix 
Genechip 250k 
SNP array 
WG Amniocentesis 
= 28 
CVS=3 
Blood=5 
Fibroblasts=2 
AUD =32 
AFK=4 
FIS=1 
Karyotype not 
possible =1 
35 
3 excluded 
as no 
karyotyping 
performed 
95 
 
11 Park JH et 
al (80) 
2010 Prospective Customised M-
chip MacArray 
TG Amniocentesis 
=94 
AMA=42 
MSS=38 
AUS=12 
FIS=2 
ICSI=6 
Rubella=1 
Other=3 
93 
1 excluded 
as no 
karyotype 
12 Evangelid
ou P et al 
(75) 
2010 Prospective Cytochip focused 
constitutional 
(Blue Gnome 
Cambridge) 
WG Amniotic 
fluid=16 
Chorionic 
villi=9 
AUS=15 
AFK=10 
25 
13 Valduga M 
et al (76) 
2010 Retrospective Agilent 44k 
oligonucleotide 
array 
WG FBS=26 
Tissue=21 
Cultured 
amniocytes=2 
Cultured 
chorionic 
villi=2 
Fetal anomaly  50 
14 Fiorentino  
F et al 
(52) 
2011 Prospective Cytochip focused 
constitutional 
(Blue Gnome 
Cambridge) 
WG Amniotic 
fluid=919 
CVS =99 
Cultured cells 
in AF =15 
Uncultured 
cells in AF= 4 
AMA=444 
MSS=13 
AUS=48 
AFK=8 
FIS=11 
PA=484 
Cell culture failure 
=4 
1029 
Although 
1037 arrays 
performed 
only 1030 
karyotypes 
performed 
and 1 case 
of false 
positive 
excluded 
 
Used in 
meta-
96 
 
analysis For 
abnormal 
karyotype 
over array 
and VOUS 
15 Park SJ et 
al (74) 
2011 Not stated Customised 
MacArray Karyo 
1440 BAC-chip 
WG Amniotic fluid 
=4033 
Chorionic 
villus = 40 
 
FIS 
AMA 
AUS 
MSS 
PA 
4073 
prenatal 
(postnatal 
excluded) 
16 Leung TY 
et al (77) 
2011 Retrospective Fetal DNA 
chip(44K) Agilent 
technologies 
TG Chorionic villi Increased NT>3.5 47 (1 
excluded as 
result not 
validated) 
17 D’Amours 
G et al 
(53) 
2011 Prospective Signature chip 
WG v1.0.1 
Nimblegen CGX-
12 
Signaturechip 
oligo solution v1.1 
Signaturechip 
oligo solution v2.0 
WG Amniocentesis 
=30 
Chorionic 
villus=4 
Cord blood=2 
Placenta =2 
Tissue =11 
AUS 
 
49 
18 Schmid M 
et al (71) 
2012 Prospective Affymetrix SNP 
array 6.0 
WG Amniocentesis 
=11 
Chorionic 
villius=1 
Cardiac anomaly 12 
19 Lee CN et 
al (51) 
2012 Prospective 1MB BAC=2497 
followed up by 
105K 
oligonucleotide 
60K 
oligonucleotide  
WG Chorionic villi 
=16 
Cultured 
chorionic 
villi=66 
Uncultured 
AMA=1911 
PA=989 
AUS=194 
AFK=51 
MSS=25 
194 
97 
 
amniotic fluid 
=19 
Cultured 
amniotic fluid 
=2977 
Cord blood=93 
20 Breman A 
et al (70) 
2012 Retrospective BCM V4, V%, V6 
BAC arrays 
n=282 
All others client 
customised 
oligonucleotide 
array 
TG/WG Amniotic fluid 
=840 
Chorionic 
villus =273 
Cystic 
hygroma fluid 
n=1 
Fetal blood = 1 
AUS =410 
AMA= 394 
FIS=137 
AFK=61 
MSS=37 
PA=61 
Other=4 
Not provided =12 
1116 
Unable to 
draw 2x2 
table not 
included in 
meta-
analysis 
21 Srebniak 
MI et al 
(78) 
2012 Prospective HumanCytoSNP-
12Array Illumina 
WG Not stated AUS 207 
22 Armengol 
L et al (79) 
2012 Prospective BAC TG Chorionic 
villus=164 
Amniocentesis
= 728 
Fetal blood=14 
 
AUS=173 
MSS=235 
HIS=145 
AMA=273 
PA=60 
Other = 20 
906 
23 Fiorentino 
F et al 
(69) 
2012 Prospective Cytochip focused 
constitutional 
(Blue Gnome 
Cambridge) 
TG Amniocentesis
=2660 
Chorionic 
villus = 308 
Cultured 
amniocytes = 
32 
 
AUS=95 
AMA=1118 
PA=1675 
AFK=25 
MSS=29 
FIS=25 
Cell culture failure 
=33 
3000 
 
Used in 
meta 
analysis for 
abnormal 
karyotype 
over array in 
98 
 
 abnormal 
scan results 
24 
 
 
 
 
 
Wapner R 
et al (65) 
 
 
 
 
2012 Prospective 44k 
oligonucleotide 
array customised 
Affymetrix SNP 
6.0 masked to be 
equivalent of 44K 
WG Chorionic 
villus sampling 
=2209 
Amniocentesis
=2073 
AMA=1085 
MSS/AUS/FIS/PA 
Mosaicism 
excluded 
4282 
25 Shaffer 
LG et al 
(68) 
2012 Retrospective Signature 
prenatal chip V 
4.0 
 
 
 
 
 
 
 
 
 
Signature Chip 
Whole Genome 
 
TG 
 
 
 
 
 
 
 
 
 
 
WG 
Cultured 
amniocytes = 
3269 
Amniocytes = 
343 
Cultured 
chorionic villus 
= 854 
Chorionic 
villus = 63 
Fetal blood = 
25 
Products of 
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AFK=Abnormal fetal karyotype 
AMA= Advanced maternal age 
AUS=Abnormal UltraSound findings 
BAC=Bacterial Artificial Chromosome 
BCM=Baylor College of Medicine 
CH = Cystic hygroma 
CNS= Central Nervous System 
CVS=Chorionic Villus Sampling 
FIS=Family history of genetic condition 
GI = Gastrointestinal 
ICSI= Intracytoplasmic sperm injection 
IUGR = Intrauterine growth restriction 
MCA = Multiple congenital abnormalities 
MSS=Abnormal maternal serum screening 
NT = Increased Nuchal translucency 
NF = Nuchal Fold 
PA = Parental anxiety 
SUA = Single Umbilical Artery 
TG=Targeted array 
WG=Whole Genome array 
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Figure 13 STROBE quality assessment of included figures 
  
 
 
 Legend: STROBE is used to assess the quality of the papers included in the systematic review 
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Results 
Chromosomal testing for any clinical indication 
When microarray and conventional karyotyping were performed for any clinical 
indication (details in Table 10) the overall agreement between the two tests was good 
93.4% (95% CI 90.4-96.5), these data were heterogeneous (Chi2 p=0.017). 21 
cohorts out of the 23 included in the meta-analysis were used here. Two were 
excluded as the information could not be used to extract a 2x2 table (51;69). In the 
Birmingham BAC cohort study the results used were where the G-banding karyotype 
analysts had been blinded from the microarray results.  
 
I attempted to meta-analyse the rate of CMA detection over karyotyping. However 
when the referral indication was taken into account (various) the results were highly 
heterogeneous (Chi2 p=0.00) with CMA detection over karyotyping ranging from 
0.4%-50%. Four papers seemed to contribute disproportionately to the ‘high’ 
heterogeneity of these data. In three cases this can be explained by small samples 
size (D’Amours et al n=49, Schmid et al n=12 Faas et al n=35) and is likely not to be 
representative of the true detection rates by CMA (53;71;73). The fourth paper used 
a high resolution CMA (Affymetrix SNP 6.0) but did not use parental samples to 
follow up results of unknown significance therefore presenting a unusually high 
detection rate by CMA (43).  
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Even when I performed a sensitivity analysis by removing these four papers the 
detection rate of chromosomal imbalances detected by CMAs over karyotyping was 
still unexplained (Chi2 p=0.00). I therefore felt a pooled result would be misleading. 
Although heterogeneous all cohorts showed a positive result with CMA finding 
chromosomal abnormalities over and above standard G-band karyotyping. 
 
Conventional karyotyping detected an extra 0.6% (95%CI 0.2-1.6%) abnormality rate 
when microarrays were normal. These data are also heterogeneous (Chi2 p=0.00). 
Eight papers were excluded from this meta-analysis (42-44;53;69;71;76;77) as 
microarray analysis was only performed on samples that had a known normal 
karyotype by G-band analysis.  
 
The rate of VOUS was 1.4% (95%CI 0.5-3.7%) when samples were analysed for any 
indication. The meta-analysis was performed using VOUS rates from 17 cohorts. In 
the cohort from Wapner et al the reclassified VOUS rate from 2012 was meta-
analysed (65). In 4 papers the VOUS rate could not be extracted (69;74;75;80). The 
Tyreman et al  paper was excluded from this analysis as parental samples were not 
tested in order to reclassify results as benign or pathogenic, leaving a 
disproportionate proportion of VOUS 25. I excluded the Hillman et al cohort as by 
using a targeted array the VOUS rate was low (0.4%) in comparison to other cohorts 
but it did not change this meta-analysis significantly; 1.5% (95% CI 0.5-4.2%). 
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Sub group analysis by date of publication for any clinical indication 
In order to see if I could account for the heterogeneity within the meta-analysis, 
publications were subdivided into those published in 2009 or before and those 
published after 2009. Publication from 2009 or before had a lower detection rate by 
microarray over karyotyping compared with 2010-2012 publications but both 
analyses were still heterogeneous (Chi2 p=0.00).    
 
Addition of 60K data 
The analysis examining CMA detection rates over full, conventional, karyotyping  
(when testing performed for any clinical indication) was then repeated adding data 
from the 60K cohort This is the cohort presented in Chapter 3 and contains 62 
samples (19%) of the original Birmingham BAC cohort presented in Chapter 2. The 
data was still heterogeneous so a pooled meta-analysed percentage is not presented 
but the additional cohort within the forest plot is presented in Figure 14. 
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Figure 14 Forest plot of percentage of chromosomal anomalies found by CMA 
over karyotyping including 60K cohort all indications for testing 
 
 
Legend Figure 14: Forest plot showing the amount of extra information (in terms of 
chromosomal abnormalities) detected by CMA over karyotyping for ant referral 
indication. In theis case the data was too heterogenic to perform a meta-analysis  
 
 
Author, Year Percentage (95%CI) 
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Figure 15 Funnel Plot looking at publication bias for CMA detection over 
karyotyping when referral was for any indication 
 
There was no significant publication bias present confirmed by Egger test P = 0.6646 
However Funnal plot represented by Figure 15 above does show a tendency to 
publication bias as there is a lack of small trials with a small treatment effect.  
 
I noted an increase in the number of VOUS as the detection rate by CMA increases 
(i.e. as the resolution of the array increases). For all papers published from 2010 
onwards I performed a Spearman’s rank correlation looking at the association 
between the overall detection rate by CMA and VOUS rate. For these 12 publications 
((53;65;68;71-73;76-79)) Spearman's rank correlation coefficient (Rho) = 0.809108 (P 
= 0.0012  (H1: positive correlation). This shows a significant positive relationship 
between the increase in VOUS rate and the overall detection rate by CMA.  
Precision 
Treatment effect (Log (odds ratio)) 
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Abnormal ultrasound scan findings 
Data from 16 cohorts plus my own were used to compare conventional karyotyping to 
microarray when the indication was the detection of a suspected structural 
abnormality on ultrasound scan (39;42-45;52;53;65;68;69;71;73;75-79). Here the rate 
of detection by CMA over full karyotyping is 10% (95%CI 8-13) (Figure 16) (Chi2 
p=0.00).  Again I excluded the Hillman et al cohort to see if it would have a significant 
effect on the meta-analysis rate which it did not at 10.5% (95%CI 8.4-13.1%). This 
means that the results from the Birmingham BAC cohort were not an “outlier” and are 
in keeping with other recently published cohorts. 
 
Conventional full karyotype detected only 0.8% (95%CI 0.2-2.4%) more 
chromosomal abnormalities than microarray using data from 9 cohorts plus my own 
(39;45;52;65;68;73;75;78;79), the main examples being balanced rearrangements 
and triploidy.  Both analyses were heterogeneous (Chi2 p=0.00).    
 
The VOUS rate was meta-analysed using data from 16 cohorts (39;42-
45;53;65;68;71;73;75-79). When indication for testing is an “abnormal scan” the 
VOUS rate is 2.1% (95%CI 1.3-3.3), higher than the meta-analysed rate of 1.4% for 
any indication. Exclusion of the Hillman et al cohort did not change this meta-analysis 
significantly at 2.3% (95%CI 1.5-3.5%).  
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Figure 16 Forest plot showing percentage of chromosomal anomalies detected 
by CMA over karyotyping when indication is abnormal ultrasound scan 
 
Legend: Forest plot showing the extra information (in terms of chromosomal abnormalities) detected 
by CMA over karyotypingwhen the indication is abnormal ultrasound scan. Here the meta-analysed 
rate is 10%(95% CI 7.9-12.5). 
 
 
 
 
 
Author, Year Percentage (95%CI) 
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Figure 17 Funnel plot for publication bias when referral for testing was for 
abnormal findings on fetal ultrasound. 
Bias assessment plot
0 1 2 3 4
0.6
0.4
0.2
0.0
Log(odds ratio)
Standard error
 
There was no significant publication bias as confirmed by Egger test 0.7221 (Forest 
plot represented by Figure 17). The funnel plot above also shows no evidence of 
publication bias. 
 
 
 
 
 
 
 
Precision 
Treatment effect (Log (odds ratio)) 
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Sub-group analysis by date of publication for abnormal ultrasound scan 
findings 
Given the increasing resolution of CMA over time and the heterogeneity present in 
the meta-analysis, I performed sub-group analysis by date of publication when the 
indication for CMA was abnormal USS findings. 2011-2012 saw the publication of 
many larger cohorts of fetuses having CMA for abnormal USS findings 
(52;65;68;69;77-79). In this sub analysis two papers were removed. Schmid et al (78) 
had a 50% detection rate by CMA over Karyotyping, partly due to a very small 
sample size (n=12), a high resolution array (SNP 6.0 Affymetrix) and no evidence 
that parental samples were analysed to see if the CNV was de novo. This paper was 
therefore excluded. The second paper to be excluded was D’Amours (53). It also was 
an outlier having a detection rate by CMA of 20.4% over full karyotyping. This was in 
part due to a smaller cohort size (n=49) and the use of 4 custom-designed arrays. 
 
Sub-analysis of the remaining 7 cohorts (included Hillman et al, 2013) still gave a 
heterogeneous outcome statistically (Chi2 p=0.00) but the graphical representation 
(Figure 18) shows the analysis to appear more homogeneous than previously 
discussed (Figure 16).  This sub-analysis using cohorts published between 2011 and 
2012 demonstrates that the detection rate by CMA for an “abnormal ultrasound” scan 
finding appears to be 7% (95% CI 5 -10) over conventional karyotyping. I believe this 
to be a more accurate detection rate when performing CMA for abnormal scans.  
 
 
110 
 
 
Figure 18 Forest plot of percentage detection of chromosomal anomalies by 
CMA over karyotyping when the indication is an abnormal ultrasound scan 
2011-2012 
 
Legend: Forest plot showing the amount of extra information gained by CMA over 
karyotyping when the indication is an structural anomaly found on prenatal 
ultrasound. Studies included are those published between 2011-2012. CMA detected 
7.2% (95% CI 5.4-9.8) over karyotyping. 
 
 
 
 
Author, Year Percentage (95%CI) 
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Addition of 60K array 
The analysis looking at CMA detection rates over karyotyping when testing for 
abnormal fetal ultrasound findings was then repeated, adding data from the 60K 
cohort. (Figure 19). This increase the detection rate by CMA over karyotyping to 
8.3% (95%CI 6.2-11.2). 
Figure 19 Forest plot percentage of chromosomal anomalies detected by CMA 
over karyotyping 2011-2012 including 60K cohort 
 
Legend: Forest plot showing the amount of extra information gained by CMA over 
karyotyping when the indication is an structural anomaly found on prenatal 
ultrasound. Studies included are those published between 2011-2012 including our 
60K. CMA detected 8.3% (95% CI 6.2-11.2) over karyotyping. 
 
Author, Year Percentage (95%CI) 
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Targeted FISH 
Using eight cohorts (seven other cohorts plus my own) it was possible to analyse the 
detection rate of 22q microdeletion (Di George) syndrome, if FISH were used instead 
of CMA for samples that had been sent for testing due to a fetal cardiac anomaly 
(43;44;51;68;71;73;78). Meta-analysis revealed a 4% (95%CI 1-10) detection rate of 
a 22q microdeletion in those samples requesting testing due to a fetal cardiac 
anomaly. This would imply a similar level of detection by microarray (for any clinical 
indication) across the genome compared with clinician request for specific FISH 
probes based on the prenatal phenotype.  
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Discussion 
Results from my prospective, case cohort BAC study found that chromosomal 
microarray had an increased detection rate over conventional karyotyping in 4.1% of 
cases (10/243) (Chapter 2) when a fetal abnormality was suspected on ultrasound 
scan. This is lower than the reported literature to date, with a meta-analysed rate of 
10%. Our group chose to use a purposefully conservative microarray design for 
prenatal diagnosis at the time of inception of the project. This was to limit, in theory, 
the amount of parental follow up required and VOUS detected.  
 
Our referring region within the United Kingdom also has a high number of 
consanguineous families. According to the UK Census 2001, 13.5% of Birmingham 
residents are Asian (66,085 UK Pakistanis) compared to 3.5% in the whole of the 
UK. The prospective Birmingham Births study by Professor Bundey and colleagues 
(81;82) established that the high neonatal and childhood mortality observed in West 
Midlands families of Pakistani origin is mostly attributable to recessive inherited 
disease. Approximately 75% of Pakistani marriages in the West Midlands were 
consanguineous (in many cases the degree of consanguinity is higher than first 
cousin equivalents) and there was a 1 in 10 risk of serious genetic disease in the 
children of these consanguineous unions. This may have lowered the detection rate 
by CMA as the actual cause of the scan findings may be autozygosity associated 
with a single gene autosomal recessive condition, undetectable by CMA platforms 
not containing SNP probes.  
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The meta-analysis rate of 10% may also have been raised by inclusion of some 
studies with artificially elevated detection rates (due to small cohort numbers, not 
testing parents for inherited CNVs and high VOUS rates) (43;53;71). The sub-
analysis using papers between 2011and 2012 showed a detection rate by CMA of 
7% which I believe is closer to the actual rate detected by CMA over full karyotyping 
using up to date microarray platforms, although addition of the 60K data increased 
this to 8.3%, in part due to the increased VOUS detected in this cohort (see Chapter 
3). 
 
The Birmingham BAC Study’s lower detection rate cannot be solely attributed to the 
targeted nature of the BAC array as other studies using the same array (Fiorentino 
and Lee (51;69) reported detection rates above karyotyping of 6.3% and 8.2% 
respectively) have shown higher detection rates. However both of these studies 
report chromosomal differences >10Mb in size missed by CMA. I conclude that the 
high quality preparations for full G-band analysis available in our laboratory have also 
contributed to the lower detection rate by CMA above conventional karyotyping.  
 
This meta-analysed result further strengthens the evidence for the use of microarray 
technology for this particular prenatal indication. When microarray is performed for an 
abnormal scan (suspected congenital malformation) the VOUS rate is higher (2.1%) 
than when performed for any indication (1.4%). This is likely to be due to the 
increased chromosomal pathology (pathogenic CNVs) within this sub-cohort. With 
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time some of the VOUS detected will be redefined as benign but some will also be 
reclassified as pathogenic variants.  
 
The systematic review and meta-analysis of outcomes was performed in order to 
answer important questions regarding overall detection rates by CMA over 
conventional, full karyotyping, the rate of VOUS and how this has changed over time. 
The concern with increasing resolution of CMA is the potential subsequent increase 
in VOUS rate. Certainly in papers published from 2010 onwards a higher detection 
rate is positively correlated with a higher VOUS rate as was seen by the positive 
Spearman rank correlation. It is therefore going to become fundamentally important 
that as CMA platforms increase in resolution that there is national and international 
guidance regarding reporting of VOUS in the prenatal setting. When performed for 
any indication, conventional karyotyping has an additional abnormality detection rate 
of 0.6% over CMA. However, as I and others have shown, the majority of this can be 
explained by balanced inversions and translocations.  These are unlikely to cause a 
phenotype in the absence of a phenotype in the parent, and when accompanied by a 
normal microarray result provide reassurance that the rearrangement is balanced. 
Triploidy can also be detected by conventional karyotyping and missed by microarray 
analysis. However it is likely to be “picked up” by other tests such as studies for 
maternal cell contamination or QFPCR for common Trisomies.  
 
There would have been a 4% detection rate by targeted FISH for 22q microdeletion 
(Di George) Syndrome (if the clinical indication was a suspected cardiac anomaly on 
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echocardiogram scan). This is interesting as it shows that “intelligent targeting” of 
FISH probes according to the phenotype on ultrasound still only yields the same 
detection rate as microarray when performed for any indication (4%). I only had the 
data available to look for the potential detection rate of DiGeorge Syndrome, but the 
same analysis could be performed to look at potential detection rates of Miller Dieker 
when a neuronal migration order was detected, or Pallister Killian Syndrome when 
Congenital Diaphragmatic hernia is identified on fetal ultrasound. In addition FISH 
only examines a single chromosomal locus whereas CMA interrogates thousands or 
even millions of loci simultaneously, without requiring prior knowledge by the clinician 
to request tests for particular chromosomal anomalies. 
 
This systematic review contained data on 17,113 pregnancies, substantially larger 
than the 751 pregnancies included in the first systematic review (Chapter 1) (31) and 
is likely to be more representative of the true detection rate of microarray over 
karyotyping. These data are, however, still heterogeneous.  This is possibly due to 
smaller cohorts with an artificially high detection rate, and the different platforms used 
in the different chromosomal microarray studies. The time in which these articles 
were published ranges from 2004-2012.  During this period, although microarray 
design has changed and increased in resolution, subgroup analysis by time of 
publication did not account for the heterogeneity.  
 
Statements issued by the American College of Obstetrics and Gynecology (ACOG) 
(48) and Italian Society  of Human Genetics (SIGU) (83) have recommended that 
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karyotyping should remain the principal cytogenetic tool in prenatal diagnosis and 
microarray used as an adjunct when a structural anomaly is seen on scan. This 
presents collective evidence for the higher detection rate by CMA not just for 
abnormal scan referrals but for other indications for invasive testing. 
 
 
 
 
 
 
 
 
Submitted manuscript from chapter 4 
The following manuscript from Chapter 4 has been published 
Hillman SC, McMullan DJ, Hall G, Togneri FS, James N, Maher EJ, Meller CH, 
Williams D, Wapner RJ, Maher ER, Kilby MD. Use of prenatal chromosomal 
microarray: prospective cohort study and systematic review and meta-analysis. 
Ultrasound Obstet Gynecol. 2013 Jun; 41(6):610-20. 
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CHAPTER 5 QUALITATIVE ANALYSIS 
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Introduction 
“The challenge... during these times of sophisticated genetics and technological 
manoeuvres will be not to distance ourselves from the individuals we are caring for” 
(84). 
 
As prenatal diagnostic tests that examine fetal chromosomes increase in resolution  
their ability to detect significant as well as potentially insignificant chromosomal or 
genetic anomalies increase also. It is important that prenatal diagnostic tests are 
employed because it is the right and accepted thing for families  to know if their baby 
has differences and to have the choice to decide on pregnancy outcome and not just 
because the technology is available.  
 
As medicine is becoming increasingly technologically advanced, it is at the same 
time becoming less paternalistic (85). Though we endeavour to offer patients a 
choice about prenatal testing in pregnancy, the inevitable stress which is evermore 
apparent when an abnormality has been found on scan, may be increased by the 
complex and ambiguous results which the technology offers.    
 
The situation is compounded by the biological timetable of pregnancy, particularly as 
many structural anomalies are not detected until the 18-21 week anomaly scan and 
the UK law dictates that 24 weeks is the legal limit for termination of pregnancy under 
the Abortion Act clause 1a. It is further compounded by the scheduling of testing and 
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the greater clinical and emotional difficulties of late abortion, all of which create a 
sense of time pressure (86).  
 
It has been argued that, when events are out of the ordinary, people need a sense of 
what the expected response is (a “social ritual”).  In this case, with the newness of 
the technology, no ritual exists: but this “cultural lag” offers an opportunity to 
understand more fully what people actually feel, and would therefore be an 
appropriate time to perform qualitative work (87).  
 
It has been argued that “doctor-patient communication” is a transaction between the 
biomedical world of the doctor and the life-world of the patient (88). The patient’s 
primary orientation is a social domain where the meaning of health and illness are 
firmly situated within their life history, social and environmental situations (89). The 
doctor is concerned with the technical aspects of predicting and controlling health 
conditions (85). Studies in prenatal genetic decision-making often concentrate on the 
biomedical perspective (90).  
 
It is vital that we seek to understand the effect this new technology (and the 
uncertainty it can sometimes create) is having on couples. If not, we risk incorrectly 
assuming those women and their partners are making properly informed decisions.  
In order to achieve aim 5 “To perform qualitative work to evaluate how women and 
their partners feel about the use of CMA testing, particularly when a result has 
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uncertainty attached” I chose to undertake a qualitative research method as it gives 
access to the thoughts of those most concerned and enabled me to discover aspects 
of reality that I could not necessarily anticipate (91;92).   
 
Methods 
As described in Chapter 2, from December 2009 - April 2012 at Birmingham 
Women’s Hospital I prospectively recruited women (with a fetal structural anomaly on 
USS) for microarray testing in addition to karyotyping. The women then received 
QFPCR results (for Trisomy 13, 18 and 21) followed by results of the CMA alongside 
the results of the karyotype. 
 
Interviews were conducted by myself (n=22) or Miss Amie Wilson (n=3) (a research 
midwife) and were 20min - 60min in length. 25 interviews were conducted in total, 16 
with women who had a normal microarray report and 9 with women who had an 
abnormal report. In 23 cases the woman had received all the results of the testing but 
in two cases (4b and 9b) results were inconclusive and further tests were required. In 
12 cases the interview was conducted with just the woman, in 12 cases the partner 
was also present and in 1 case the woman’s father was present. 
 
Interviews were conducted using a semi-structured interview format (appendix F).  
This interview schedule was developed by myself, Professor Elaine Denny of 
Birmingham City University and Miss Elizabeth Quinlan Jones (research midwife). 
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Professor Elaine Denny and Elizabeth Quinlan Jones  have previous experience of 
prenatal interviews (93). Demographic data on patient’s age, ethnicity, parity and 
anomaly on USS were collected. Information on religion and education was not 
routinely requested (unless voluntarily given during the course of an interview) so as 
not to bias the interviewer. 
 
Analysis 
Interviews were transcribed verbatim. Data was analysed using Framework Analysis 
and was performed using previously described methodology (94;95). To gain 
familiarization of the interviews, transcripts were read and re-read by myself and a 
sample by Elizabeth Quinlan Jones. Throughout this process key ideas and recurrent 
themes were noted. A thematic framework was then identified by recognising 
emerging themes. The framework was refined as transcripts were added. The 
thematic framework was agreed between two researchers (myself and Elizabeth 
Quinlan Jones). All text was indexed numerically, with numbers placed in the margin 
beside the text. The original pieces of data were charted using Excel (Microsoft Word 
2010©). Charts were developed using themes and subthemes (charts are presented 
as appendix G). 
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Results 
At the time of interview the median age of women was 29.6yrs (range 19-40 years). 
23 (92%) were British (all were Caucasian), 1 woman was Spanish and 1 woman 
was Polish. The fetal anomaly for which the testing had taken place is recorded in 
Table 11. 
Table 11 Demographics of women interviewed 
Microarray 
result 
Age Living 
children 
Country of 
birth 
Scan abnormality 
1a normal 25 0 UK Bilateral Talipes 
2a normal 40 3 UK Ascites, echogenic bowel 
3a normal 20 0 UK Cardiac anomaly 
4a normal 19 0 Spain Cystic hygroma 
5a normal 31 4 UK Absent forearm 
6a normal 28 3 UK Abnormal lower limbs 
7a normal 31 0 UK Megacystis 
8a normal 25 1 UK Small cerebellum 
9a normal 35 0 UK Pleural effusion 
10a normal 36 5 UK Cleft lip/palate 
11a normal 38 1 UK Talipes/renal pelvis 
dilatation 
12a normal 31 1 UK cardiac/polydactyl 
13a normal 38 1 UK Increased Nuchal 
translucency 
14a normal 20 0 UK Increased Nuchal 
translucency 
15a normal 27 2 UK cardiac 
16a normal 37 1 UK cardiac 
1b abnormal 35 ? UK Holoprosencephaly 
2b abnormal 24 1 UK Increased Nuchal 
translucency 
3b abnormal 33 1 UK Dandy Walker 
malformation 
4b abnormal 32 2 UK Megacystis 
5b abnormal 30 1 UK Cardiac 
6b abnormal 19 0 UK Increased Nuchal 
translucency 
7babnormal 34 2 UK Cardiac 
8b abnormal 32 0 Poland Increased Nuchal 
translucency 
9b abnormal 26 1 UK Encephalocele/absent 
corpus callosum 
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There were five themes identified. The thematic framework is presented below.  
Thematic framework 
1: Diagnosis 
This theme is concerned with the way the diagnosis was explained and received by 
the woman, including the differences between her experience at local and tertiary 
centres 
1.1 Explanation of scan findings (the interviewee explains how they were made aware 
that there was a problems with the baby’s scan and what was explained to them). 
1.2 Explanation of possible genetic causes (the interviewee explains how they were 
made aware there could be a genetic problem and how this was explained to 
them). 
1.3 Information forms and sources (hospital/family/others). What forms and sources 
of information were made available to them, how did they gain further knowledge 
of the condition. 
1.4 Differences between local and tertiary care 
1.5 Waiting for a tertiary appointment 
 
2: Genetic testing  
This theme is concerned with the way the test was explained and understood by the 
woman, what influenced her to have the testing and experience of receiving the 
results. 
2.1 Understanding of the genetic test  
2.2 Influences to have the genetic test 
2.3 Receiving results of the genetic test 
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2.4 Timing of the genetic results 
2.5 Usefulness of having the genetic test 
 
3: Family and support 
This theme is concerned with the Implications for the spouse/dependents of the 
woman and the support available to her. 
3.1Impact (on other people apart from woman i.e. spouse/family) 
3.2Comparison to other pregnancies/children 
3.3Support from friends and family 
3.4Support from health care professionals (hospital/Community Midwife/unique) 
 
 4: Reflections of the treatment received 
This theme is concerned with particularly good or bad communication between health 
care professionals and the woman and specific improvements to the service 
suggested by the woman 
4.1Communication 
4.2improvements 
 
5 Emotions 
This theme is concerned with the woman’s emotions that permeated the experience 
5.1Highs and lows and the effect of time on emotions 
5.2Uncertainty 
5.3Blame 
5.4Hope 
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Results of themes and Indicative Quotations 
1.1 Diagnosis 
1.1.1 Explanation of scan findings (This initial scan was performed at the patient’s 
local hospital) 
Although many interviewees described factually what was seen on the USS others 
reflected on their experience. One interviewee (2a) described a sense of detachment: 
“Nobody said anything really they were just busy measuring and I felt just a bit 
like a patient on the table” 
 
Another (partner of 4b) describes how the reaction of health care professionals had a 
direct impact on him: 
“doctors looked like they were panicking and that panics you” 
 
In three cases interviewees described how they were taken into a different room to 
wait for someone to explain the scan findings. Although done for confidentiality, 
couples remembered this poignantly as if this represented their transition from a 
normal to abnormal pregnancy.  
 
 In four cases interviewees discussed realising that something was wrong as the 
scan was taking a long time or additional people came into the scan room. This 
created anxiety, particularly when the HCPs would not allude to why they were 
concerned. 
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1.1.2 Explanation of possible genetic causes  
In most cases interviewees were satisfied with the way possible chromosomal 
anomalies were explained. Three recalled being told about the possibility of Trisomy 
13, 18 and 21.These being the most commonly found chromosomal anomalies it 
makes sense that counselling should be, in part, directed towards these findings. 
However both conventional G-band karyotyping and particularly CMA testing are 
testing for far more than this and it is concerning that couples did not remember this 
from their counselling experience. 
Only one interviewee (11a) found the explanation insufficiently full: 
“They skirted around the edges” 
 
1.1.3 Information forms and sources  
Seven women described having written information to take home. This is good as a 
source of information when couples have had time to reflect on what has happened 
at their early appointment. It can be read on multiple occasions and also translated 
for non-English speakers.  
Five interviewees spoke about their experiences with the internet. In three cases they 
were clearly negative, as here (5b)  
“I tried to find out on the internet and it scared me”  
 
One interviewee acknowledged the possible skewing of information on the internet 
(3b) 
“Heart-warming as these stories are they tend to be the better ones” 
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Patients experienced an overload of information on the internet and without advice or 
direction to good websites could easily end up misinformed. This is concerning for 
patients who may develop a schema stemming from a misunderstanding and HCPs 
who would then be required to “undo” these incorrect beliefs before imparting correct 
information.  
Only one woman described her experience with the internet as positive (8b) 
“I think the internet was a nice source of helping me to survive” 
 
They found that it “bridged a gap” while they were waiting for appointments and was 
a way of finding a “community” of others that had a similar experience. 
 
1.1.4 Differences between local and tertiary care 
Ten people reported a negative experience at their local hospital. Some interviewees 
concluded that this was due to a lack of knowledge (3b): 
“They didn’t have a clue” 
 
Others decided it was because the HCPs didn’t want to be the bearers of bad news 
(partner 2b).  
“Just to pass it on to someone else” 
 
From the patients point of view this was annoying as they had to wait for an 
appointment at the tertiary centre before they could be given any definite information, 
leaving them in a state of “limbo”. However from the local hospitals point of view they 
are not specialists and would not have wanted to misinform patients. It is also the 
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place often in which the abnormality was first detected and therefore it may be 
inevitable that the patients will remember their interaction with them negatively.  
 
1.1.5 Waiting for a tertiary appointment 
Eight interviewees made reference to the wait between appointments at the local and 
tertiary centre. In six cases the appointment was the next day, which people reported 
as “good”. In two cases the delay was a week and both stated that this wait was 
“hard”. 
“We were trying to put our thoughts in different things. We bought ourselves a 
play station and computer games” 
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1.2 Genetic testing 
1.2.1 Understanding of genetic testing  
In five cases the interviewee could not recall detail of the microarray counselling (9a): 
“I don’t remember a lot, you just get told so much and then it’s hard for it to go 
in” 
 
In these cases it may be that women had just received a new or more complex 
diagnosis regarding the fetal structural abnormality than expected. It is then hard for 
further information to be retained, particularly regarding complicated chromosomal 
testing.  
 
In seven cases the interviewee could recall that the microarray test may pick up 
something that conventional testing may miss, which is indeed correct.  
In three interviews women remembered being told about possible VOUS (11a): 
“it would perhaps be able to offer more detail, we got the impression that that 
detail might not necessarily be that helpful because you don’t have enough 
detail to interpret properly but that over a period of years then that information 
might be useful for somebody” 
 
Counselling about VOUS and the potential for this testing outcome is important 
regardless of whether the VOUS is to be reported or not. This should be a particular 
focus point when counselling for CMA so that women may, with this information, 
choose not to have the test; or if a VOUS does occur women and their partners are 
not completely unprepared.  
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In two interviews the women recalled information incorrectly (14a): 
“It (microarray) was looking through a telescope not just the naked eye”  
 
Here it is possible that the patient has incorrectly recalled information about 
karyotyping being analysed through a microscope. 
A second woman (7b) incorrectly recalled that microarrays could: 
“pick up anything with the baby, even down to a small skin tag.”  
 
It is possible that the woman recalled the increased detail in which microarrays 
analyse fetal chromosomes, but has translated this into increased detail of the baby’s 
structural abnormalities.  
 
It is inevitable that some misunderstandings may occur particularly when counselling 
in stressful situations making it particularly important that written information is given 
and a point of contact for questions to be answered. 
 
1.2.2 Influences to have the genetic test 
People had five reasons for undergoing CMA testing. Firstly that it required no further 
invasive sampling and no extra risk of miscarriage. Secondly was to accept every test 
in order to find an explanation for the problems on USS. Thirdly was for reassurance.  
Fourthly that they had “no other choice” and finally, as an act of benevolence, to help 
in the future through research. 
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1.2.3 Receiving results of genetic test 
Women were asked about receiving the result of the microarray testing.  
Women who had normal results described the telephone call as “clear”, “good”, 
“helpful”. Three women described the relief that they felt with the result (16a) 
“it was just relief I was just crying, it’s one thing off the worry list” 
 
Those whose results were abnormal reflected that the telephone call was 
“complicated”, they “were stressed” and they “thought the worst”.  
 
It may be inevitable that women will view a telephone conversation to give a positive 
chromosomal result as being poorly conducted compared with one to give a negative 
result.  However HCPs may be able to limit this by having as much information to 
hand as possible, and importantly a plan of follow up including an appointment to see 
a clinical genetics specialist as soon as is feasible. 
Only one woman felt she was not given enough information about the abnormal 
result. (8b) 
“they said they will talk to me later.  I thought I want to talk about the results 
now. They were afraid that it would be too upsetting so they just gave me the 
minimal information” 
 
In three interviews women described how after receiving the results of the QFPCR 
test they then expected the subsequent tests (including the microarray) to be normal.  
(Partner 3b),  
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“I certainly walked away thinking great chromosomes not an issue and then to 
get a phone call a few days later to be told actually it’s chromosome 6, it’s far 
worse than we first thought, is slightly misleading because you sort of walk 
away thinking great this is do-able” 
 
It could be that inadequate counselling had led to the woman and her partner 
believing that QFPCR was a definitive test. It could be a misunderstanding by the 
patient or it may be that they were “blindsided” into thinking that the remaining tests 
would be normal as the most common chromosomal anomalies had been ruled out. 
 
Two people described getting the result of unknown significance (VOUS). (Partner 
4b) 
“You never think a doctor’s going to go, phew, don’t know what it is” 
 
Uncertainty is a particularly difficult concept as a HCP to relay to patients. A VOUS 
may be viewed as conveying a lack of information and it should be considered if this 
is in the best interests of the patient. VOUS need to be considered by a multi-
disciplinary team on a case by case basis. 
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1.2.4 Timing of results 
Eight women spoke about the wait for the results following the invasive testing. It was 
described as “hard”, “stressful”, “hell”, and “like a weight on your shoulders”. One 
woman described in detail how her testing had spanned the Christmas holidays and 
how this meant she would be 24 weeks gestation (the legal limit for termination of 
pregnancy under the Abortion Act clause 1a).(Woman 11a) 
“Because of the Christmas holidays that was my 24 weeks - there wasn’t 
going to be any time to have a result and make a decision, so you had to think 
it through probably further than you would have wanted to.” 
 
CMA is particularly amenable to high throughput, with often the availability for 
multiple patient samples to be analysed on one array slide. However this can 
sometimes mean, for economy, that samples are held and then “batched” so as not 
to waste resources and money. 
 
1.2.5 Usefulness of having the genetic test  
Five women reported normal microarray results as reassuring. However normal 
results may lead to a mistaken idea that there could not be a genetic abnormality, 
when the resolution of the microarray is limited and single gene mutations may be 
missed.  
Five women described microarray as “useful” as it had provided, or may have 
provided, extra information. For one woman this was to “prepare” the family.   
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In two cases women were interviewed when the results of the testing were VOUS. 
Although people found it hard when HCPs could not fully interpret the findings, all 
were still pleased they had the testing and did not regret their decision. Although the 
result was uncertain they still seemed to value the information, which was given to 
them sensitively and clearly by a clinical genetics consultant (partner 4b):  
“the more information they can give you the better, if they need to do 4 tests 
and each test will give us 4 pieces of information then we will have 4 tests” 
 
Only one woman (whose baby had a pathogenic chromosomal difference identified 
on both conventional karyotyping and CMA) expressed any regret at having the 
testing. (6b) 
                “I wish I daren’t have the test done cause it’s broke me inside” 
 
However the same woman later reported how the information of an abnormal 
microarray (and karyotype) helped her make a decision about interrupting the 
pregnancy (6b) 
 “I don’t feel so bad about ending it ‘cause I know this child wouldn’t of had a 
life” 
 
Three women stated that they had not found the microarray testing useful. In all 
cases this was because the result was normal and had not provided them with any 
additional information. In one case there was a family history of an undiagnosed 
genetic condition and the women and her partner were hoping that this technology 
could have provided long awaited answers.  
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1.3 Family and support 
1.3.1 Impact  
In four interviews the woman described the impact of the abnormal USS and testing 
on her children. Two women described the impact on their partners; one how it was 
the first time she had seen him cry, while another described how the situation 
resulted in physical symptoms (4b) 
“We had to take him to A and E with chest pains and they said “I think it’s just 
basically stress”” 
 
An abnormal genetic result can have implications for the wider family. One woman 
described the impact of a chromosomal abnormality on the X chromosome (5b) 
“’cause there are a lot of girls in my family - it’s like a bomb. It scares me that 
she’ll (her daughter) have to go through what I’ve had to go through” 
 
It is important when counselling for chromosomal testing that that the impact of a 
diagnosis not only relates to the fetus but back through an entire family, sometimes 
providing long awaited answers but sometimes providing unwanted information. 
 
 
1.3.2 Comparison to other pregnancies/children 
In three cases people described how different this had been to their previously 
“normal” pregnancies. Two described how they had undergone something similar 
previously (12a): 
“when they confirmed it was just like here we go again” 
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One woman compared the possibility of having a disabled child to her healthy two 
year old (3b): 
“When you have got a two year old running around the house he owns the 
house. You do compare” 
 
Three women compared the outcome of their pregnancy with other people’s children, 
in two cases comparing to “everyone else healthy babies” or not being “like everyone 
else’s”. Comparison may be inevitable, but help maybe gained from directing women 
to groups and charities (Unique and Antenatal Results and Choices) that might put 
them in touch with families with affected children, so they can draw on similarities. 
 
 
1.3.3 Support from friends and family 
15 women described support from friends and family, and in most cases input was 
helpful. 
In three cases however it was described negatively, with one woman describing how 
she was defensive discussing her pregnancy.  In two cases the feelings of others 
were perceived as inappropriate (3b) 
““It happens” which is a phrase that’s been thrown around, it is because 
nobody knows what to say” 
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1.3.4 Support from health care professionals/support groups 
14 women mentioned support they had received from health care professionals or 
official support groups including Unique and Antenatal Results and Choices (ARC). 
Women and their partners were complimentary about the support they had received 
using words such as “satisfied”, “excellent” and “helpful”. One woman commented 
that although her family had contacted ARC she was reluctant to: (9b) 
“I have been a bit too scared because I am quite emotional and I don’t really 
want to cry in front of anybody” 
 
Only one couple felt that they had not received adequate support (4a) 
“there is no help really out there where you can phone or speak to anybody” 
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1.4 Reflections of the treatment received 
1.4.1 Communication 
Three women commented on the amount of information that was communicated to 
them. One said it was “a lot of information to take in”. Surprisingly in two cases 
women said that they had not received enough information. One of these cases 
involved an uncertain chromosome result where no accurate information was 
available: the patient’s feeling of inadequate information is therefore justified but 
inevitable. In the second case the woman felt she was told too little as they were 
“afraid of upsetting her”. This may be due to HCPs withholding information as they do 
not understand it in order to convey it, and are concerned that they may convey 
something incorrectly. Information should not be retained so as not to upset someone 
as this information may be required in order to make important decisions, such as the 
termination of a pregnancy. Two women commented on the use of medical language 
in the consultation. One said she had to “look up new words”, the second that HCPs 
should alter their language (9a) 
“get past all the doctor jargon and get it into plain English”  
 
All HCPs should be aware of this important problem in their own practice, particularly 
when conveying complicated concepts.  
1.4.2 Improvements 
Women suggested that HCPs should be “as open as possible as early as possible”, 
provide quicker follow up, provide access to support groups, counselling and 
direction to good websites, and that a letter should be sent after the appointment 
summarising what had taken place.  
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1.5 Emotions 
1.5.1 Highs and lows and the effect of time on emotions 
Women used many words to express their emotions during this entire experience. 
Some of the more common were “devastated”, “shocked” and “worried”. Three 
women described the effect that time had on their emotions; “like a roller coaster”: 
some days things would be better but something like a hospital visit would put them 
back to “square one” (3b) 
“It’s peaks and troughs isn’t it, it’s not something that is in the forefront of your 
mind all the time, but coming to the hospital visits it becomes a lot more 
apparent” 
 
 
1.5.2 Uncertainty 
Many women and their partners expressed uncertainty and lack of control over the 
situation. 
Two women expressed distress at not knowing if their unborn child would live or die: 
One woman commented that uncertainty surrounding the prognosis meant she could 
not make decisions about continuation of the pregnancy, and one woman expressed 
her concern that the same thing could happen in a subsequent pregnancy. Five 
interviewees spoke of their uncertainty when the HCPs did not have the answers. (2a 
normal result) 
“I assume nobody really knows and because they don’t know they can’t tell 
me” 
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1.5.3 Blame 
Women discussed the blame that they felt using phrases such as “it’s my fault”, “you 
blame yourself ”  and “typical me”.  
In two cases the baby had inherited a chromosomal problem from the woman. One 
woman seemed to find the information helpful. (5)  
“Because I carry too much X chromosome I have got something to blame (for 
previous miscarriages)” 
 
The second woman however blamed herself (9b) 
“then it came back that it was carried from me which is even harder to register 
really because I had given the baby whatever it is. I feel like it is my fault” 
 
Blame may be encountered when a structural anomaly is found on scan, as a mother 
attempts to find a cause, often blaming something she may have done or not done in 
pregnancy. Genetic diagnoses, particularly when inherited, are also associated with 
blame as they “passed it on”. The combination of the two means that HCPs should 
be particularly alert to this and attempt to discuss and counsel where appropriate. 
 
 
1.5.4 Hope 
In two cases women discussed the hope that could be given to them by a HCP. For 
one woman it was the hope that research could provide answers in the future, and for 
another woman the hope that a subsequent pregnancy would not be affected. Two 
women discussed grasping or holding on to hope that everything would be alright. 
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Discussion  
This qualitative work gives a first-hand insight into the experiences of women and 
their partners diagnosed with an abnormality on prenatal USS and accepting genetic 
testing including microarray testing (Figure 20). Previous qualitative work in this field 
is limited to women’s experience of prenatal genetic testing or women’s experience 
of having an abnormal ultrasound scan.  
 
Women described being detached from the scan and being able to tell something 
was wrong as the scan was taking a long time. Women are alert to verbal and non-
verbal expressions from health care professionals and other studies have similarly 
found silence creates anxiety (96).  One study also described women feeling like 
passive objects “lying on the table” and having the scan “done” to them (97).  
 
Couples found the wait between initial and tertiary appointment hard, especially if it 
was more than a few days. Other studies have shown that while the time between 
appointments is useful in terms of recovery from the shock of diagnosis, it is also a 
time of great stress when parents need support  (98). 
 
Women and their partners struggle to recall the details of genetic testing and the 
differences between genetic tests. Often women have only just had a diagnosis of an 
abnormal scan and under stressful circumstances it is unsurprising that little 
information is retained. Previously authors have commented that it is virtually 
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impossible to counsel in these circumstances (99). It is possible that when pregnant 
women find themselves in a stressful position, they cope by complying with what they 
believe is the health care professional’s recommendations (100). They may also feel 
that complying with testing is their way of showing that they are, or will be, a “good 
parent” (101).  
 
A recent publication by Bernhardt et al (66) also looked at prenatal microarray 
testing, but they interviewed women with abnormal or uncertain microarray results. 
The cohort also included women tested for reasons other than abnormal ultrasound 
scan findings (such as advanced maternal age or a positive screening result). One of 
the similarities when comparing this study with ours was the theme of support found 
in both papers. In the main both found HCPs, support groups, and friends and family 
to be supportive.  
 
The internet as a source of information was often found to be unhelpful and even 
worried participants in the cohort. This is similar to other prenatal and postnatal 
cohorts that have found the internet confusing or that it did not yield much information 
(66).  
 
Newer experiences specific to prenatal microarrays testing included examining the 
reasons that women accepted microarray testing (to gain extra information, to make 
informed decisions and prepare adequately). These women were sometimes 
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disappointed by a normal or a “negative result”. Some people requested the 
microarray for reassurance, which is a concern. Although the testing is at very high 
resolution a negative result does not mean there is no possibility of a chromosomal 
abnormality or single gene disorder.  
 
My study showed that women were keen to have results as quickly as possible. This 
is a potential advantage of microarray as it can be performed on uncultured cells and 
therefore more quickly. When the result showed a chromosomal difference the 
women felt that the telephone call was sometimes complicated or uncertain. This is a 
difficult telephone call for the HCP and woman. Other studies have found poor 
understanding during such telephone calls due to strong emotions and grief (102).  
 
Similar to the study by Bernhardt et al, women in this study felt that they chose to 
have microarray testing as it was an offer “too good to pass up” considering they had 
already decided to have an invasive procedure, and the test required no further risk 
of miscarriage. Bernhardt et al concluded that as there was no further risk of 
miscarriage, women and their partners may have opted for the microarray testing 
understanding less about the test than they might have done if it had conferred a risk. 
In their study this was the case, particularly when there was an abnormal ultrasound 
finding and the couples were under emotional stress (66). If this was the situation, it 
may account for why women and their partners could often recall little, or recalled 
misinformation, about the microarray test in the cohort. This could be a particular 
problem if they have not comprehended the possibility of a VOUS.   
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Communication of VOUS presents a particularly difficult challenge. People appeared 
to be particularly concerned when the HCP did not know the meaning of the result. 
Here patients require rapid follow up with a consultant clinical geneticist. Even when 
this has occurred people may make incorrect conclusions to fit in with their own 
schemata. In my experience having a VOUS did not lead to a termination of 
pregnancy, a fear previously expressed (103). The recent publication by Berhardt et 
al interviewed 14 women with VOUS. Many of them considered this knowledge to be 
information that they wished they did not have (“toxic knowledge”) (66). Women were 
left feeling anxious, and these concerns lingered into worries about their child’s 
development.   
 
Interestingly, in a postnatal setting when a microarray was performed, parents 
expressed similar views regarding the understanding of the scientific uncertainties, 
regardless of whether the result was a pathogenic variant or a VOUS.  This may be 
because similar uncertainties can surround both pathogenic results and VOUS, 
particularly if the pathogenic finding is rare, or newly identified, and limited prognostic 
information exists (104). In this study some parents reported feeling relieved when 
the result was a VOUS, and they also felt that the result (both pathogenic and VOUS) 
was valuable and empowered them particularly to access educational services (104). 
Perhaps then, VOUS should not be reported prenatally but only when testing is 
performed postnatally. Both in my study and the Bernhardt study women felt that 
after receiving initial normal results (in my study QFPCR) they were “blinded” by the 
normal results and expected the next set of results to be normal. They were therefore 
shocked if the results of subsequent studies were abnormal.  The Bernhardt et al 
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cohort found this to be the case when testing was performed for a reason other than 
abnormal ultrasound scan findings (66). However in my cohort (with abnormal 
ultrasound scan findings) I found differently and women were still blinded by normal 
QFPCR results expecting subsequent results to be normal. 
 
Limitations 
This study was limited by the demographics encountered: all participants were 
Caucasian. Although 25 is a reasonable sample size for qualitative work, only nine 
had abnormal chromosomal results. Women often talked about the experience as a 
whole and it was therefore sometimes difficult to extract what was applicable to the 
scan, invasive test, or results of a test.  
 
Conclusion 
My study has given insight into the thoughts, feelings and perceptions of couples 
during this time. Interviewees often parcelled abnormal scan findings and 
chromosomal testing together, viewing the experience as a whole. There were 
frequent misunderstandings and misconceptions by couples regarding aspects of 
counselling/testing; proving that reinforcement with information to take home is 
paramount. Good clear communication by HCPs is essential.  
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Recommendations 
Results from my qualitative analysis have led me to propose that in clinical practice: 
 When counselling women and their partners for fetal chromosomal testing, 
HCPs should explain that although the most common, Trisomy 13,18 and 21 
only account for some of the chromosomal changes resulting in abnormal 
scan findings 
 HCPs should be aware that often people remember a small amount when 
counselled so it must be backed up with patient-friendly literature to take home 
 If possible, women and their partners should be directed to good websites 
 Partners should be involved in the counselling process where possible  
 Information for support groups such as ARC (http://www.arc-uk.org/) and 
Unique (http://www.rarechromo.org/html/home.asp) should be given 
 Medical language should be as minimal as possible 
 When results of QFPCR testing are telephoned it should be reinforced that 
there are further results to come 
 When a chromosomal abnormality is diagnosed, rapid referral to a clinical 
geneticist is paramount 
 A letter should be sent to the woman following an appointment with a 
geneticist/genetic counsellor summarising what was discussed 
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Figure 20 Experiences of women undergoing CMA testing for a structural anomaly on ultrasound scan (USS) 
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Legend: Diagram of the influences and experiences undergone by women and their partners when they have CMA testing for a structural anomaly detected on fetal 
ultrasound. Women and their partners are at the centre of the diagram surrounded by their emotions. Other influences (family, medical and the internet) communicate 
with them.  
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Manuscript submitted from Chapter 5 
The following manuscript from chapter 5 has been published: 
Hillman SC, Skelton J, Quinlan-Jones E, Wilson A, Kilby MD. "If it helps..." the use of 
microarray technology in prenatal testing: patient and partners reflections. Am J Med 
Genet A. 2013 Jul; 161A(7):1619-27. 
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CHAPTER 6 HEALTH ECONOMIC MODEL BASED EVALUATION: 
CHROMOSOMAL MICROARRAY (CMA) USE FOR THE PRENATAL DETECTION 
OF CHROMOSOME ANOMALIES 
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Introduction 
CMA technology is increasingly being used to discover and define chromosomal 
anomalies in the prenatal setting. It has increased detection rates of pathogenic 
CNVs over standard techniques (as described in Chapters 1, 2 and 3).  However, 
when applied to clinical practice, the cost-effectiveness of CMA is yet to be 
established. I sought to assess the cost effectiveness of chromosomal microarray 
compared against standard cytogenetic tests (105).  
 
In order to achieve this a decision tree was built (106). A decision tree is used in 
health economic modelling and graphically represents different pathways that 
patients can take through various decisions or chances that incur costs along their 
particular path. The path may diverge into branches at a “node” either because of a 
chance of a different outcome (chance node e.g. chance fetus had chromosomal 
abnormality vs. chance did not have a chromosomal abnormality), or because of 
different paths due to a decision (made by a HCP or patient e.g. decision to have 
karyotype testing vs. decision to have CMA testing). The branches of the tree have a 
probability attached, with the sum of the branches adding up to 1. Chance nodes are 
traditionally represented by a circle while decision nodes are typically represented by 
a square. The final outcome of a path is called a terminal node shown by a triangle. 
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A decision tree was built and populated using three different sets of data: 
1) that of my cohort, comprising of 309 fetal samples, where testing was performed 
for structural abnormalities on fetal ultrasound scan (Chapter 2).  
2) that of the literature, comprised of data from 22 journal articles and 13755 fetal 
samples, where there was a range of indication for testing (Chapter 4). 
3) and finally, using the literature and data from 17 cohorts where the indication for 
testing had been abnormalities on fetal ultrasound scan (4276 fetal samples are 
included) (Chapter 4).  
 
Developing the model structure 
To assess the cost effectiveness of the various tests, or combination of tests, 
decision trees were created using TREEAGE software (Treeage software inc., 
Williamstown, MA, USA) (Figure 21).   Three models were developed: 
 
1) The first model is populated using data from my prospective cohort (described 
in Chapter 2). This was a study running from December 2009 until April 2012 
at Birmingham Women’s Foundation Trust. When a fetal anomaly scan 
showed a significant structural anomaly, women were counselled and offered 
fetal chromosome testing by invasive sampling. If accepted, women were also 
offered, counselled and consented to have chromosomal microarray testing in 
addition to standard cytogenetic testing.  309 women were recruited and had 
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cytogenetic testing performed.  Nine options for testing within the model were 
considered using combinations of the tests; QFPCR (Quantitative 
Fluorescence Polymerase Chain Reaction), conventional G band karyotyping, 
CMA, FISH (Fluorescence In Situ Hybridization for 22q11.2 microdeletion 
syndrome on remaining fetal samples with cardiac abnormalities). The 
definition of these alternative options is presented in Table 12.  
 
2) The second model was constructed following a systematic review of the 
literature. MEDLINE (1970–June 2012), EMBASE (1980–June 2012), Cinhal 
(1982-June 2012) were searched electronically. Selected studies had >5 
cases and microarray testing was performed prenatally in addition to 
karyotyping. Search yielded 559 citations. Full manuscripts were retrieved for 
85. Data from 21 primary studies (including the Birmingham BAC cohort 
described in Chapter 2) were used to populate the model (38;39;43-
45;52;53;65;71-80;107). In total 13,755 results were included.  In this model 
QFPCR and FISH were not included as diagnostic tests (as the majority of 
papers in the literature did not contain this information). The five options 
considered for testing were; karyotyping alone, CMA alone, karyotyping then 
CMA, CMA then full karyotyping, full karyotyping and CMA. Here the referral 
reasons for fetal chromosomal testing were a mixture of indications including a 
“high risk” on antenatal screening for Down’s Syndrome, a family history of 
fetal anomalies, parental anxiety, or advanced maternal age. 
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3) The third model was also constructed from data collated from the systematic 
review described above. Here data were extracted only when testing had been 
performed because a structural anomaly had been found on fetal ultrasound 
scan (USS). From the 22 primary studies 17 had this information (39;42-
45;52;53;65;68;71;73;75-79). In total 4,276 results were included. The same 
five testing options were considered as in model 2; karyotyping alone, CMA 
alone, karyotyping then CMA, CMA then karyotyping, karyotyping and CMA. 
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Figure 21 An example of an "arm" of the decision tree for "karyotype only" 
 
Legend: An arm of a decision tree. Circles represent chance nodes and triangles are terminal nodes, # is 1 
minus the probability in the parallel arm (i.e. the first # is 1 minus pPrevalence).  
Table 12 shows the different strategies of chromosomal testing that were 
analysed within model 1. 
Option Test 1  Followed by Test 2  Followed by Test 3  
1 QFPCR - - 
2 G-band karyotyping - - 
3 CMA - - 
4 QFPCR Then G-band 
karyotyping (if QFPCR 
negative) 
- 
5 QFPCR Then CMA (if QFPCR 
negative) 
- 
6 G-band karyotyping And CMA (regardless 
of G-band karyotyping 
result) 
- 
7 QFPCR Then G-band 
karyotyping (if QFPCR 
negative) 
And CMA (regardless 
of G-band karyotyping 
result) 
8 QFPCR Then FISH (if QFPCR 
negative) 
- 
9 QFPCR Then G-band 
karyotyping (if QFPCR 
negative) 
Then FISH (if G-band 
karyotyping negative) 
QFPCR= Quantitative Fluorescence Polymerase Chain Reaction  
CMA= Chromosomal microarray 
FISH= Fluorescence In Situ Hybridization for 22q11.2 microdeletion syndrome on remaining fetal 
samples with cardiac abnormalities 
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Assumptions for the model 
Some assumptions were required in order to develop a workable model: 
1) In cytogenetic testing a result may be positive or negative but (more so in 
CMA testing) it is possible to have a result of uncertain clinical significance 
(VOUS) (see Chapter 1). This result has the potential to be pathogenic but 
may, with future research, prove to be a benign variant, that is normal 
chromosomal variance within the population. In these models, due to the 
possible pathogenic nature of these results, I treated them as positive and 
allowed for the costs of parental follow up to be included and the effectiveness 
score attributed to the result was the same as a pathogenic one. Recent 
prospective studies have reported these results to patients (65). However not 
all VOUS will be true positive findings and over time some will be determined 
as being benign. By treating all VOUS as true positives I may well 
overestimate the effectiveness of CMA testing in detecting chromosomal 
variants. To allow for this all models were re-run treating the VOUS results as 
false positives and the effectiveness score attributed was zero (the same as 
an incorrect or false positive finding). The results of this “sub-analysis” are 
included. 
 
2) That the starting point for the testing was that no prior testing had been 
performed on the sample acquired from the fetus. This was done to simplify an 
already complex model and so that all “samples” were entered at the same 
point in the tree.  
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3) That autosomal Trisomies, sex chromosome aneuploidies and Triploidies 
would require no parental follow up. In reality it may be that parental 
karyotyping is performed (for instance in a finding of Down’s Syndrome) if 
array had shown trisomy 21 and the aetiology was unknown, or karyotyping 
had shown trisomy 21 from Robertsonian translocation. By testing parents 
HCPs can give important information as to the chance of recurrence in future 
pregnancies. However it will not affect this current pregnancy, only 
subsequent pregnancies, and was therefore not included. 
 
4) That a true positive or true negative result gave an effectiveness score of one 
and a false positive or false negative gave an effectiveness score of zero. 
However for some patients if there was any uncertainty (a VOUS) associated 
with the results they may have ranked their efficacy at less than one. However 
this information is currently unavailable.  
 
 
5) The CMA costed is the Birmingham BAC array (BlueGnome, Cambridge, UK) 
as this was the prenatal array being used in the WMGL. I acknowledged that 
this array is more expensive and more targeted then other prenatal arrays 
used and for this reason the analysis includes a threshold analysis, reducing 
the cost of the CMA test.  
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Test accuracy data 
Tests accuracy data in the first model (Table 13)(Appendix J) was taken using the 
data from my own prospective cohort. When calculating the sensitivity of CMA 
and karyotyping it was assumed that the overall result would be positive if either 
test was positive on its own. The sensitivity therefore increased as all individuals 
that tested positive on either test were potentially positive cases. The specificity 
therefore falls as there are more false positives and it is lower than the specificity 
of each test alone. The CMA used in the first model is a targeted BAC focused 
constitutional array (Bluegnome Cambridge). This has a lower resolution than 
other prenatal array used but also limited the number of VOUS found (n=1).  
 
 
Table 13 Test accuracy data taken from Birmingham BAC array prospective 
cohort 
Screening test Probability parameter 
(Sensitivity) 
probability parameter 
(Specificity) 
QFPCR 66/91 (73%) 218/218 (100%) 
Karyotyping 82/91 (90%) 217/218 (99.5%) 
CMA 87/91 (96%) 215/218 (99%) 
Karyotyping and 
CMA 
91/91 (100%) 214/218 (98%) 
FISH 4/7 (57%) 34/34 (100%) 
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Test accuracy data for the second model (Table 14) was based on the values 
estimated by the systematic review  (39;42-45;52;53;65;68;71;73;75-79). Here the 
indication for performing CMA is any clinical indication. As well as including those 
that were referred for abnormal scans it also includes; those that were referred for 
abnormal Down’s Syndrome screening,  those that had testing because of a family 
history of chromosomal problems, those that had testing for advanced maternal age 
and those that requested testing for parental anxiety.  Here the resolution (and 
therefore detection rate) of the CMA varied depending on the platform used.  
 
Table 14 test accuracy data when performing CMA for mixed referral reasons 
Screening test Sensitivity (95% CI) Specificity (95% CI) 
Karyotyping 54.5% (51.7-57.2) 99.9% (99-100) 
CMA 86% (84.2-88) 99.9% (99-100) 
Karyotyping and CMA 100% (100-100) 99.9% (99-100) 
 
Test accuracy data for the third model (Table 15) were also based on values from the 
systematic review(39;42-45;52;53;65;68;71;73;75-79). Here all testing was 
performed because of at least one structural anomaly detected on fetal ultrasound 
scan and  the sensitivity of CMA is somewhat increased. The resolution also varied 
depending on the platform used.  
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Table 15 Test accuracy data when testing performed for abnormal ultrasound 
findings 
Screening test Sensitivity (95% CI) Specificity (95% CI) 
Karyotyping 53.5% (50.1-56.9) 99.9% (99.8-100) 
CMA 96%(94.9-97.5) 99.9% (99.8-100) 
Karyotyping and CMA 100% (100-100) 99.8% (99.7-100) 
 
 
Cost and resource data 
In order to have cytogenetic testing a patient must be counselled by an appropriately 
trained health care professional (HCP) and have an invasive test performed 
(amniocentesis, chorionic villus sampling or fetal blood sampling). The sample is then 
sent to an approved laboratory for testing and results are disseminated to HCPs. If 
negative/normal they are telephoned to the patient, but if abnormal the patient re-
attends for further counselling by HCPs and in some cases cytogenetic testing on 
parental samples is performed. 
 
Here I have only included costing from when the sample arrives at the laboratory and 
then subsequent follow-up costs. The initial cost of a consultation and the invasive 
test procedure were not included as it was assumed that these would be the same 
for all cases. Base costs are calculated as if the invasive sample taken was amniotic 
fluid by amniocentesis. However, the models have been recalculated for CVS 
samples.  
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The costs of resources utilised were those that were directly incurred by the NHS. 
The laboratory costs were calculated by the West Midlands Genetics Laboratory 
(WMGL). Costs of the cytogenetic tests included; DNA extraction, cost of the base 
test and consumables, staffing costs, capital costs (such as the scanner service 
contract) and administration costs. 
 
Staffing costs for the laboratory work were calculated by timing staff performing the 
procedures. The average salary of those routinely doing the work was then used and 
the cost per hour of their time calculated. For the staffing costs for those performing 
the analysis work, as this can be highly variable depending on the complexity of the 
case, the average time was estimated. Capital costs such as the scanner service 
contract were calculated by taking the cost of the contract and dividing it by the 
number of samples processed over the time of the contract.  Administration costs 
have been previously calculated by the laboratory per test and are included.  
Consumable costs were then recorded as those directly incurred by the NHS. Cost of 
follow-up included costs of seeing a consultant clinical geneticist and specialist 
midwife. This was based on a thirty minute appointment. These costs were taken 
from Unit Costs of Health and Social Care 2011(108) (Table 16). Costs used were 
those calculated by the laboratory for the years 2011/2012.  
 
It was assumed that follow-up with parental samples would be required for any 
abnormal cytogenetic test unless the results was an autosomal triploidy, trisomy or 
sex chromosome aneuploidy. If a trisomy 13, 18 or 21 was detected in the model by 
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CMA or QFPCR the cost of parental follow-up was not included (to determine if the 
trisomy was from a Robersonian translocation) as this cost is required for future 
counselling regarding recurrence risk but would not change the outcome for the 
current fetus. This is as opposed to parental follow up for VOUS which would alter 
the outcome for the current fetus when determining pathogenicity of the 
chromosomal anomaly. 
 
Table 16 Cost resource data 
Screening test Unit cost source 
QFPCR trisomy 13,18 
and 21 and sex 
chromosome aneuploidy 
£129 WMGL 
Karyotyping 
Amniocentesis 
£223 WMGL 
Karyotyping Chorionic 
villus sampling 
£265 WMGL 
CMA (1Mb BAC array) £405 WMGL 
FISH for 22q11.2 DS £186 WMGL 
Parental CMA £350 WMGL 
Parental karyotype £382 WMGL 
Follow up specialist 
midwife per 30 mins 
£48.50 Unit Costs of Health and 
Social Care 2011(108)  
Follow up clinical 
geneticist (consultant) 
per 30 mins 
£81 Unit Costs of Health and 
Social Care 2011(108) 
WMGL= West Midlands Genetics Laboratory 
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Outcome 
In this analysis outcomes are reported in terms of the additional diagnoses provided 
by CMA compared to conventional G-band karyotyping. The results are reported in 
terms of the Incremental Cost Effectiveness Ratio (ICER) (Appendix J) based on the 
additional cost for every chromosomal abnormality detected.  
 
Sensitivity analysis 
In addition to the base case analysis I carried out deterministic sensitivity analysis. 
This is a form of sensitivity analysis where input parameters are assigned different 
values (109). Here the following changes were made: 
1) In the CMA arm when VOUS were found they were removed from being true 
positive and treated as false positive results.  
 
2) The cost for laboratory karyotyping were changed from £222 (karyotyping 
performed on cells obtained from amniotic fluid), to £265 (karyotyping 
performed on cells obtained from chorionic villus sampling (CVS)). This was to 
see the effect the type of invasive test was having on the cost effectiveness. 
 
 
3) Threshold sensitivity analyses were carried out to establish the critical value of 
CMA that would change the deterministic results in terms of ICERs and may 
affect the decision of policy makers. This meant decreasing the cost of CMA 
testing and seeing its effect on the cost effectiveness of the technology. The 
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last few years have shown a decrease in the cost of this technology, whereas 
conventional karyotyping is a more stable price having been used for a much 
longer time period.  
 
A probabilistic sensitivity analysis was also undertaken to determine the uncertainty 
of the model. A probabilistic sensitivity analysis is when probability distributions are 
applied to the ranges for a model’s input parameters, samples from the distribution 
are then drawn at random to generate an empirical distribution of the relevant 
measure of cost effectiveness (109). A beta distribution was assigned to each true 
positive, true negative, false positive and false negative parameter. Cost 
effectiveness results were then calculated by simultaneously selecting random 
values from each distribution. A Monte Carlo simulation repeated the process 10,000 
times. A Monte Carlo simulation evaluates the effect of uncertainty by running a large 
number of simulations for each of which values are drawn from distributions assigned 
to uncertain parameters, the aim of which is to construct an empirical probability for 
the overall results (109). This gave an indication of how variation in the test sensitivity 
and specificity lead to variation in the results of cost and effectiveness (109).  
 
The decision uncertainty surrounding the use of CMA as a replacement for 
karyotyping was examined with the cost-effectiveness acceptability curve (CEAC). A 
CEAC curve is a graphical representation of the results from a cost effectiveness 
analysis allowing assessment of the probability of the assessed interventions being 
cost effective at various levels of a decision maker’s willingness to pay for an 
165 
 
 
additional unit of health outcome (109) .This plots the probability that CMA will be 
cost effective as compared to conventional G-band karyotyping at a given threshold 
of willingness to pay (WTP) that decision makers may be willing to pay for a gain in 
effectiveness. In this case a gain in effectiveness is an extra case of fetal 
chromosomal anomaly detected.  
 
Results  
1) Incremental Cost Effectiveness Ratios (ICERS) treating VOUS as true 
positives and using amniocentesis as the invasive test performed 
The base case deterministic results of the strategies based on the outcome of cost 
per case detected are presented in Tables 17-19 (respectively model 1-3). A strategy 
is said to be dominated if it is more costly but less effective than another strategy. 
Dominated strategies are omitted from the table. They are at the base cost of £405 
for CMA and £222 for karyotyping. This is assuming all invasive samples were 
amniocentesis. In these analyses VOUS were treated as true positive results (and 
awarded an effectiveness score of 1). Here incremental cost and incremental 
effectiveness are relative to the previous strategy i.e. In Table 17 if the test of choice 
was QFPCR, then FISH for DiGeorge Syndrome, the ICER is £2500; so it would  cost 
an extra £2500 per extra case detected over the previous strategy using QFPCR 
alone. 
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The effectiveness measure is the cost per case of chromosomal anomaly detected 
by a test (or a positive test result). The Incremental Cost Effectiveness Ratio is in 
pounds sterling and represents the cost per additional case of chromosomal anomaly 
detected.  
 
Table 17 ICERs using model one populated using “Birmingham BAC” cohort 
data and amniocentesis. VOUS are true positives.  
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER 
(£) 
QFPCR only 173  0.9159   
QFPCR then 
FISH Di 
George 
syndrome 
205 32 0.9288 0.0129 2500 
Karyotype 
only 
298 93 0.9644 0.0356 2600 
QFPCR then 
karyotype 
then FISH 
DiGeorge 
411 112 0.9774 0.0129 8700 
CMA only 490 80 0.9806 0.0032 24600 
Karyotype 
and CMA 
722 232 0.9832 0.0026 90500 
QFPCR=Quantitative Fluorescent Polymerase Chain Reaction 
FISH= Fluorescence In Situ Hybridization 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
Explanation of table: incremental cost and Incremental effectiveness are relative to the previous 
strategy i.e. if the test of choice was QFPCR, then FISH for DiGeorge Syndrome the ICER is £2500, 
so it would  cost an extra £2500 per extra case detected over the previous strategy using QFPCR 
alone. 
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Table 18 ICERs using model two populated using systematic review data where 
prenatal chromosomal testing is performed for any clinical indication and the 
invasive test is amniocentesis. VOUS are true positives.  
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER (£) 
Karyotype 
only 
238  0.9578   
CMA only 437 199 0.9871 0.0292 6800 
Karyotype 
then CMA 
646 209 0.9997 0.0127 16500 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
 
 
Table 19 ICERs using model three populated using systematic review data 
where prenatal chromosome testing is performed for abnormal scan findings 
and the invasive test used is amniocentesis. VOUS are treated as true 
positives.  
 
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER (£) 
Karyotype 
only 
255  0.9107   
CMA only 469 214 0.9925 0.0819 2600 
CMA then 
karyo 
655 185 0.9991 0.0066 28300 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
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2) Deterministic sensitivity analysis 
2.1) Using Chorionic Villus sampling instead of amniocentesis.  
As part of the deterministic sensitivity analysis the cost of the invasive test was 
changed from that of amniocentesis to chorionic villus sampling. The following three 
Tables (20-22) use the same populations as above but the cost of the karyotyping is 
increased to £265 as this is the cost of karyotyping chorionic villus samples. In these 
analyses VOUS were again treated as true positive results with an effectiveness 
score of 1:  
Table 20 ICERs using Model one populated using “Birmingham BAC cohort” 
data using Chorionic Villus Sampling. VOUS are treated as true positives.  
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER (£) 
QFPCR only 
 
173  0.9159   
QFPCR then 
FISH 
DiGeorge 
205 32 0.9288 0.0129 2500 
Karyotype 
only 
 
341 136 0.9644 0.0356 3800 
QFPCR then 
karyotype 
then FISH 
DiGeorge 
444 103 0.9774 0.0129 8000 
CMA only 
 
490 46 0.9806 0.0032 14200 
Karyotype 
and CMA 
756 266 0.9832 0.0026 103800 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
 
169 
 
 
Table 21 ICERs using model two populated using systematic review data where 
prenatal chromosomal testing is performed for any clinical indication and 
using Chorionic Villus sampling. VOUS are treated as false positives.  
 
Strategy Cost (£) Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER 
(£) 
Karyotype 
only 
281  0.9578   
CMA only 437 156 0.9871 0.0292 5300 
CMA then 
karyotype 
688 252 0.9997 0.0126 19900 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
 
 
Table 22 ICERs using model three populated using systematic review data 
where prenatal chromosome testing is performed for abnormal scan findings 
and using Chorionic Villus Sampling. VOUS are treated as true positives.  
 
Strategy Cost (£) Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER 
(£) 
Karyotype 
only 
298  0.9107   
CMA only 469 171 0.9925 0.0819 2100 
CMA then 
karyotype 
690 221 0.9991 0.0066 33700 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected 
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2.2) Treating VOUS as false positives 
As part of the deterministic sensitivity analysis VOUS were treated as false positives 
with an effectiveness score of zero rather than as true positives with an effectiveness 
score of one. In reality women may view the “effectiveness” or “worth” of a VOUS as 
somewhere between zero and one, but as this information is not available the 
extremes were analysed.  
 
Test accuracy data was determined as above; model 1 from the prospective BAC 
cohort (Table 23) and models 2 and 3 from systematic review data but here VOUS 
for CMA were treated as false positive results (Table 24 and 25).   
 
Table 23 Test accuracy data "Birmingham BAC cohort” when VOUS are treated 
as false positive 
 
Screening test Sensitivity Specificity 
QFPCR 72.5% 100% 
Karyotyping 90% 99.5% 
CMA 95.6% 98.5% 
Karyotyping and CMA 100% 98.2% 
FISH 57% 100% 
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Table 24 Test accuracy data using systematic review data (any indication for 
chromosomal testing) and VOUS treated as false positives 
 
Screening test Sensitivity Specificity 
Karyotyping 64.6% 99.9% 
CMA 83.6% 98.4% 
Karyotyping and CMA 100% 98.4% 
 
 
Table 25 Test accuracy data using systematic review data and testing for 
abnormal fetal ultrasound findings, VOUS treated as false positives 
 
Screening test Sensitivity Specificity 
Karyotyping 66% 99.9% 
CMA 95.5% 95.6% 
Karyotyping and CMA 100% 95.5% 
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The base case deterministic results of the strategies, based on the outcome of cost 
per case detected, are presented in Tables 26-28 (respectively models 1, 2 and 3). 
The strategies presented are again undominated (so not dominated by a more cost-
effective strategy). They are at the base cost of £405 for CMA and £222 for 
karyotyping. This is assuming all invasive samples were amniocentesis. In these 
analyses VOUS were treated as false positive results. 
Table 26 ICERs using model one populated using “Birmingham BAC cohort” 
data using Amniocentesis as the invasive test and treating VOUS as false 
positives. 
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER (£) 
QFPCR 
only 
173  0.9191   
QFPCR 
then FISH 
DiGeorge 
205 32 0.9320 0.0129 2489 
Karyotype 
only 
298 93 0.9676 0.0356 2616 
QFPCR 
then 
karyotype 
then FISH 
DiGeorge 
411 112 0.9806 0.0129 8670 
QFPCR 
then 
karyotype 
and CMA 
719 309 0.9871 0.0065 47697 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected  
Here CMA alone is dominated by the strategies above due to the reduced 
effectiveness of CMA if the VOUS results were treated as false positives. 
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Table 27 ICERs using model two populated using systematic review data where 
prenatal chromosomal testing is performed for any clinical indication and 
using amniocentesis as the invasive test. VOUS are treated as false positives.  
 
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER 
(£) 
Karyotype 
only 
238  0.9723   
karyo then 
CMA 
646 408 0.9852 0.0129 31500 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected  
Here CMA alone is dominated by the strategies above due to the reduced 
effectiveness of CMA if all VOUS results were treated as false positives. 
 
Table 28 ICERs using model three populated using systematic review data 
where prenatal chromosomal testing is performed for abnormal ultrasound 
scan and using amniocentesis. VOUS are treated as false positive. 
 
Strategy Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness Incremental 
Effectiveness 
ICER 
(£) 
Karyotype 
only 
255  0.9474   
CMA only 469 214 0.9558 0.0084 25400 
CMA then 
karyo 
655 185 0.9623 0.0065 28300 
ICER = £ per additional chromosomal abnormality detected 
Effectiveness = Proportion of chromosomal abnormalities correctly detected  
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2.3) Threshold analysis reducing cost of CMA testing 
As the cost of CMA is decreasing it was appropriate to model this decrease in cost 
and the effect it would have on the willingness to pay (WTP) for a chromosomal 
anomaly to be detected.  
 
This “threshold analysis” was done twice for the Birmingham BAC cohort, once when 
VOUS treated as true positives (Figure 22) and once with the VOUS  treated as a 
false positive (Figure 23). It was also performed for models 2 and 3 using systematic 
review data, here the VOUS are treated as true positives (Figure 24 and 25).  The 
cost of CMA was reduced from its base case value of £405 to £100. 
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Figure 22 Threshold analysis reducing the cost of fetal and parental CMA. 
Using “Birmingham BAC cohort”. VOUS treated as true positive findings. 
 
 
CMA= Chromosomal Microarray 
FISH= Fluorescent In Situ Hybridisation 
Karyo= Conventional G Band Karyotype 
QFPCR= Quantitative Fluorescence Polymerase Chain Reaction 
VOUS= Variant Of Unknown Significance 
 
Legend: The threshold analysis above shows the effect of decreasing the cost of fetal CMA and 
parental CMA (presented in brackets) and the effect of this on the willingness to pay for fetal 
chromosomal anomaly to be detected. In this analysis VOUS are treated as true positives.   
 
Graph Interpretation: at a given cost of fetal CMA of £400when the willingness to pay for a 
chromosomal abnormality to be detected is <£2000 the test of choice is QFPCR. When the WTP is 
between £2000 and £8000 then the test of choice is karyotyping. When it is above £8000 but below 
£22,000 the tests of choice are QFPCR followed by karyotype (if QFPCR negative) followed by FISH 
for Di George (if other tests negative and a cardiac anomaly). If the WTP is above £22,000 but below 
£90,000 the CMA is the test of choice.  
         (45)              (95)            (145)              (195)                (245)             (295)           (345)           (395)  
 Cost of fetal (parental) CMA  
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Figure 23 Threshold analysis reducing the cost of fetal and parental CMA. 
Model one “Birmingham BAC cohort”, but VOUS treated as false positives.  
 
  
CMA= Chromosomal Microarray 
FISH= Fluorescent In Situ Hybridisation 
Karyo= Conventional G Band Karyotype 
QFPCR= Quantitative Fluorescence Polymerase Chain Reaction 
VOUS= Variant Of Unknown Significance 
WTP= Willingness To Pay 
 
Legend: The threshold analysis above shows the effect of decreasing the cost of fetal 
CMA and parental CMA (presented in brackets) and the effect on the willingness to 
pay for detection of a chromosomal anomaly. In this analysis VOUS are treated as 
false positives.   
 
       (45)           (95)         (145)          (195)       (245)        (295)      (345)                   
Cost of fetal (parental) CMA 
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Figure 24 Threshold analysis reducing the cost of fetal and parental CMA. 
Model two using systematic review data and any indication for testing, VOUS 
treated as true positives 
 
 
 
Legend: The threshold analysis above shows the effect of decreasing the cost of fetal 
CMA and parental CMA (presented in brackets) and the effect on the willingness to 
pay for detection of a chromosomal anomaly. In this analysis VOUS are treated as 
true positives and the analysis was populated with systematic review data where the 
indication for testing was “any clinical indication”.   
 
 
 
 
 
 
         (45)                   (145)                  (245)                (345)                (445)               (545)       
Cost of fetal (parental) CMA 
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Figure 25 Threshold analysis reducing the cost of fetal and parental CMA. 
Model Three using systematic review data and abnormal ultrasound scan as an 
indication for testing, VOUS treated as true positives  
 
 
 
Legend: The threshold analysis above shows the effect of decreasing the cost of fetal 
CMA and parental CMA (presented in brackets) and the effect on the willingness to 
pay for detection of a chromosomal anomaly. In this analysis VOUS are treated as 
true positives and the analysis was populated with systematic review data where the 
indication for testing was abnormal fetal ultrasound findings  
 
 
 
         (45)               (145)               (245)              (345)                (445)              (545)             (645) 
Cost of fetal (parental) CMA 
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3) Results of probabilistic sensitivity analysis  
A sensitivity analysis was performed as previously described using a Monte Carlo 
simulation. This allows the extent of the uncertainty surrounding the result to be 
graphically represented. The probabilistic sensitivity analyses are presented for the 
Birmingham BAC cohort Model 1 (both when VOUS are treated as true positive and 
false positive findings) (Appendix H). These sensitivity analyses were performed 4 
times looking at the probability that CMA is cost effective over 4 different strategies; 
1) Karyotyping, 2) QFPCR, 3) QFPCR then FISH for DiGeorge, 4) QFPCR then 
Karyo then FISH for DiGeorge. 
 
The probability that CMA is positive over karyotyping for Model 1 both when VOUS 
are treated as true positives and false positives is described and represented as 
Figures 26-29.  
 
Probabilistic sensitivity analyses are also performed for Models 2 (Figures 30-31) and 
3 (Figures 32-33) using systematic review data. Here the probability that CMA is 
cost-effective over karyotype is also considered.  
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Figure 26 Cost effectiveness scatter plot. Model 1 “Birmingham BAC cohort”.  
VOUS treated as true positives, CMA over karyotyping 
 
Legend: Each point plotted is one sample. The area covered by the plot represents uncertainty. 
Interpretation: Here the effectiveness of CMA over karyotyping is mostly positive around an 
incremental cost of £180. 
Figure 27 CEAC of CMA over karyotyping “Birmingham BAC cohort” model 1, 
treating VOUS as true positives 
 
Legend: Cost effectiveness analysis curve showing the probability that CMA is cost effective over 
karyotyping as the willingness to pay (WTP) for every extra case detected by CMA increases. Here the 
case rate cost of CMA is £405. There is an 80% probability that CMA is cost effective over karyotyping 
when the WTP for a positive diagnosis is £40,000 and a 50% probability that it is cost effective when 
the WTP is £13,000. 
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Birmingham BAC cohort Model 1 VOUS treated as false positive:  
Figure 28 Cost effectiveness scatter plot. Model 1 “Birmingham BAC cohort” 
VOUS as false positives CMA over karyotyping 
 
Legend: Here the effectiveness of CMA over karyotyping is mostly positive around an incremental cost 
of £180 
Figure 29 CEAC Model 1 “Birmingham BAC cohort”, VOUS as false positives, 
CMA over karyotyping 
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Legend: Cost effectiveness analysis curve showing the probability that CMA is cost effective over 
karyotyping as the willingness to pay (WTP) for every extra case detected by CMA increases. Here the 
case rate cost of CMA is £405 but VOUS are treated as false positives. There is a 77% probability that 
CMA is cost effective when the WTP for a case to be detected is £50,000 and 50% probability that it is 
cost effective at a WTP of £20,000.  
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Figure 30  Cost effectiveness scatter plot. Model 2 using systematic review 
data (all indications for testing) VOUS treated as true positives, CMA over 
karyotyping 
 
Legend: Here the effectiveness of CMA over karyotyping is always positive around an incremental 
cost of £199. Note there is no zero on incremental cost scale purposefully to aid interpretation of the 
plot. 
Figure 31 CEAC Model 2 Systematic review data, all indications for testing, 
treating VOUS as true positives 
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Legend: Cost effectiveness analysis curve showing the probability that CMA is cost effective over 
karyotyping as the willingness to pay (WTP) for every extra case detected by CMA increases. Here the 
base rate cost of CMA is £405. This curve is populated by data taken from systematic review analysis 
when the indication for chromosomal testing is any indication. CMA has a 95% probability of being 
cost effective over karyotyping when the willingness to pay is £7500. 
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Figure 32 Cost effectiveness scatter plot. Model 3 systematic review data when 
testing performed for abnormal ultrasound anomalies, CMA over karyotyping 
 
Legend: Here the effectiveness of CMA over karyotyping is always positive around an incremental 
cost of £214. Again there is no zero on the incremental cost scale.  
Figure 33 CEAC Model 3 systematic review data, testing performed for 
abnormal ultrasound scan findings, treating VOUS as true positives CMA over 
karyotyping 
 
Legend: Cost effectiveness analysis curve showing the probability that CMA is cost effective over 
karyotyping as the willingness to pay (WTP) for every extra case detected by CMA increases. Here the 
base rate cost of CMA is £405. This curve is populated by data taken from systematic review analysis 
when the indication for chromosomal testing if an abnormal fetal ultrasound scan finding. CMA has a 
95% probability of being cost effective over karyotyping when the willingness to pay is £2830. 
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Discussion 
To summarise, decision modelling was used to examine whether prenatal CMA was 
a cost effective option, either when referral occurred for any indication (including 
advanced maternal age, parental anxiety, family history of increased prenatal 
screening result), or referral was for abnormal findings on ultrasound when compared 
to karyotyping or other conventional cytogenetic testing (QFPCR for common 
trisomy, FISH for Di George). This was performed using data from the Birmingham 
BAC cohort and also using data available from systematically reviewing the literature. 
These methods produced differing results and the benefits and limitations of these 
will be discussed.  
 
Treating VOUS as true positives 
Data accuracy  
When looking at the sensitivity of karyotype this was lower for the systematic review 
data (models 2= 54.5% and 3= 53.5%) than for the BAC cohort (Model 1 = 89%). 
This appears to be because the higher detection rate by CMA in the systematic 
review data (both as a combination of higher resolution arrays and more pathogenic 
results but also higher VOUS rate) increased the prevalence of chromosomal 
anomalies and decreased the sensitivity of karyotyping. 
 
CMA had a lower sensitivity when calculated from systematic review data for any 
indication (model 2 = 86%) compared with both the BAC cohort of abnormal scan 
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findings (model 1 = 96%) and the systematic review data array performed for 
abnormal scan findings (model 3 = 96%). This may be because the data used to 
calculate CMA sensitivity when performed for any indication included samples where 
there was a known abnormal karyotype that would not be detected by CMA (such as 
a balanced rearrangement) and this may have artificially lowered the sensitivity of the 
array. Although balanced rearrangements will exist within the population, these had 
been selected to test on CMA and the numbers may not be representative of the 
incidence within the population. Balanced rearrangements are also unlikely to be 
pathogenic and lead to a phenotypic effect. 
 
ICER treating VOUS as true positives 
The ICER was significantly higher for CMA testing using model 1 rather than models 
2 or 3. Using model 1 the limited resolution of the Birmingham BAC array (and 
therefore limited detection rate) and the finding of 4 submicroscopic deletions in the 
DiGeorge region (detectable by FISH analysis as well as CMA), the ICER of CMA 
over a combination of QFPCR followed by karyotype followed by FISH (for DiGeorge 
in known fetal cardiac anomalies) was £24,600. This means that it would cost an 
extra £24,600 for every extra case detected by CMA over the above combination of 
tests (QFPCR then Karyotype then FISH Di George).  
 
This result is very different to Models 2 and 3 using SR data where the ICER for CMA 
over karyotype is £6,800 for every extra case detected by CMA where there was any 
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indication for testing and £2,600 for every extra case detected by CMA over 
karyotyping where the indication was abnormal scan finding.  
 
This could be due to the fact that: 
1) Models 2 and 3 could not include QFPCR and FISH (for DiGeorge region) 
data as there was insufficient information available from the published cohorts. 
 
2) VOUS will have increased overall prevalence rates in models 2 and 3 (as 
higher resolution array were used which will have increased the VOUS rate 
and artificially lowered the sensitivity of karyotype and over-inflated the 
sensitivity of CMA).  
 
3)  VOUS were given an effectiveness score of 1, the same as pathogenic 
results. This is because we lack the information on how women view these 
results and the value that they would afford them. Current qualitative data 
seems to suggest that parents have mixed feeling about their worth, 
depending upon whether they are given pre- or postnatally and that prenatally 
they may be given a limited value, or even a negative value (66;90) (Chapter 
5). 
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Deterministic sensitivity analysis  
Treating VOUS as false positive 
Data Accuracy 
When VOUS are treated as false positive findings karyotype still has a lower 
sensitivity when compared with CMA. This is more profound in the systematic review 
models 2 and 3, then the Birmingham BAC model 1. This is because the higher 
resolution CMA platforms in the systematic review data will increase the prevalence 
of chromosomal anomalies in the model and decrease the karyotype’s sensitivity. 
  
CMA sensitivity was higher for the Birmingham BAC model 1 and the systematic 
review for abnormal scans model 3 (96%) than the systematic review model for all 
indications model 2 (84%). This was because model 2 included samples with a 
known balanced rearrangement on karyotype and therefore none detectable by CMA 
which would lower the CMA sensitivity.  
 
ICERs treating VOUS as false negatives 
CMA alone is dominated by other strategies (more costly but less effective)  when 
VOUS are treated as false positives in models 1 and 2. The only model in which 
CMA alone featured as an undominated strategy was model 3 (systematic review 
data testing performed for an abnormal scan finding). Here the ICER for CMA alone 
over karyotype alone would cost £25,400 for an extra positive diagnosis by CMA. 
However treating all VOUS as false positives will underestimate the specificity of 
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CMA as some VOUS will in time be determined as benign but others will be 
pathogenic.  
 
Threshold analysis 
The current base rate cost of CMA in these 3 models was the cost of £405 for a 
Birmingham BAC array. However the cost of CMA is rapidly decreasing and higher 
resolution CMA platforms are now being costed at £350 or lower. A threshold 
analysis was therefore performed to see what would happen to the cost effectiveness 
of the tests as CMA decreased in price. Using data from the Birmingham BAC cohort 
model 1 when CMA costs £360 or lower and the willingness to Pay (WTP) for a 
positive diagnosis is £9768 then CMA is cost effective over karyotyping. Using the 
same cohort when VOUS are treated as false positive results, then CMA has to cost 
£302 or less and the WTP for a positive diagnosis has to be £9185 or less for CMA to 
be cost effective over karyotyping. If the WTP stays below £9768 and the CMA cost 
stayed above £360 then karyotyping is the test of choice. If the WTP increases but 
the cost of CMA stays at £360 or lower then QFPCR, followed by Karyotyping (if 
QFPCR negative), followed by FISH for DiGeorge syndrome (if karyotype negative 
and cardiac anomaly) becomes the testing strategy of choice.  
 
In comparison when the threshold analysis was performed for systematic review 
testing for all indications (model 2) when CMA was under £210 it was always the test 
of choice and at its current cost of £405 or lower if the WTP for a positive diagnosis 
was at least £6807 then CMA was the test of choice. 
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Using model 3 (systematic review abnormal scan data) CMA becomes the most cost 
effective test at or below £210. At its current cost of £405 if the WTP was at least 
£2613 for a positive test CMA would be the test of choice. 
 
Models 2 and 3 found CMA to be more cost effective at a lower WTP is because: 
1) Models 2 and 3 included higher resolution CMA platforms and therefore had a 
higher detection rate by CMA making it more cost effective. 
 
2) Models 2 and 3 included VOUS as true positives and therefore overestimated 
the effectiveness of CMA. 
 
3) Models 2 and 3 were not as complex and could not include further testing 
(QFPCR FISH for DiGeorge syndrome) as the information was not extractable 
from the published articles. 
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Probabilistic sensitivity analysis.  
Cost Effectiveness Analysis Curves (CEAC) 
CEACs were calculated for the base rate cost of £405 for CMA. Using data from the 
Birmingham BAC Cohort (model 1) there is an 80% probability that CMA is CE over 
karyotyping when the WTP for a positive diagnosis is £40,000 and 50% probability 
that it is CE when the WTP is £13,000. 
 
In contrast using systematic review  data, when chromosomal testing is performed for 
any indication there is a 95% probability that CMA is cost effective over karyotyping 
when the WTP is >£7500 (model 2). When chromosomal testing is performed for 
abnormal fetal ultrasound (also using systematic review  data) there is a 95% 
probability that CMA is cost effective over karyotyping when the WTP is >£2830 
(Model 3).  
 
The reason there is such a difference in CEAC curves for models 1 vs. 2 and 3 is 
because of the higher resolutions of CMA included in models 2 and 3 and therefore 
their high detection rates of both pathogenic variants and VOUS. It must be stressed 
that these curves were produced for the base case cost of £405. When the 
Birmingham BAC model was reduced to £350 there was an 80% probability that 
CMA was cost effective when the WTP for a positive diagnosis was £25,000. 
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Strengths and Limitations 
The first model’s strength was that only one array platform was used and therefore 
there was no heterogeneity in the data that would have existed had various arrays 
been used at differing resolutions. It was primary data taken from a complete data set 
so I was able to perform complex modelling using various testing strategies. This was 
in contrast to models 2 and 3 using systematically reviewed data that used 
heterogeneous CMA Platforms and lacked the information to provide more detailed 
modelling of tests other than CMA and karyotype.  
 
There were limitations and assumptions made. Firstly, that the outcome was 
measured as effectiveness in terms of extra cases detected. In economic evaluation 
this is seen as an intermediate outcome because the final pathway that is followed 
based on the detection of a positive case is not explored in terms of the additional 
costs and effects that are likely to be incurred. Yet chromosome testing is done and 
the purpose of the current evaluation is to explore which is the most cost effective 
option for detecting an anomaly, so for that end the intermediate outcome is justified. 
Furthermore, no numerical figure could be placed on the benefit that women and 
their partners would state for a positive result, particularly if that positive result had 
some uncertainty attached (such as a VOUS). Also this analysis treated all 
chromosomal anomalies as equivalent and in reality some may be more severe than 
others and so the WTP might vary with severity of the chromosomal anomaly 
detected.  Quality Adjusted Life Years (QALYs) are not appropriate as the resulting 
conditions are heterogeneous. For instance the lifetime social and medical cost for 
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caring for someone with Down’s Syndrome will be higher than a chromosomal 
anomaly leading to a perinatal lethal condition. Also there is no “treatment” for a 
positive result at present, the only action that can be taken is to terminate the 
pregnancy. This is a complex medical problem with many ethical dimensions and it 
cannot be reduced to an economic argument based on an outcome measure. 
 
Secondly, it is acknowledged that the 1 Mb BAC array is more expensive than other 
prenatal arrays used. For this reason the analysis includes reduction in the cost of 
the CMA test which is also included within the sensitivity analysis. I also 
acknowledge the targeted nature and conservative resolution of the array (and hence 
its decreased detection rate) but this platform was chosen in the knowledge that the 
rate of variants of unknown significance (VOUS) would also be significantly 
decreased. This would therefore not create potentially unnecessary uncertainty/worry 
for women and their partners.  
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Conclusion 
Prenatal targeted CMA platforms (such as the targeted BAC array) may not presently 
offer good value for money in terms of cost per case detected. However increasing 
resolution and decreasing costs of CMA mean that it is likely to become a cost 
effective option in the future. Before this can be ascertained VOUS must be awarded 
an effectiveness score. Current qualitative data seems to suggest that parents have 
mixed feeling about their worth, depending upon whether they are given pre or 
postnatally and that prenatally they may be given a limited value, or even a negative 
value (66). If awarded a negative value it may be better to not report them to parents 
at all.  
 
If VOUS continue to be reported to patients they should continue to be modelled as I 
have done (as true positive results) but with an adjusted effectiveness score. If an 
international decision is made to not report VOUS they could be re-modelled as true 
negative results but with associated parental follow-up costs.  Modelling VOUS as 
false positives (as I have done in my sensitivity analysis) may be inaccurate as many 
will turn out to be pathogenic findings.  
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Submitted manuscript from Chapter 6 
The following manuscript has been submitted to the Fetal Diagnosis and Therapy 
and is pending amendments: 
Chromosomal microarray for prenatal detection of chromosome anomalies in fetal 
ultrasound anomalies: an economic evaluation Hillman SC, Barton PM, Roberts TE,  
Maher ER,  McMullan DJ and Kilby MD 
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CHAPTER 7 THE ETHICS OF PRENATAL MICROARRAY TESTING 
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Introduction 
In this Chapter I will discuss some emerging ethical concerns related to chromosomal 
microarray testing (CMA) and draw from this discussion some tentative 
recommendations for guidelines for future practice. 
 
As I have previously discussed, in pregnancy couples seek information regarding 
their fetus’ chromosomes due to; a “high risk” screening result, a family history of 
genetic conditions, structural abnormalities seen on ultrasound scan, advanced 
maternal age or even for parental anxiety/reassurance.  Prenatal chromosomal 
testing in some form has been available since the 1960s. 
 
The main ethical argument for providing this testing is that of reproductive autonomy 
by providing people with an option of termination of pregnancy should a fetal 
chromosomal anomaly be found. For some they would view this as prevention of any 
suffering that a child with a chromosomal anomaly may experience, as well as 
prevention of financial and emotional stress on a family. For those that oppose 
termination of pregnancy it would still be of benefit if this knowledge could be used to 
plan for the future, prepare for the birth and tailor medical treatment of the child 
effectively (110). 
 
Counter ethical arguments lie in the concern that women may be coerced into 
prenatal testing either by society as a whole, by the medical profession, or by a 
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patriarchal partner (110-112). There is also an argument that prenatal testing and 
termination of pregnancy of fetuses with chromosomal disorders may be seen as a 
way of “dealing” with disability, and that chromosomal disabilities could be viewed as 
increasingly rare with limited services being distributed to people with these 
diagnoses. Society may view people with chromosomal anomalies as the ones that 
were “missed” by prenatal testing. The attempt to eliminate chromosomal anomalies 
may even be viewed as a form of eugenics (110;111). 
 
Debate has always existed around prenatal testing and how the reproductive 
autonomy of women can be balanced against any rights that may be afforded to the 
fetus (111;113). I will, however, leave these mentioned issues aside in favour of 
highlighting the newer more specific challenges posed by microarray technology. 
 
CMA allows high resolution of analysis, detecting chromosomal differences that 
would be missed by conventional testing. It also allows thousands, even millions of 
loci throughout the genome to be analysed simultaneously and is amenable to high 
throughput. Results may show a pathogenic chromosomal variant known to cause a 
definite syndrome in the baby. They may, however, also show a Variant of Unknown 
Clinical Significance (VOUS), where current databases/literature suggests a possible 
effect in the baby but the findings are still uncertain. Microarrays can also reveal 
incidental findings such as a susceptibility to adult onset disease. The detail that can 
be generated by this testing creates ethical concerns that, although not new, will be 
more commonly encountered with microarray technology. How do we gain informed 
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consent for a prenatal test that is so detailed it would take an unfeasible amount of 
time to discuss every possible outcome? Should VOUS be communicated to 
parents? Do we report incidental findings that may not manifest until adulthood? Are 
we (further) removing the child’s right to an open future?  
 
The technology to detect fetal chromosome abnormalities has left a “therapeutic gap” 
(110); the information generated can only be used as the basis for a decision about 
whether or not to terminate a pregnancy rather than to inform options for treating the 
abnormality detected.  Those offering the test therefore have a responsibility to 
ensure that couples/women are counselled accurately about the possible outcomes 
of the test prior to consent for testing and that results are conveyed to women clearly 
and honestly.  
 
Genetic testing in both the prenatal and postnatal setting remains controversial and 
chromosomal microarray testing shares all of the controversial features of more 
routine testing. Since the invention of prenatal chromosome analysis in the 1960s 
women have had the opportunity to have prior knowledge of their fetus’ 
chromosomes.  
 
As described in Chapter 2, at Birmingham Women’s Hospital Foundation Trust in the 
United Kingdom we have been providing microarray testing alongside standard full, 
conventional karyotype testing under local research ethics approval between 2009-
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2012. I interviewed some of the research participants and where appropriate the 
words of these women or their partners have been used to illustrate my key points 
(Qualitative work in full is presented in Chapter 5 and Appendix G).  
 
Gaining consent to microarray testing 
To give consent, the patient must have an adequate understanding of what the test 
involves, what the possible benefits, drawbacks and outcomes are and any realistic 
alternatives (114). Information needs to be tailored to the individuals so that s/he can 
make a well-informed decision. The patient must have the capacity to understand the 
information and form a reasoned judgment. This must be done voluntarily without any 
coercion. Informed consent protects self-determination and rational decision-making 
(115).  
 
Prenatal microarray testing poses particular challenges for the Health Care 
Professional (HCP) aiming to gain valid consent for the test. Pregnancy is a highly 
emotional time for women and their partners in “normal” circumstances. When 
something in the pregnancy has already caused concern, such as following a “high 
risk” screening result or an abnormal finding on ultrasound, then counselling for 
genetic testing becomes even more difficult. Stress may limit the amount of 
information retained (99).  
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“I think because in the last few weeks we have been to that many appointments and 
tried to absorb so much and at the same time trying to come up with a decision, it 
has been hard to decipher” (Interview 9b) 
 
It is for this reason that women and their partners need to be given opportunities to 
revisit the idea of testing at subsequent visits if initially unsure, and the opportunity to 
withdraw from the testing should they change their mind. Of course this indecision 
regarding the testing cannot be endless given the time frame of pregnancy or even 
possible in some pregnancies. Likewise once the microarray test has been 
processed and analysed it should be reported. Women should also be given written 
information to take home. This written material is a source of reference not only so 
patients can reflect on what the microarray test is but what their results may show 
and how these results will be disseminated back to them. It should also contain 
contact details should the patients have any further questions.  
 
This already stressful situation is further compounded by the biological timetable of 
pregnancy, the scheduling of testing and the greater clinical and emotional difficulties 
of late abortion all of which create a sense of time pressure (86). 
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“Because of the Christmas holidays that was my 24 weeks (twenty four completed 
weeks is the legal limit for the majority of clauses for the Abortion Act, 1967), if it was 
really bad (the result) you just have the time factors, there wasn’t going to be anytime 
to have a result and make a decision so you had to think it through probably further 
than you would have wanted to.” (Interview 11a) 
 
The current lack of guidance for prenatal microarray testing may encourage the 
standard of information given during counselling to fall as its use becomes more 
widespread. Current guidance from the American College of Obstetrics and 
Gynaecology (published 2009) and the Italian society of Human genetics (2011)  
state that in the prenatal context CMA should not be first line and not without 
conventional karyotyping. Neither give any advice on the reporting of results to 
patients when the result is of an uncertain nature (48;83). Many obstetricians receive 
no training in medical genetics beyond that given in medical school, and some 
qualified before chromosomal microarray technology was available. A lack of 
understanding on behalf of HCPs will lead to misunderstanding or miscommunication 
when performing pre-test counselling, leading to a failure to gain truly informed 
consent.  
 
It can be a challenge to gauge how much information to give, treading a fine line 
between “information-overload” and too little for the patient to have a realistic notion 
of what is being consented to. The National Institutes for Health – Department of 
Energy (NIH-DOE ) Task Force on genetic testing by the Ethical, Legal and Social 
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Implications (ELSI) branch of the Human Genome Project developed guidelines for 
ensuing quality and appropriate use of genetic tests (116). It contains a large number 
of recommendations for validation of tests, quality assurance, genetic education, 
confidentiality and consent. These, however, refer to testing for a single disease and 
may not readily translate to microarray testing, which tests many regions of the 
chromosome in parallel (117). It would be impossible to explain in detail all the 
possible syndromes and diseases that could be detected by the array before the test 
is performed; predictive testing for the BRCA 1 and BRCA 2 gene mutations (utilised 
to discuss risk of developing breast cancer) commonly require 1-2 hours of 
counselling alone for instance (117).  
 
Instead a model of generic consent before the testing could be used with detailed 
information provided when a positive result is found. Such generic consent would 
need to include examples of potential findings so that the woman and her partner can 
put the counselling into context. This approach would be similar to that prior to a 
physical examination (115) where the patient is unaware of every positive finding that 
could be discovered but gives consent knowing that the purpose of the examination 
is to determine potential problems. Larger cohort studies have shown that microarray 
testing will give a normal or a “negative” result between 88%-98% of the time 
(52;65;68;74); so hours of explanation prior to testing will ultimately be irrelevant for 
the majority of patients and may arguably also waste valuable clinical resources.  On 
the other hand, the minority of patients for whom a positive result is found may feel 
that this approach was paternalistic, or even deceptive, in the hindsight of their 
positive result.  
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Pre-test counselling for chromosomal microarray testing however does need to be 
more detailed than counselling that normally occurs for prenatal cytogenetic testing, 
and with the average reading age in the UK being that of an educated nine year old a 
conscious effort needs to be made to keep counselling and literature as simple as 
possible. Darilek et al suggest that pretest counselling should include a review of 
chromosomes and genetic structure, a description of the CMA to be used, and the 
extent of its coverage as well as the spectrum of disorders that can be detected 
(118).  In addition I suggest that pretest counselling should include why parental 
blood samples are needed (to assess inherited anomalies), the chances of finding an 
abnormality and examples of abnormalities that can be detected by genome-wide 
array including: 
 
• Pathogenic chromosomal changes explaining or likely to result in fetal (ultrasound) 
anomalies 
• De novo chromosomal changes of unknown clinical significance (VOUS) 
• Inherited chromosomal changes of unknown significance 
• Incidental findings-chromosomal variants that are health debilitating and may cause 
adult onset conditions (99). 
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Accepting testing 
Prenatal screening and testing has become so embedded into the routine of prenatal 
care that there is an expectation that women will inevitably accept an offer to learn 
more about the health of their unborn child (66).  
 
HCPs and patients may have different reasons for offering or accepting microarray 
testing. Hunt et al found that clinicians valued prenatal genetic testing as a means of 
enabling patients to prepare for an affected birth, or to use information to decide 
whether to continue the pregnancy. As microarray testing provides more information 
than standard karyotyping (31)  its “detection rate” is higher and HCPs are therefore 
more likely to offer it. Conversely patients put emphasis on protecting and nurturing 
their baby: they sought reassurance rather than to isolate a potential problem (85).  
“Once I had those tests and if they came back clear I could mark out and put those 
sorts of things to the back of my mind” (Interview 8a) 
 
“You just want as many tests done as you can to see like if the baby’s gonnna be 
OK” (Interview 9a) 
 
Patients may not be as interested as HCPs in this higher “detection rate” and may 
prefer fewer results that can be fully interpreted. This mismatch between the HCPs’ 
quest for positive results to provide information versus the patients’ quest for a 
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negative result to provide reassurance presents a potential tension that must be 
explored during counselling before testing. Accepting microarray testing solely for 
reassurance, particularly when the test is being performed as a screening tool, 
should be discouraged as the rationale of testing is to find chromosomal 
abnormalities. Women and their partners must be left in no doubt that the test may 
detect a pathogenic finding that will present them with difficult decisions. Furthermore 
a negative microarray result will not guarantee a baby without a 
chromosomal/genetic abnormality and there is a possibility that if a child with the 
negative microarray result subsequently exhibits developmental problems these will 
be dismissed as behavioural on the erroneous assumption that any genetic element 
would have been detected by the microarray test.  
“Now I definitely know that everything to do with the chromosomes is ok” (Interview 
14a)  
 
 Microarrays have a limit to their resolution and will still miss some genetic problems - 
a further piece of information that women need to understand before consenting to 
testing.  
 
The participants in my study, in all of whose fetuses structural abnormalities had 
already been found on ultrasound scanning,  gave four broadly interpreted reasons 
for undergoing microarray testing the third of which was they felt they had “no other 
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choice” but to agree to testing 2. My cohort was using microarray testing as a 
diagnostic tool (post-abnormal scan) rather than a screening tool of the kind that 
might be introduced for patients with advanced maternal age, and their views may 
not, therefore, represent those of a screening population.   
  
Other studies have similarly found that women and their partners feel they have “no 
choice” (111) but to accept testing. Women may not be describing coercion from 
HCPs or family (although this is a possibility) but rather “the possibility that my child 
could be born with a chromosomal problem that I could have prevented is so 
unacceptable to me that I have no choice but to accept testing” (111). This was my 
impression during the qualitative work performed locally. 
“Taken into consideration the reason and the risks there wasn’t really any alternative 
choice” 
(Interview 4a). 
 
Coercion to accept testing is a possibility and it is not unlikely that as microarray 
testing becomes widely available parents will feel under obligation to accept testing 
(119). Refusing prenatal testing may leave parents feeling responsible for knowingly 
risking bringing a disabled child into the world, where suffering could have been 
avoided (by terminating the pregnancy) (120). One coping strategy of pregnant 
                                            
2
 Their other reasons were:  i) they were willing accept every test in order to find an explanation for the problems on ultrasound scan; ii) they 
wanted reassurance that the structural abnormality was not caused by a chromosomal difference (that would worsen the prognosis) ;  and, iii) they 
benevolently wanted to help those in their position the future by participating in the research 
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women who find themselves in a stressful position is to comply with what they believe 
is the health professional’s recommendations (100).   
“We just agreed to everything” (Interview 6a) 
 
It is therefore important that counselling for microarray testing is non-directive so that 
women and their partners do not feel that accepting or declining testing is conforming 
to a professional recommendation. We aim to be non-directive when counselling and 
consenting women for chromosomal testing, but in reality this is extremely difficult to 
achieve. Prior knowledge of the circumstances surrounding the referral will alter the 
way that HCPs counsel women. Lippman et al looked at the counselling of women 
undergoing genetic testing for Down’s Syndrome (Trisomy 21) prenatally compared 
with postnatally. In both situations the information was factually correct but the before 
birth information was largely negative, focusing on medical complications and 
physical limitations, where the after birth information tended to be more positive 
highlighting medical resources (121). Jameton and colleagues found that HCPs often 
weave in professional and personal biases with what they present to patients (122). 
 
Reporting of variants of unknown significance 
Up to 12% of the human genome contains variance (27). Much of this is benign 
variation in the population, with specific ethnicities having variation throughout the 
genome. Pathogenic results can be conveyed with a degree of certainty. These occur 
when the variation causes disruption of genes with known pathogenic significance 
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causing structural problems for the fetus visible on ultrasound or causing a well-
recognized syndrome. There are, though, many areas of the genome where variation 
is not thought to be benign but the effects of the variation are unknown. These so 
called “Variants Of Unknown Significance” (VOUS) present probably the biggest 
dilemma associated with microarrays both for HCPs and patients. They are a 
particular problem in the prenatal setting because of limited evidence available to us 
from ultrasound scan. For instance, we are not able to judge from the scan if the child 
has clinical signs of autism.  
 
There is no national or international guidance on whether VOUS should be 
communicated to women in the prenatal setting. The recent US National Institute of 
Child Health and Human development NICHD study involved 4406 participants: only  
25% of these had received an abnormal ultrasound scan, microarray testing was 
conducted in the remainder for advanced maternal age (47%), positive Down 
syndrome screening (19%) and other reasons including elective request (9%) (65). In 
this study VOUS were reported back to women and their partners. 
 
In my cohort women were referred for microarray testing due to structural 
abnormalities seen on fetal ultrasound scan (such as a congenital cardiac anomaly). 
The pregnancy had therefore already become “abnormal” and microarray testing was 
performed to find out if a chromosomal anomaly had caused the abnormalities found 
on the scan so as to further inform the prognosis. In my cohort only one VOUS was 
defined and reported to the patient. In this case the couple seemed to base their 
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decisions on the “certain” information - the scan findings - rather than the uncertain 
array findings and they chose to continue the pregnancy. This one case is insufficient 
to allow generalisation but some of the women who were given information about 
VOUS in the much larger NICD study are reported to have considered it “toxic 
knowledge” (66). There is, of course, a danger that if the parents continue the 
pregnancy after having been informed of a VOUS, they will experience additional 
anxiety. The NICHD study found that even after delivery of a healthy baby 50% of 
these women (n=16) admitted to lingering worries about their child’s development 
(66). 
 
Although potentially paternalistic, “protecting” patients from uncertain results may not 
only prevent some of the additional anxiety associated with the uncertainty of those 
who decide to go to term, it may also prevent them from making a decision to 
terminate that they may later regret. I make this point not to suggest that those who 
decide to terminate should or necessarily will feel regret.  Rather, to echo the view of 
Shuster, suggesting that the quest for a healthy baby may ironically result in never 
having a baby at all, as CMA testing could lead to increasing numbers of terminations 
of pregnancies where the fetus actually has uncommon benign chromosomal 
variation (103). Informing patients, who have an otherwise normal fetus of a VOUS, 
may change their perception of the pregnancy from being a normal to abnormal one, 
which is by no means the case. Yet what needs to be stressed here is that what is 
being withheld is not information as such, but is rather uncertainty. Accordingly, I 
suggest that not telling potential parents about VOUS is justified. Recent work 
emerging (66) suggests that this approach may also reflect what women feel. Others 
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disagree such as McGillvray et al who suggest that if a woman chooses to avoid the 
birth of a child when confronted by uncertainty, than this is a legitimate exercise of 
her reproductive autonomy, just as she may choose to terminate a pregnancy 
because of uncertainty surrounding her social circumstances (123).  
 
It could be argued that there are advantages to parents of having VOUS reported 
ahead of the child’s birth: any potential problems such as learning difficulties may be 
identified earlier due to the high index of suspicion and access to specialist services 
and schooling will, therefore, be easier. This argument seems flawed. If the child has 
a clinical condition it should be detected regardless of previous microarray results, 
and if the condition warrants it the array could be re-run using updated and more 
accurate databases. We would therefore try to elicit causes for a condition when they 
exist rather than before they exist (as of course they may never exist and a child is 
inappropriately labelled as having some unknown condition). This issue relates to 
concerns that children should have an open future, which is discussed further below. 
 
If the decision is made not to tell parents about VOUS this must be very explicit in the 
pre-test microarray counselling, potentially even going as far as directing women to 
an online database describing which conditions will be reported and examples of 
those that will not. 
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Late onset diseases 
The aim of prenatal CMA testing is to detect pathogenic copy number variants that 
are associated with conditions that have either caused congenital malformations,  will 
lead to a  genetic syndrome, or are a large deletion/duplication that will affect many 
genes causing a phenotype that will affect the child from birth. It is not to find 
susceptibility to adult onset diseases. As the array is genome-wide it is able to detect 
variants that predispose the child to conditions in later life. Examples include the 
BRCA1/2 mutation giving susceptibility to breast and/or ovarian cancer, or a deletion 
of the gene PMP22 leading to adult onset hereditary neuropathy with liability to 
pressure palsies. Although relatively rare (1-2 per 1000 (99)), they present an 
significant ethical concern about disclosure: should we inform woman and their 
partners about these incidental findings? Are they entitled to this information about 
their unborn children? These questions maybe even more difficult to answer in the 
pre vs. postnatal setting. 
 
The answers to these questions depend on how we balance the parental autonomy 
and the child’s potential autonomy or “right” to an open future (124;125). These latter 
are “rights in trust” for the child until they reach adulthood and can exercise their 
rights for themselves (124). Knowledge without consent intrudes on the privacy of the 
adult that this child will become, but more than this is the impact it may have on their 
future life affecting their ability form relationships, seek employment, and gain health 
insurance. It may also affect subjects own reproductive decisions. This limitation of 
the child’s open future may be unnecessary if the concern is regarding a condition 
212 
 
 
that the child, as an adult, never develops (as the chromosomal change may show 
susceptibility rather than an absolute risk of getting the disease). Most HCPs would 
not recommend genetic testing for BRCA1/2 gene mutations in a child as it predicts 
the risk of a condition for which there are no interventions in childhood. There are 
inconsistencies between restrictions regarding genetic testing in children and testing 
for the same conditions prenatally (126). Finding this information in a prenatal setting 
may well therefore impact on their right to an open future. By informing the woman of 
the fetal chromosomal status we may be inadvertently informing women and their 
partners’ of their own chromosomal status, information which may not be wanted. 
Where practitioners feel, in contradiction to my argument, that they must disclose this 
information it should be discussed in pre-test counselling. 
 
On the other hand it has been argued that subjects are entitled to information about 
their children that might limit the child’s right to an open future, since as children are 
always guided by their parents’ beliefs and wishes their future can never truly be 
open (127).  
 
One of the potential solutions to this problem may be a selective filter on the arrays to 
avoid diagnosing known serious and non-treatable late onset disorders such as 
Huntington’s disease. The filters could then be removed or reset (or tests repeated) 
in later life at the request of the now adult nee fetus, if new information came to light 
that would put them at increased risk (such as a parent developing breast cancer). 
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This would ensure that results are not ‘lost’ but merely withheld until the relevant 
adult wishes to have them.   
Recording of array findings 
The child’s open future is also potentially compromised by the way in which the 
findings of prenatal microarrays are recorded. Results of known pathogenicity will be 
recorded in the mother’s notes and automatically transferred to the child’s records at 
birth, thereby recording that the nature and origin of their condition to enable future 
medical and educational interventions to be appropriately targeted. The much more 
difficult decision is whether VOUS or susceptibility to adult onset conditions should 
be transferred. It may be that leaving these findings in the mother’s medical records, 
and not retesting the baby, and transferring them to the live born child’s records 
could limit the impact these results have. However this would be of no merit if the 
parents choose to tell the child. Of course if these findings were not reported to the 
parents after testing they would not be recorded in either record. 
 
The need for guidance 
International guidance is required regarding the reporting of VOUS, adult onset 
disorders and record keeping as well as the minimum information required in order to 
consent for prenatal microarrays. Until guidance regarding prenatal arrays is 
published these issues will continue to be contentious and practice will continue to 
vary dramatically.  If medical and ethical leaders within their professional institutions 
within this field fail to provide guidance it is likely that standards will be set by courts 
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of law in reaction to currently prevailing standards and practices applied to difficult 
cases, which is a suboptimal solution for HCPs and patients. 
 
Conclusion  
CMA is quickly becoming part of the prenatal diagnostic process. They ought to be 
used to gain knowledge of chromosomal differences that are known to have caused 
problems seen on fetal ultrasound scan, or by finding known chromosomal 
differences that will cause well recognised problems for the baby. It is not appropriate 
to use them to provide reassurance and patients should be counselled as such. I feel 
that results disclosed to patients should only include any pathogenic chromosomal 
changes and not VOUS. As far as possible prenatal CMA design should avoid areas 
of adult onset conditions. Appropriate pre-test counselling remains of paramount 
importance but needs to be tailored to the complexity of the results achievable and 
be feasible to deliver on a larger scale than is currently the case. This may mean 
providing detailed generic information rather than information on every possible 
outcome as would usually precede genetic testing. A clinical geneticist must be 
involved with any abnormal CMA results in addition to an obstetrician.  Guidance on 
the disclosure of VOUS and incidental findings would be welcome by both HCPs and 
patients alike.  
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Recommendations 
In relation to consent 
 Pre test information must include an explanation about VOUS and make clear 
that they will not be reported 
 Pre test information must make clear that predisposition to adult onset 
diseases will not be disclosed OR must make clear what the implications for 
the parents as well as the child will be if they are disclosed. 
For reporting  
 Abnormal findings should trigger an urgent appointment with a clinical 
geneticist as well as an obstetrician 
 VOUS revealed by prenatal microarray testing should not be reported to 
women and their partners  
 Filters should be set as far as possible to minimise the findings of adult onset 
conditions 
 Reports of known pathogenicity (i.e. recognised syndromes) should be 
transferred from the mother’s notes to the child’s notes; all other reports 
should stay in the mother’s records.  
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CHAPTER 8 DISCUSSION OF PRENATAL MICROARRAY TESTING AND THE 
FUTURE OF PRENATAL DIAGNOSTICS 
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Evidence for prenatal CMA testing presented within the thesis 
There is increasing evidence in postnatal and prenatal cohorts that CMA will increase 
the detection rates of pathogenic microscopic chromosomal anomalies that will 
adversely affect children’s outcome, including long-term morbidity. 
 
This research proposal set out to define the detection rate of pathogenic CNVs using 
a  ‘relatively conservative’, targeted CMA platform over conventional, full G-band 
karyotyping when there was a structural anomaly present on fetal ultrasound scan.  
These data defined this in a prospective cohort as 4.1% using the 1Mb BAC array 
(Bluegnome Cambridge, UK) but I indicated the limitations of this platform in that it 
was prospectively chosen to target disease regions known to be associated with 
congenital structural anomalies. The1Mb targeted BAC array was purposefully not 
analysing regions/genes known to cause adult onset diseases and areas of the 
genome where little is known about the pathogenic nature of a variance. This 
strategy was outlined to limit the detection of VOUS and indeed in the prospective 
cohort of 243 samples, I only encountered one difficult counselling situation because 
of such an association. In 2009, when the project was initiated, there was no national 
or international guidance as to how (or if) VOUS should be reported to women and 
their partners.  However, there is emerging evidence from qualitative work in the 
prenatal period (66) that giving uncertain information is viewed negatively by parents, 
leading to increased anxiety in pregnancy that extends after the birth of the child.  
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I have acknowledged in Chapter 2 that other published prenatal studies using the 
same 1Mb BAC array noted higher pathogenic detection rates over G-band 
karyotyping (51;52), but that these studies had lower chromosomal detection rates 
using conventional G-band karyotyping.   At our Regional cytogenetic laboratories we 
have high quality assurance and good quality prenatal G-band preparations that 
would have would have lowered the comparative detection rate of CMA. My 
prospective dataset confirmed an increased detection rate of fetal chromosomal 
anomalies by CMA within the UK when a structural anomaly is identified on 
ultrasound scan.  
 
Critical appraisal of the published literature for cohorts between 2011-2012 are 
examined and meta-analysed (Chapter 4) (using a variety of CMA platforms). The 
excess CMA detection rate over full karyotyping is 7.2% (95%C 5.4 - 9.8). This figure 
does include the reporting of VOUS (which may account for up to 2.1% of the overall 
figure). It is therefore likely from the literature that prenatal diagnosis using CMA 
would note 5% more information of certain pathogenicity that would be reportable to 
parents and potentially adversely affect fetal outcome. It is possible therefore that the 
1 Mb BAC targeted array used may not have such a decreased detection rate 
compared with other platforms and in addition would eliminate much uncertainty at 
the analysis/counselling stage of testing due to its avoidance of VOUS. 
 
The second aim of this thesis was to perform a relatively high resolution CMA (60K 
oligonucleotide array, the International Standard for Cytogenomic Array (ISCA) 
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design v2.0) in a small sub-set of the prenatal cohort (performed after birth) to 
compare this to the BAC array and to compare the detection rates and also VOUS 
rates. Using this 60K array my data noted an extra 4.8% (3 out of 62) pathogenic 
CNVs but, in addition, a 13% (8 out of 62) VOUS rate. Thus, utilising a prenatal CMA 
platform of increasing resolution is likely to increase pathogenic CNV detection in 
babies with congenital malformations but also increase the VOUS rate significantly.    
 
Within Chapter 4, I demonstrated evidence that an increase in CMA resolution results 
in an increase in VOUS rate. I conclude that when prenatal array testing is 
undertaken and in the absence of national/international guidance, particularly as 
CMA resolutions increase, a decision should be made prospectively as to the 
reporting of VOUS to patients locally (in collaboration with clinical genetic support). 
Alternatively international consensus may indicate that not to report VOUS may be 
the preferred option. I do not believe that giving parents a choice about reporting of 
VOUS prior to testing is wise, as many will not comprehend or have full insight into 
the added anxiety that uncertain knowledge (in the presence or absence of a fetal 
structural anomaly) will  give them and that their feelings in retrospect may change 
(66).  
 
The application of new technologies has a financial impact upon all health 
economies.  However, in the United Kingdom, the National Health Service (NHS) 
usually only implements new technologies after independent review by agency such 
as the National Institute of Clinical Excellence (NICE). One of my chapters (Chapter 
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6) presented the results of a formal, objective health economic analysis to examine 
the added costs per additional case detected by CMA over the present prenatal 
karyotype regimen. When the health economic model was populated using data from 
the Birmingham BAC cohort study (model 1), this analysis indicated that when CMA 
is costed at £360 or lower (per test) and the willingness to Pay (WTP) for a “positive 
diagnosis” is £9768; the new technology of CMA is cost effective over full, 
conventional karyotyping. In this analysis, I used the targeted BAC array, the present 
cost being £405 (per test). However CMA technology is becoming more widely 
introduced leading to decreasing cost of the platforms.  This effect is compounded by 
an increase in the number of samples it is possible to analyse on a single slide and 
increased automation. Current, contemporary oligonucleotide arrays are available at 
less than £340 per sample. CMA analysis is currently still a skilled process, as 
intelligent decisions relating to the use of ‘software’ to identify and classify CNVs are 
required, and consideration of the detected CNVs in relation to the associated 
phenotype is important. However in the future analysis will be a much speedier 
process involving less reliance on the analyst and more on complete databases and 
intuitive software.   
 
One cost that was not included was the cost of retraining clinical staff (obstetricians, 
paediatricians and clinical geneticists) in genetic technologies that have developed 
since the onset of their careers. This will need to be undertaken to ensure thorough 
and correct counselling of women and their families both when consenting for testing 
and reporting of results. Studies such as those described are helping to inform a 
generation of clinicians through peer review publications and presentations at clinical 
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conferences. It is vitally important that clinicians are the advocates of patients as new 
technologies become available and it is their responsibility to ensure they understand 
and counsel accurately about a test they offer. Clinicians are in a privileged position 
to ensure that as prenatal diagnostic testing becomes available it is offered in the 
interest of patients and not merely because it can be done. 
 
The ‘impact’ upon new prenatal diagnostic technologies on the individual patient is 
potentially high and qualitative research will go some way to answering the question 
“How do women and indeed couples, feel about the use of CMA testing?” In this 
qualitative analysis, most couples sampled were positive about the new CMA testing 
and keen for as much information as possible from the fetal DNA sample that was 
taken by prenatal testing, so as to inform ‘choices’ relating to their unborn baby with a 
congenital malformation. Many expressed that a “quick result” was important in 
pregnancy and this is an advantage the CMA has over conventional G-band 
karyotyping. Analysis raised the unanticipated finding that some women choose to 
have CMA testing for “reassurance”. The data though presented in this thesis (and 
indeed in the literature) indicates that such feeling should probably be  discouraged 
as the reason for testing is to try and find a chromosomal cause for the abnormalities 
seen on scan and there is the potential to identify ‘anomalies of unknown 
significance’ (VOUS). Women and their partners also highlighted that they struggled 
to recall and retain information prospectively delivered by healthcare professionals at 
the time of the prenatal test. This is not a unique point to prenatal CMA testing (as 
indeed it applies to all prenatal diagnosis) but reinforces that as testing options get 
more complicated it is becoming increasingly important to counsel women and their 
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partners on more than one occasion and make sure they have written information to 
take home. Signposting to relevant websites rather than the patient “becoming 
scared” with inaccurate or irrelevant web material was also a highlighted point from 
the qualitative work.  These qualitative studies will aid our professions to understand 
how women and their partners felt about VOUS. In one case vignette, one couple 
struggled with the uncertainty of such information and fortunately, after further 
detailed analysis, the identified CNV was rare but no gene involvement was 
identified. The conservative nature of the BAC array used in my prospective case 
cohort study meant that only a single true VOUS was identified. However, other 
studies that revealed VOUS, such as the NIH-funded prospective study (65), 
performed qualitative interviews with patients who underwent prenatal diagnosis 
using a higher resolution 44K array where more VOUS were identified. The 
qualitative theme was identified that the information became “toxic knowledge” and 
this ‘uncertain information’ had a negative value causing them anxiety(66).  
 
There are potential ethical dilemmas related to the introduction of prenatal array 
testing and this was examined in one of my chapters (Chapter 7).  Working with Dr 
Heather Draper, in the University Department of Medical Ethics, this work has made 
potential recommendations for practice.  These include the recommendation that 
“Pre-test information” must include counselling about potentially unexplainable 
information (i.e. VOUS) and make the case for the consideration of not reporting 
such information.  Pre-test information should be clear and document if a 
predisposition to adult onset diseases (by the application of predefined filters) will be 
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disclosed and must make clear the potential implications this information has for the 
parents as well as the child. 
 
Recommendations also include that an “abnormal findings” should trigger an urgent 
appointment with a multidisciplinary team of individuals, including a clinical geneticist.  
 
The future 
I have examined in my PhD thesis the potential for the introduction of CMA into 
prenatal practice when a congenital, fetal anomaly is identified using ultrasound 
scanning in pregnancy. However prenatal diagnosis is a rapidly evolving speciality 
and already ‘newer technologies’ such as whole genome and exome sequencing are 
available for use. So where does the future lie for such technologies in prenatal 
diagnosis?  
 
Next generation sequencing 
Until relatively recently the overwhelming majority of DNA sequencing was performed 
on a version of Sanger sequencing (128;129). However in the past 3 years exome 
and genome sequencing have rapidly matured. Several countries are starting to use 
exome sequencing in paediatric and adult clinical practice when there is a high 
chance of a monogenic disorder.  An example would be for the investigation of a 
child with unexplained developmental morbidity (130). In the UK, the Health 
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Innovation Challenge Fund has supported the “Deciphering Developmental 
Disorders” (DDD) project which is recruiting in a multicentre case-cohort to attempt to 
identify diagnoses for children with development disorders (www.ddduk.org/). The 
first 288 trios of which have had a diagnostic rate of 15-30%, depending on whether 
CMA had been previously performed. However in the last few months, a single case 
cohort has been published indicating the use of whole genome sequencing in 
prenatal diagnosis(131). By comparison our group at Birmingham with the Sanger 
Institute Cambridge have performed a relatively large and comprehensive preliminary 
analysis of thirty prenatal cases with congenital anomalies that were included in the 
Birmingham BAC cohort. Parents gave informed consent (and their DNA) to have 
exome sequencing performed in fetal ‘trios’. The analysis and interpretation of results 
took many weeks and they were not available for discussion within the time frame of 
the pregnancy.  However, any results of potential pathogenicity that were considered 
to be causative to the findings of the ultrasound scan or post mortem (if applicable) 
will be relayed to families.  
 
Thirty fetal “trios” (fetal samples, maternal and paternal samples) were sent to the 
Wellcome Trust Sanger Institute (WTSI) in Cambridge in a collaboration with Dr M. 
Hurles.  Of these,   27 ‘trios’ were processed and 3 failed initial quality control criteria 
for DNA. The staff at the WTSI analysed the results and observed a spectrum of 
pathogenicity. The analysis concentrated on de novo mutations, autosomal recessive 
and X linked inheritance models. In two cases the exome sequencing found genes 
were disrupted causal to the phenotype. The first was in a male fetus with scan 
findings of skeletal dysplasia where a de novo mutation of the gene FGFR3 was 
225 
 
 
found (132). The second was in a fetus with increased nuchal translucency and 
severely abnormal hands and feet in which a de novo mutation of the gene COL2A1 
was found (133).  In 8 cases the genes that were found had potential pathogenicity 
but without further studies (such as modelling in zebrafish or mice) information 
surrounding causality is uncertain. In one cases a potential pathogenic mutation in 
SMARCC1 was flagged up but on follow up with the mother the child (who in utero 
had a hydrothorax) was asymptomatic and had normal development aged 2 ½ years. 
This may represent a false positive. Finally, in 17 cases nothing was found by the 
exome sequencing.   
 
This small pilot study is proof of principle for the use of exome sequencing in prenatal 
diagnosis and indicates that some causative candidate genes may be identified but 
also highlights the identification of ‘candidate genes of unknown significance’. A 
larger prospective study will be needed in order to answer questions such as 1) 
whether the average amount of DNA acquired from an invasive sample would be 
enough for sequencing or if culturing would be required, 2) whether exome 
sequencing has the potential to be performed within a realistic timeframe of a 
pregnancy (i.e. 4 weeks), 3) how much certain causative information it could provide, 
and how much uncertain information (akin to the VOUS elicited by CMA) it would 
detect 4) how often adult onset disorders would be uncovered and, of course, the 
ethical implications of sequencing in the prenatal period. To address these issues a 
collaborative grant between research groups at the University of Birmingham, 
Birmingham Women’s Foundation Trust, the WTSI and Great Ormond Street Hospital 
has been submitted (and shortlisted) to the Health Innovation Challenge Fund for 
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funding to exome sequence 1000 fetal samples (with maternal and paternal 
samples).  
 
Non invasive prenatal diagnosis (NIPD) 
The goal in prenatal diagnosis is to provide the maximum amount of accurate 
information causing the least amount of risk to the mother and her unborn baby. To 
this effect NIPD is an ultimate goal. In 1997, cell-free fetal DNA (cffDNA) was 
discovered in maternal plasma (134).  This opened up the possibility of non-invasive 
testing of fetal DNA, eliminating the risk of miscarriage (~1%) associated with 
invasive testing. Since then clinical applications have included fetal sex determination 
(135), fetal rhesus status in mothers with a history of haemolytic disease of the 
newborn (136) and, in a very few, single gene disorders (137). Fetal DNA accounts 
for just 3-10% of the total free DNA the vast majority being maternal. The proportion 
of cffDNA increases with gestation and disappears after delivery.  
 
This approach has rapidly been introduced into clinical practice in the US and Asia 
for the non-invasive prenatal testing (NIPT) of aneuploidies and is also used in the 
UK for some single gene testing, e.g. for achondroplasia(138). However robust 
genome-wide detection of all types of causal variant has proven challenging, 
especially for de novo single nucleotide variants and indels (insertions and deletions) 
(139). Nevertheless it is possible that, within the next 5-10 years, exome sequencing 
of the fetal genome will be achievable through none invasive means.  
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Conclusion 
I have shown that CMA is a robust, accurate tool within prenatal diagnostics, with a 
quick turnaround time. The technology can be implemented within the NHS and will 
lead to a higher rate of diagnoses due to chromosome abnormalities within the 
prenatal setting. I have shown that prenatally its main advantage lies in detection of 
chromosome anomalies when a structural difference is found on prenatal ultrasound 
scan. I have highlighted the potential problems caused by the discovery of variants of 
unknown significance (VOUS) and that I believe these variants should not be 
reported to women and their partners. As the cost of CMA is currently decreasing it is 
likely to present a cost effective option for prenatal chromosome testing and provide 
the necessary “bridging” technology between traditional G-band karyotyping and 
sequencing.  
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APPENDICES 
Appendix A Original Proposed protocol  
Structural chromosomal anomalies leading to chromosomal copy number imbalance 
are often associated with perinatal mortality and morbidity. It is well described that 
congenital structural malformations are associated with chromosomal anomalies. The 
more structural abnormalities that exist in a fetus, the greater the risk of chromosome 
abnormality. Congenital structural malformations are associated with a significant risk 
of aneuploidy but our group has also described an association with subtle 
chromosomal rearrangements, more likely to be detected when fetal lymphocytes are 
obtained by cordocentesis for cytogenetic evaluation.   
Clinical cytogenetics is being transformed by widespread implementation of array 
comparative genomic hybridisation (array CGH). This technique represents arguably 
the most powerful direct application of the human genome mapping project in 
medicine today, both in terms of design of microarrays to interrogate the human 
genome in one assay (at previously unthinkable resolution) and in terms of 
establishing very accurate phenotype-genotype correlations from the results 
obtained. 
Over the last 10 years, our multidisciplinary group has published numerous large 
cohort studies investigating congenital heart disease and prognosis appears worse in 
those babies who are prenatally diagnosed. This appears to be because of 
associated anomalies and in particular, chromosomal anomalies; a ‘marker’ 
significantly worsening prognosis and increasing associated morbidity.  
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We wish to investigate prospectively a cohort of fetuses with a prenatally detected 
structural abnormality to examine the association with subtle chromosomal anomalies 
identified using microarrays. We wish to see if this is so using microarray studies.  
The primary research question is:  
“Will the addition of microarray testing in prenatal chromosomal assessment of 
fetuses with structural malformations give clinically relevant information (in terms of 
diagnostic and prognostic information) in a timeframe and format acceptable to 
patients and health care providers?” 
The aims of the three year research proposal are:  
To determine the prenatal detection of significant chromosomal abnormalities 
associated with prenatally diagnosed structural malformations using Affymetrix 60K 
oligonucleotide array 
2) To evaluate the health economics of prenatal diagnosis using microarray analysis 
in the above cohort of fetuses. 
3) To assess the acceptability of the test to the patients both pre- and postnatally. 
4) To develop a care pathway for the application of microarray. 
5) If novel genes are suspected from results of array testing to perform further 
analysis in the form of sequencing to discover unique genes.  
The project has evolved from the longstanding collaboration between Mrs Davison 
and Professor Kilby on studies of cytogenetic anomaly associated with congenital 
malformations in the fetus.  That collaboration is in turn based upon the extensive 
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clinical and research expertise of Professor Kilby in the area of fetal growth and 
malformations syndromes, together with ready availability of clinical cases through 
the tertiary referral activity of the Fetal Medicine and Genetic service at the 
Birmingham Women’s NHS Foundation Trust.  
The proposed research will be a prospective cohort study. The study will consist of 
ten phases in order to achieve the above aims: 
1) Women who have been found to have a fetus with an anomaly at their routine 12 
or 20 week scan will be referred to Birmingham women’s hospital/ City Hospital 
/University hospital Coventry and Warwickshire. The anomalies include: 
a. Central nervous system (brain) anomalies i.e. hydrocephalus, holoprosencephaly, 
cerebellum anomalies and agenesis of the corpus callosus). 
b. Diaphragmatic hernia. 
c. All cardiac disease. 
d. All anterior abdominal wall defects. 
e. Urinary tract anomalies (lower urinary tract obstruction, severe upper urinary tract 
obstruction). 
f. Nuchal fold/translucency over 3.5mm/ cystic hygromata   
g. fetal hydrops 
h. severe skeletal dysplasia 
i. multiple soft markers (i.e. at least 3) 
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After confirmation of the anomaly (through re-scan) patients will be counselled as 
they would be routinely regarding the significance of the anomaly and the effect this 
may have on the baby once born. It will be explained that some structural anomalies 
are associated with chromosomal problems and that these babies have a poorer 
prognosis. The patients will then be counselled regarding invasive testing for 
chromosomal testing and the risks associated with this. Patients will be offered 
karyotyping (as routine) and also microarray analysis. They will also be offered and 
consented to genetic sequencing on umbilical cord blood at delivery. This will be 
included in the consent form but patients will be able to opt for microarray testing 
prenatally and decline genetic sequencing after delivery. 
Full genetic counselling from a fetal medicine specialist (trained in counselling for 
genetic tests) will take place prior to taking informed consent. This will include 
information about basic genetics, the sort of problems that may be detected, the 
accuracy/limits of the test, the possibility of detecting a genetic “difference “ of 
unknown significance, and the possibility of detecting susceptibility to a disease that 
we are not routinely looking for. The implications not just for the baby but also the 
parents and wider family will also be discussed. Genetic counselling will be given not 
just to women who are having the test performed but also for their partners. Sample 
acquisition and failure rates due to inability to culture cells (although not such a 
problem with microarray technology) will also be routinely discussed.  
Patients will then be given a patient information sheet. Patients will be consented 
prior to the testing by the members of the fetal medicine team as stated above. The 
patients will be informed that in order to analyse the significance of some 
chromosomal aberrations it may be necessary to also run the microarray testing on 
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parental blood samples. Parental samples will be taken (EDTA and Lithium heparin 
from both). These are sent along with the fetal sample with a form requesting 
karyotyping and array analysis (“blue” sticker). 
Patients that opt for genetic sequencing  on cord blood at delivery will be given a 
“pack” to bring with them at time of delivery, this will include; a letter for the midwife 
looking after them in labour explaining the request for cord blood, two blood bottles 
(lithium heparin and EDTA) and a form with a “green” sticker on it for the West 
Midlands genetics laboratory. Also a “pink” sticker is included in the patients hand 
held record to inform health care professionals that the patient is to cord blood taken 
at delivery.  
Results from the karyotyping will be fed back by telephone. Results from the 
microarray testing will be fed back to the patient within 14 days again by telephone 
and if abnormalities are found a consultation will be organised. A standard 60K 
oligonucleotide array (currently becoming  standard use for prenatal samples) will be 
used.  
2) The results will be fed back to patients within 14 days.   
3) When the parents have received the results of all the tests (including genetic tests) 
in combination with full counselling from a fetal medicine specialist they may opt to 
stop the current pregnancy.  If patients decide to terminate the pregnancy they will be 
asked to consider genetic sequencing. Full genetic counselling as described earlier 
will take place. Results for this will not routinely be fed back to patients and are for 
research purposes.  
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There will be a time period of at least 24 hours to one week before they have an 
appointment for the termination procedure and consent for sequencing will be taken 
at this time by the above members of the fetal medicine team. A fetal blood sample 
will be acquired at the time of termination of pregnancy (acquiring a blood sample at 
this time is currently standard practice) if a patient has fetocide. If patients have a 
medical termination of pregnancy (not requiring fetocide) the sequencing will be 
performed on a placental sample. A letter will be given to the patient to give to the 
nursing staff on the ward as well as a universal container and a cytogenetics form 
with a “green “ sticker on it so that a placental sample can be sent to the west 
midlands genetics laboratory.  
4) At a follow up appointment patients will be invited to take part in a semi-structured 
interview to establish parental views on the array testing.  
5) For those pregnancies that continue women will have fetal cord blood taken at the 
time of delivery (either at normal delivery or at caesarean). This blood will be used for 
either high resolution CMA and/or exome sequencing. This consent will be taken as 
part of the initial consent form. If cord blood is required for a standard clinical test 
then the standard test will take priority. Results of this testing will not routinely be fed 
back to patients and are for research purposes. 
6) If the baby is born alive, consent will be sort to examine the medical records of the 
baby. If the patients opt for a termination or the baby is stillborn, post-mortem 
examination will be discussed.  
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7) Semi structured interviews will also take place postnatally if the infants is born 
alive to determine whether their views on the testing are altered by the birth of their 
baby. 
8) If found to be cost effective and acceptable to patients a care pathway will be 
developed for the introduction of microarray analysis in the above cohort of patients.   
9) Dissemination of results nationally and internationally through the use of peer 
review scientific publications, guidelines and conferences. 
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Appendix D Laboratory Methods for the 1Mb targeted BAC array (Blue Gnome 
Cambridge) 
Typically >10mg of CVS or >12mls of amniotic fluid were required to perform CMA.  
DNA was extracted using QIAGEN EZ1 DNA extraction as per manufacture’s 
protocol. 
 
Quality Control 
DNA was the quality controlled (QC). If the sample was from tissue QC on a 1% 
agarose gel was performed in addition to the method described. DNA was incubated 
on a hot block at 37oc for 30 minutes to equilibrate. DNA was then vortex and spun 
and 1.5 µl was transferred onto the Nanodrop spectrophotometer to give 260/280 
(<2.2 and >1.8 ideally) and 260/230 (<2.2 and >1.5 ideally) ratios. Concentration of 
DNA is also estimated and ideally should be ≥38ng/µl.  
 
DNA clean up procedure 
If DNA concentrations or ratios are particularly low/high then DNA clean up 
procedures can be applied. Using the information generated by the nanodrop 
spectrophotometer the volume of DNA required to give 10,000ng of DNA is 
calculated. Samples are topped up to 100µl with sterile water. 10µl of cold 3M 
sodium acetate and 200 µl of 100% ethanol are added. Tubes are inverted and 
stored at -80oc for 30 minutes. Samples are then centrifuged at 4oC for 30 minutes. 
Samples are examined for a pellet and the supernatant removed. 500µl of cold 70% 
ethanol are added and tubes inverted. Samples are centrifuged for 15 minutes again 
at 4oC. The samples are then once again examined to identify the pellet and the 
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supernatant removed. Tubes are left open for a maximum of 5 minutes to let the 
remaining ethanol dissolve. DNA pellet are dissolved in TE buffer, the volume 
depending on the volume of DNA precipitated. Tubes are sealed and placed on a 
37oC hot block overnight. The following day samples are vortexed and spun and then 
re-tested on the nanodrop spectrophotometer according to the method described 
above.  
 
BlueGnome constitutional BAC array procedure 
Random prime labelling 
Test DNA is thawed and briefly centrifuged as is the reference DNA.  400ng of DNA 
is transferred and topped up to 23µl with water. Labelling “master mixes” (Cyanine; 
Cy3 and Cy5) are prepared. The volume required for 1 reaction is 10µl of reaction 
primer, 10µl or random primer, 5µl of deoxycytidine triphosphate (dCTP) mix and 1 µl 
of Cy3 or Cy5 dCTP dye (all reagents are provided by the company Bluegnome). 
26µl of labelling master mix is then transferred to the corresponding DNA sample, 
Cy3 to fetal test DNA and Cy5 to reference DNA. Each tube is mixed and denatured 
on a hot block at 94oC for 5 minutes and then transferred immediately to ice for 5 
minutes. Tubes and pulse spun and 1µl of klenow enzyme (formed by the treatment 
of Escherichia coli DNA polymerase) is added to each tube before being spun again 
and added to a hot block overnight at 37oC. The reaction is stopped the next morning 
by adding 5µl of ethylenediamine tetraacetic acid (EDTA) stop buffer. Samples are 
mixed and spun. An Autoseq G50 gel column is then prepared for each sample as 
per manufacturer’s guidance. Each labelling reaction is then added carefully to the 
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gel and are centrifuged at room temperature for 1 minute. Gel columns are then 
discarded and the tube sealed vortexed and spun. The sample is then tested on the 
Nanodrop spectrophotometer as described above but successful labelling reactions 
should meet the criteria: Concentration >150ng/µl, pmol dye/µl >3. Each labelled fetal 
test DNA is then combined with its corresponding labelled reference DNA. 25µl of 
COT1 DNA (used to block repetitive elements to prevent non-specific hybridisation) 
are added to each sample. For precipitation 12.5µl of 3M sodium acetate are added 
followed by 312µl of 100% ethanol and inverted. They are then stored at -80oC for 2 
hours. Samples are then centrifuged at full speed (~14,000rpm (equivalent to 
~18,000 rcf/xg)  for 30 minutes at 4oC.  
 
Array hybridisation 
Samples are centrifuged at full speed and 4oC for 10 minutes. Supernatant is 
disguarded and 312 µl of 70% ethanol are added inverted and centrifuged again at 
4oC for 5-10 minutes. The supernatant is decanted and disguarded and excess 
ethanol is removed with the tube left open for no more than 5 minutes for the 
remaining ethanol to evaporate. The sample is then re-suspended in 21µl of 15% 
denaturation Solution hybridisation solution (the solution is pre warmed in a 75oC 
water bath). Tubes are sealed and placed in the 75oC water bath for 5-10 minutes 
until the pellet is completely dissolved and allowed to denature for a further 10 
minutes in the water bath. Samples are then spun for 20 seconds and allowed to cool 
to room temperature. 18µl of labelled DNA is then transferred to the cover slip of the 
microarray slide and the array slide is then lowered onto the cover slip. The slide is 
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then placed into a chamber and the chamber incubated in the hybridisation oven at 
47oC for 16-21 hours. Four separate wash steps are then prepared and the slide is 
washed in sequence as follows; wash 1 2x saline-sodium citrate (SSC)(/0.05% at 
room temperature for 15 minutes, Wash 2 1xSSC at room temperature for 15 
minutes, Wash 3 0.1SSC at 60oC (hybex) for 5 minutes. Wash 4 0.1%SSC at room 
temperature for 1 minute. The slides are then transferred to the mini slide centrifuge 
and spun for 20 seconds to dry. The slide is then removed a plastic slide holder is 
applied. Slides are then transferred to the scanner (Agilent scanner, model G2939A). 
After scanning raw TIFF images are transferred to Bluefuse multi software. 
 
Quality Control of array Image 
To get an impression of array quality and exclude mosaicism standard devistion of 
the autosomes should be between 0.03 and 0.07, percentage BAC inclusion should 
be >95%.  
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Appendix E Laboratory Methods for the higher resolution 60K cytochip 
oligonucleotide array (Bluegnome Cambridge) 
The CMA used was the 8x60K cytochip oligonucleotide (Bluegnome Cambridge).  
 
Diluting 
DNA samples are incubated on a hot block for 30minutes set at 37oC to equilibrate 
DNA before dilution. 0.5ml microtubes are labelled for each sample and for each 
reference.  Each genomic DNA and corresponding reference DNA is then diluted 
using sterile water for injection (equivalent to 0.4-0.5µg of DNA in a total volume of 
13µl).  
 
Labelling 
DNA and references samples are vortexed and pulse spun. All labelling reagents 
(provided by Bluegnome) are thawed on ice, with exception of the klenow enzyme 
kept in a -20 oC freezer until required. 2.5µl of random primers are then added to 
each reaction tube. The contents of each reaction tube are denatured at 95oC for 
10minutes and then transferred immediately to ice for 5 minutes. 
On ice “master mixes” of Cy3 and Cy5 are prepared (42 µl of 5x buffer, 21 µl of 
10xdUTP and 12.6 µl of Cy3/Cy5).  
On Ice 9 µl of Cy3 master mix is added to each patient sample and 9 µl of Cy5 
master mix are added to each reference. 0.5 µl of exo-Klenow fragment are added to 
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each reaction tube. Reaction tubes are then incubated at 37oC for 4 hours. To stop 
the reaction samples are then incubated at 65 oC for 10 minutes.  
 
A new set of 1.5ml microtubes are labelled and an AutoseqG50 gel column prepared 
for each labelling reaction by inverting the column, snapping off the bottom closure, 
placing each column in a collection tube and spinning at room temperature at 2000g 
for 1 minute and then placing each column into a prelabelled 1.5ml microtube.  
Labelled DNA (patient and reference) are loaded onto the centre of the gel in the 
column.   
Columns are then spun at room temperature at 2000g for 1 minute. Gel columns are 
discarded and the remaining microtubes mixed and pulse spun. The nanodrop 
spectrophotometer is then used to measure dye incorporation. The concentration 
should be>100ng/ µl pmoldye/ µl>2.5.  
 
Test and reference combination and precipitation.  
Cy5 reactions (reference sample) are then transferred to Cy3 reactions (patient 
sample). 5.5 µl of cold 3M sodium acetate pH 5.2 followed by 138 µl of 100% ethanol 
to each combined sample and the samples inverted. 
The combined sample is stored at -80oC for 30 minutes to allow the precipitate to 
form. Combined samples are spun at 4oC for 30 minutes. The supernatant is 
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discarded leaving a dark purple pellet. 312 µl of 70% ethanol is added to the sample 
and inverted. 
 
Oligonucleotide Array Hybridisation 
The samples are centrifuged for 5-10 minutes. The supernatant is discarded and the 
sample pulse spun to collect any residual ethanol, which is removed using a p10 
pipette. Samples are left uncapped for <5 minutes to allow the pellets to dry. 
 
Pellets are re-suspended in 16 µl of DNA hydration solution and incubated at 73-
75oC for 2 minutes. 2 µl of COT human DNA, 4.5 µl of 10xblocking agent and 22.5 µl 
of 2x Hi-RPM buffer. Samples and mixed and pulse span and placed on a 95oC hot 
block for 3 minutes. Tubes are transferred to a 37oC hot block for 30 minutes. Tubes 
are allowed to cool to room temperature. 
 
Each sample is transferred to the correct gasket. The array slide is then placed down 
onto the gasket. The hybridization chamber is placed to cover the gasket and array. 
The chamber is then rotated to allow the sample to cover the slide. Chambers are 
then placed in the hybridization oven at 65oC for 24 hours. 
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Oligonucleotide Array Washing 
 The chambers are disassembled and the slide and gasket are submerged into the 
disassembly wash. Whilst submerged the gasket and microarray slide are separated. 
The slide is then loaded into a slide rack submerged in fresh wash buffer. When all 
slides are loaded a stirring bar is added to the dish and the wash stirred for 5 
minutes. The slides (in the rack) are then transferred to the second wash buffer at a 
temperature of 37oC for 1 minute. Slides are then transferred to the aglient scanner. 
After scanning raw TIFF images are transferred to Bluefuse multi software.  
Analysis  
(performed by myself and overseen by two members of staff at the WMRGL Mr Lee 
Silcock and Mr Dominic Mcmullan) 
Quality control of array image 
Derivative Log Ratio fused; good<0.15, OK 0.15-0.22, fail>0.22. 
Standard deviation robust; good 0.07-0.1, OK 0.1-0.17, fail <0.07 or>0.17 
 
As described in chapter 1 and chapter 2 CNVs were classified as benign, VOUS or 
pathological in accordance with the American College of Medical Genetics (ACMG) 
guidelines (50). Pathological CNV are documented as clinically significant in multiple 
peer-reviewed publications. Penetrance and expressivity of the CNV is well defined, 
even if known to be variable. They may include large CNVs not described in the 
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medical literature at the size observed in the fetus, but overlap a smaller interval with 
clearly established clinical significance.  
 
A benign CNV will have been reported in multiple peer-reviewed publications or 
curated databases as being a benign variant, particularly if the nature of the copy 
number variation has been well characterised and will typically represent a common 
polymorphism (documented in greater than 1% of the population). 
 
 
VOUS will have included findings that are later demonstrated to be either clearly 
pathogenic or clearly benign, but insufficient evidence was available for unequivocal 
determination of clinical significance at the time of reporting (50) (see table below). 
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Table taken from microarray 4.4 CNV classification guidelines version 1.1 WMGL 
Class DGV Local 
databases 
Clinical 
Databases 
Gene function HI index 
score 
Uncertai
n: likely 
Benign 
<1% of 
cases, <3 
studies or 
no similar 
cases 
>1% cases; 
same dosage 
in non 
syndromic 
regions 
Multiple similar cases 
classified as benign in 
ISCA/DECPIHER (a 
consenus classification) 
No Genes/genes of 
irrelevant function 
Intronic imbalance in 
unrelated genes 
>30% 
Uncertai
n 
No similar 
entries 
No similar 
cases 
Cases equally 
uncertain 
representing 
<1% of cases 
No similar cases and /or 
cases classified as 
uncertain in ISCA 
Uncertain funtion 
No clear link to 
phenotype but 
possible i.e. in Mouse 
Genome informatic 
curated models 
10-30% 
Uncertai
n Likely 
pathoge
nic 
No similar 
entries 
Limited 
number of 
similarly 
affected cases 
in local 
database 
No simlar 
cases but 
complelling 
biology 
Limited number of similar 
cases  
In 
DECIPHER/ISCA/literature 
Clear link to phenotype 
but not a recurrent 
syndrome 
Clear link to 
susceptibility/late-
onset disease 
<10% 
 
 
In addition to using DECIPHER, ISCA and DGV databases described above further 
analyses can be performed using further online tools. phenExplorer 
(http://compbio.charite.de/phenexplorer/) allows generation of a list of genes relevant 
to the phenotype see on ultrasound scan. Toppgene then allows prioritisation or 
ranking of candidate genes based on functional similarity between those in the 
training gene list (obtain by phenExplorer) and those in the test gene set (those 
within the CNV region).  
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STRING can be also used to search for interactions between known genes 
associated with the phenotype derived from phenExplorer and gene/s of interest from 
copy number imbalance.STRING v9.0 (http://string-db.org/)(140), is a database that 
contains known and predicted protein interactions. Interactions are classified as 
either direct (Physical) or indirect (functional); they are derived from genomic context, 
high-throughput experiments, co-expression analysis and previous knowledge and 
assigns a confidence score based on these criteria. 
 
The above are quick solutions to obtaining further evidence for causality but will often 
still result in a classification of VOUS. Functional work may be a longer term solution 
but is not possible within the time frame of a pregnancy and is therefore more 
amenable to research then diagnostic work.  
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Appendix G Thematic analysis of interview transcripts 
Provided on CD in excel spread sheet format 
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Appendix H Further CEACS and sensitivity analyses 
Figure 34 Sensitivity analysis Model 1 Birmingham BAC cohort VOUS true 
positives, CMA over karyotyping 
 
 
Figure 35 CEAC of CMA over karyotyping Birmingham BAC cohort model 1, 
treating VOUS as true positives 
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Figure 36 Sensitivity analysis, Birmingham BAC cohort model 1, treating VOUS 
as true positives, CMA over QFPCR 
 
 
 
Figure 37 CEAC of CMA over QFPCR, Birmingham BAC cohort Model 1 treating 
VOUS as true positive 
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Figure 38 Sensitivity analysis Birmingham BAC cohort model 1, VOUS as true 
positives. CMA over QFPCR then karyotype then FISH Di George syndrome 
 
Figure 39 Birmingham BAC cohort model 1, VOUS as true positives. CEAC of 
CMA over QFPCR then karyotyping then FISH Di George Syndrome  
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Figure 40 Sensitivity analysis Model 1 Birmingham BAC cohort treating VOUS 
as true positives, CMA over QFPCR then FISH for Di George Syndrome 
 
 
Figure 41 CEAC Model 1 Birmingham BAC Cohort, VOUS as true positives, 
CMA over QFPCR then FISH for Di George syndrome 
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Birmingham BAC cohort Model 1 VOUS treated as false positive:  
Figure 42 Sensitivity analysis Model 1 Birmingham BAC cohort VOUS as false 
positives CMA over karyotyping 
 
 
Figure 43 CEAC Model 1 Birmingham BAC cohort, VOUS as false positives, 
CMA over karyotyping 
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Figure 44 Sensitivity analysis Model 1 Birmingham BAC Cohort VOUS as false 
positives CMA over QFPCR 
 
 
Figure 45 CEAC Model 1 Birmingham BAC cohort VOUS as false positive CMA 
over QFPCR 
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Figure 46 Sensitivity analysis Model 1 Birmingham BAC cohort VOUS as false 
positives, CMA over QFPCR then karotyping then FISH for Di George 
 
 
Figure 47 CEAC Model 1 Birmingham BAC cohort VOUS as false positives, 
CMA over QFPCR then karyotype then FISH for Di George 
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Figure 48 Sensitivity Analysis Model 1 Birmingham BAC cohort treating VOUS 
as false positives CMA over QFPCR then FISH for Di George syndrome 
 
 
Figure 49 CEAC Model 1 Birmingham BAC cohort treating VOUS as false 
positives CMA over QFPCR then FISH for Di George syndrome 
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Figure 50  Sensitivity analysis Model 2 using systematic review data, all 
indications for testing, VOUS treated as true positives, CMA over karyotyping 
 
Figure 51 CEAC Model 2 Systematic review data, all indications for testing, 
treating VOUS as true positives 
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Figure 52 Sensitivity analysis Model 3 systematic review data when testing 
performed for abnormal ultrasound anomalies, CMA over karyotyping 
 
 
Figure 53 CEAC Model 3 systematic review data, testing performed for 
abnormal ultrasound scan findings, treating VOUS as true positives CMA over 
karyotyping 
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Appendix I Manuscripts Submitted from PhD work 
From Chapter 1 
Published 
1) Additional information from array comparative genomic hybridization 
technology over conventional karyotyping in prenatal diagnosis: a systematic 
review and meta-analysis. Hillman SC, Pretlove S, Coomarasamy A, 
McMullan DJ, Davison EV, Maher ER, Kilby MD. Ultrasound Obstet Gynecol. 
2011 Jan;37(1):6-14 
Published 
2) Microarray comparative genomic hybridization in prenatal diagnosis: a review. 
Hillman SC, McMullan DJ, Williams D, Maher ER, Kilby MD. Ultrasound 
Obstet Gynecol. 2012 Oct;40(4):385-91 
Published 
3) The use of Chromosomal Microarray (CMA) in prenatal diagnosis Hillman SC, 
McMullan DJ, Maher ER, and Kilby MD The Obstetrician & Gynaecologist. 
2013 April; 15(2):80-84 
Published 
4) Prenatal microarray technology for the identification of chromosomal 
anomalies.  Hillman SC, McMullan DJ, Maher ER, and Kilby MD. Current 
progress in Obstetrics and gynaecology 1. Chapter 10: 167-181  
 
From Chapter 2 and chapter 4  
Published: 
1) S.C.Hillman, D.J.McMullan, G. Hall, F.S. Togneri, N. James, E.J Maher, C.H. 
Meller, D. Williams,   R.J. Wapner,  E.R. Maher and M.D.Kilby. Use of Prenatal 
chromosomal microarray use: a prospective cohort of fetuses and a 
systematic review and meta-analysis. USOG 2013 Jun;41(6):610-20 
 
 
From Chapter 3 
Published: 
1) Hillman SC, McMullan DJ, Silcock L, Maher ER, Kilby MD. 
How does altering the resolution of chromosomal microarray analysis in the 
prenatal setting affect the rates of pathological and uncertain findings? 
J Matern Fetal Neonatal Med 2013; Aug 19 (e-pub ahead of print). 
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From Chapter 5 
Published: 
 
1) Hillman SC, Skelton J, Quinlan-Jones E, Wilson A, Kilby MD. "If it helps..." the 
use of microarray technology in prenatal testing: patient and partners 
reflections. Am J Med Genet A. 2013 Jul; 161A(7):1619-27. 
 
From Chapter 6 
Awaiting amendments fetal diagnosis and therapy 
1) Chromosomal microarray for prenatal detection of chromosome anomalies in 
fetal ultrasound anomalies: an economic evaluation Hillman SC, Barton PM, 
Roberts TE,  Maher ER,  McMullan DJ and Kilby MD 
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Appendix J Statistical analysis 
1)Systematic review and meta-analysis 
a)2 x 2 tables were created for each study           Karyo result 
        +ve             -ve 
    Array result +ve  a  b 
      -ve  c  d 
 
b) STATA Version 11.0   Copyright 1984-2009 Statistics/Data Analysis  StataCorp 
(http://www.stata.com) was used to perform the metanalysis. The following 
commands were used: 
To calculate percentage agreement between tests: 
gen logr = log ((a+d)/(a+b+c+d) 
gen selogr = 1/sqrt(a+b+c+d) 
metan logr selogr, fixedi second (random) eform 
 
To calculate percentage detected by karyotype over CMA and meta analyse results 
gen logr = log ((c)/(c+d) 
gen selogr = 1/sqrt(c+d) 
metan logr selogr, fixedi second (random) eform 
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To calculate percentage detected by CMA over karyotype and meta analyse results 
gen logr = log ((b)/(b+d) 
gen selogr = 1/sqrt(b+d) 
metan logr selogr, fixedi second (random) eform 
 
To calculate percentage of VOUS and meta analyse results 
gen logr = log(n/t) 
gen selogr =1/sqrt(t) 
metan logr selogr, fixedi second (random) eform 
log r is the log ratio of the output i.e. b/b+d (or extra information detected by CMA 
over karyotype. Se logr id the standard error of the log ratio. Metan is the main 
STATA meta-analysis command. This command produces both a fixed effect result 
(fixedi = inverse variance fixed effect method) as well as random effect method 
(random = Der Simonian and Laird random-effects method). The command eform 
then produces the output on a ratio scale (141). 
 
2)Heterogeneity 
A Chi-squared test was used to examine heterogeneity. Data under analysis in meet 
the assumptions of the test. 
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Heterogeneity was expected due to the known a priori variability in study 
characteristics, conduct and measurement methods. Such heterogeneity is expected 
in prognostic factor research (142). Hence our protocol pre-defined that a random 
effects approach was to be used. In relation to testing for heterogeneity, the 
Cochrane Handbook (143) states that: ‘'the choice between a fixed-effect and a 
random-effects meta-analysis should never be made on the basis of a statistical test 
of heterogeneity' A random effects analysis does estimate and therefore account for 
all unexplained statistical heterogeneity. 
  
3)Publication Bias 
Publication bias was assessed using Eggers test and the data meet the assumptions of the 
test. 
Egger’s test, is based on the Galbraith plot. This is a plot of difference over standard error 
against one over standard error. It is a regression analysis by calculating the regression of 
study difference over standard error on 1/standard error (144). 
 
 
4)Fishers exact Test 
The test is useful for categorical data that result from classifying objects in two 
different ways; it is used to examine the significance of the association (contingency) 
between the two kinds of classification. It is used in preference to the Chi-squared 
272 
 
 
test when sample sizes are small (under ten). The data meet the assumptions of the 
test. 
 
5)Sensitivity and specificity  
Sensitivity relates to the test's ability to identify positive results. 
The sensitivity of a test is the proportion of people that are known to have the disease (or 
chromosomal abnormality) who test positive for it: 
=   number of true positives 
Number of true positives+ number of false negatives 
 
Specificity relates to the test's ability to identify negative results. 
The specificity of a test is defined as the proportion of patients that are known not to have the 
disease who will test negative for it: 
=       Number of true negatives 
Number of true negatives+ number of false positives 
 
6) Incremental Cost effectiveness ratio (ICER) 
The ICER is universally accepted as the standard summary ratio that should be used 
for reporting the results of economic evaluations. The additional cost per additional 
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unit of benefit can be applied to any evaluation as long as there is a comparison of 
costs and outcomes of at least two alternative pathways or strategies. 
=      Cost 1 minus Cost 2 
   Effectiveness 1 minus Effectiveness 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
274 
 
 
REFERENCE LIST 
 (1)  Genest DR, Williams MA, Greene MF. Estimating the time of death in 
stillborn fetuses: I. Histologic evaluation of fetal organs; an autopsy study of 
150 stillborns. Obstetrics and Gynecology 1992 Oct;80(4):575-84. 
 (2)  Genest DR. Estimating the time of death in stillborn fetuses: II. Histologic 
evaluation of the placenta; a study of 71 stillborns. Obstetrics and 
Gynecology 1992 Oct;80(4):585-92. 
 (3)  Genest DR, Singer DB. Estimating the time of death in stillborn fetuses: III. 
External fetal examination; a study of 86 stillborns. Obstetrics and 
Gynecology 1992 Oct;80(4):593-600. 
 (4)  Kirchhoff M, Rose H, Lundsteen C. High resolution comparative genomic 
hybridisation in clinical cytogenetics. Journal of Medical Genetics 2001 
Nov;38(11):740-4. 
 (5)  Langlois S, Duncan A. Use of a DNA method, QF-PCR, in the prenatal 
diagnosis of fetal aneuploidies. Journal of Obstetrics and Gynaecology 
Canada 2011 Sep;33(9):955-60. 
 (6)  Brackley KJ, Kilby MD, Morton J, Whittle MJ, Knight SJ, Flint J. A case of 
recurrent congenital fetal anomalies associated with a familial subtelomeric 
translocation. Prenatal Diagnosis 1999 Jun;19(6):570-4. 
 (7)  Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et 
al. Comparative genomic hybridization for molecular cytogenetic analysis of 
solid tumors. Science 1992 Oct 30;258(5083):818-21. 
 (8)  Lichter P, Joos S, Bentz M, Lampel S. Comparative genomic hybridization: 
uses and limitations. Seminars in Hematology 2000 Oct;37(4):348-57. 
 (9)  Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene 
expression patterns with a complementary DNA microarray. Science 1995 
Oct 20;270(5235):467-70. 
 (10)  Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based 
comparative genomic hybridization for the identification of prognostically 
important genetic alterations in chronic lymphocytic leukemia. Molecular 
Diagnosis and Therapy 2008;12(5):271-80. 
 (11)  Curry CJ, Mao R, Aston E, Mongia SK, Treisman T, Procter M, et al. 
Homozygous deletions of a copy number change detected by array CGH: a 
new cause for mental retardation? American Journal of Medical Genetics 
Part A 2008 Aug 1;146A(15):1903-10. 
 (12)  Xiang B, Li A, Valentin D, Nowak NJ, Zhao H, Li P. Analytical and clinical 
validity of whole-genome oligonucleotide array comparative genomic 
275 
 
 
hybridization for pediatric patients with mental retardation and developmental 
delay. American Journal of Medical Genetics Part A 2008 
Aug;146A(15):1942-54. 
 (13)  Jacquemont ML, Sanlaville D, Redon R, Raoul O, Cormier-Daire V, Lyonnet 
S, et al. Array-based comparative genomic hybridisation identifies high 
frequency of cryptic chromosomal rearrangements in patients with syndromic 
autism spectrum disorders. Journal of Medical Genetics 2006 
Nov;43(11):843-9. 
 (14)  Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, Fiegler H, et al. 
Microarray based comparative genomic hybridisation (array-CGH) detects 
submicroscopic chromosomal deletions and duplications in patients with 
learning disability/mental retardation and dysmorphic features. Journal of 
Medical Genetics 2004 Apr;41(4):241-8. 
 (15)  Hillman SC, McMullan DJ, Williams D, Maher ER, Kilby MD. Microarray 
comparative genomic hybridization in prenatal diagnosis: a review. 
Ultrasound in Obstetrics and Gynecology 2012 Oct;40(4):385-91. 
 (16)  Hillman SC, McMullan DJ, Maher E, Kilby MD. The use of Chromosomal 
Microarray (CMA) in prenatal diagnosis. The Obstetrician and Gyanecologist 
2013;15(2):80-84 
 (17)  Hillman SC, McMullan DJ, Maher E, Kilby MD. Prenatal microarray 
technology for the identification of chromosomal anomalies. Current 
Progress In Obstetrics and Gynaecology 1st ed. 2012. Chapter 10 p. 167-81. 
 (18)  Fiegler H, Redon R, Carter NP. Construction and use of spotted large-insert 
clone DNA microarrays for the detection of genomic copy number changes. 
Nature Protocols 2007;2(3):577-87. 
 (19)  Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et 
al. Consensus statement: chromosomal microarray is a first-tier clinical 
diagnostic test for individuals with developmental disabilities or congenital 
anomalies. American Journal of Human Genetics 2010 May 14;86(5):749-
64. 
 (20)  Bodrug SE, Roberson JR, Weiss L, Ray PN, Worton RG, Van Dyke DL. 
Prenatal identification of a girl with a t(X;4)(p21;q35) translocation: molecular 
characterisation, paternal origin, and association with muscular dystrophy. 
Journal of Medical Genetics 1990 Jul;27(7):426-32. 
 (21)  De Gregori M, Ciccone R, Magini P, Pramparo T, Gimelli S, Messa J, et al. 
Cryptic deletions are a common finding in "balanced" reciprocal and complex 
chromosome rearrangements: a study of 59 patients. Journal of Medical 
Genetics 2007 Dec;44(12):750-62. 
276 
 
 
 (22)  Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-
scale copy number polymorphism in the human genome. Science 2004 Jul 
23;305(5683):525-8. 
 (23)  Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. 
Detection of large-scale variation in the human genome. Nature Genetics 
2004 Sep;36(9):949-51. 
 (24)  Sebat J. Major changes in our DNA lead to major changes in our thinking. 
Nature Genetics 2007 Jul;39(7 Suppl):S3-S5. 
 (25)  Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. 
Nature Review Genetics 2006 Feb;7(2):85-97. 
 (26)  Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing 
the landscape of chromosomes and design of disease studies. Human 
Molecular Genetics 2006 Apr 15;15 Spec No 1:R57-R66. 
 (27)  Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global 
variation in copy number in the human genome. Nature 2006 Nov 
23;444(7118):444-54. 
 (28)  Lee C, Iafrate AJ, Brothman AR. Copy number variations and clinical 
cytogenetic diagnosis of constitutional disorders. Nature Genetics 2007 
Jul;39(7 Suppl):S48-S54. 
 (29)  Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins 
and functional impact of copy number variation in the human genome. 
Nature 2010 Apr 1;464(7289):704-12. 
 (30)  Huang S, Crolla J. Comparison for cytogenetics array platforms hardware 
andsoftware for use in identifying copy number aberration in constitutional 
disorders. [Online] available from: 
http://www.ngrl.org.uk/Wessex/downloads/pdf/NGRLW_aCGH_1[1].0.pdfSail
sbury (last accessed 10/11/2013).  
 (31)  Hillman SC, Pretlove S, Coomarasamy A, McMullan DJ, Davison EV, Maher 
ER, Kilby MD. Additional information from array comparative genomic 
hybridization technology over conventional karyotyping in prenatal diagnosis: 
a systematic review and meta-analysis. Ultrasound in Obstetrics and 
Gynecology 2011 Jan;37(1):6-14. 
 (32)  Khan KS, Terriet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking 
Systematic Reviews of Research on Effectiveness CRDs Guidance for 
carrying out or commisioning reviews (2nd edn) CRD report No 4 NHS 
centre for reviews and dissemination.  University of York; 2001.  
 (33)  McKibbon A, Eady A, Marks S. Identifying and selecting studies for inclusion. 
6th edition; 1999.  
277 
 
 
 (34)  Glasziou P, Irwig L, Bain C, Colditz G. Frequency and Rate. Systematic 
Reviews in Health Care: A practical guide. 2nd edition. Cambridge University 
Press; 2001:67-73 
 (35)  Coppinger J, Alliman S, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG. 
Whole-genome microarray analysis in prenatal specimens identifies clinically 
significant chromosome alterations without increase in results of unclear 
significance compared to targeted microarray. Prenatal Diagnosis 2009 
Dec;29(12):1156-66. 
 (36)  Van den Veyver IB, Patel A, Shaw CA, Pursley AN, Kang SH, Simovich MJ, 
et al. Clinical use of array comparative genomic hybridization (aCGH) for 
prenatal diagnosis in 300 cases. Prenatal Diagnosis 2009 Jan;29(1):29-39. 
 (37)  Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke 
JP. Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. British 
Medical Journal 2007 Oct 20;335(7624):806-8. 
 (38)  Sahoo T, Cheung SW, Ward P, Darilek S, Patel A, del GD, et al. Prenatal 
diagnosis of chromosomal abnormalities using array-based comparative 
genomic hybridization. Genetics in Medicine 2006 Nov;8(11):719-27. 
 (39)  Bi W, Breman AM, Venable SF, Eng PA, Sahoo T, Lu XY, et al. Rapid 
prenatal diagnosis using uncultured amniocytes and oligonucleotide array 
CGH. Prenatal Diagnosis 2008 Oct;28(10):943-9. 
 (40)  Shaffer LG, Coppinger J, Alliman S, Torchia BA, Theisen A, Ballif BC, et al. 
Comparison of microarray-based detection rates for cytogenetic 
abnormalities in prenatal and neonatal specimens. Prenatal Diagnosis 2008 
Sep;28(9):789-95. 
 (41)  Rickman L, Fiegler H, Shaw-Smith C, Nash R, Cirigliano V, Voglino G, et al. 
Prenatal detection of unbalanced chromosomal rearrangements by array 
CGH. Journal of Medical Genetics 2006 Apr;43(4):353-61. 
 (42)  Le Caignec C, Boceno M, Saugier-Veber P, Jacquemont S, Joubert M, 
David A, et al. Detection of genomic imbalances by array based comparative 
genomic hybridisation in fetuses with multiple malformations. Journal of 
Medical Genetics 2005 Feb;42(2):121-8. 
 (43)  Tyreman M, Abbott KM, Willatt LR, Nash R, Lees C, Whittaker J, et al. High 
resolution array analysis: diagnosing pregnancies with abnormal ultrasound 
findings. Journal Medical Genetics 2009 Aug;46(8):531-41. 
 (44)  Kleeman L, Bianchi DW, Shaffer LG, Rorem E, Cowan J, Craigo SD, et al. 
Use of array comparative genomic hybridization for prenatal diagnosis of 
fetuses with sonographic anomalies and normal metaphase karyotype. 
Prenatal Diagnosis 2009 Dec;29(13):1213-7. 
278 
 
 
 (45)  Vialard F, Molina GD, Leroy B, Quarello E, Escalona A, Le SC, et al. Array 
comparative genomic hybridization in prenatal diagnosis: another 
experience. Fetal Diagnosis and Therapy 2009;25(2):277-84. 
 (46)  Stroup DF, Berlin JA, Morton SC, olkin I, williamson GD, Rennie D, et al. 
meta-analysis of observational studies in epidemiology: a proposal for 
reporting. Meta-analysis of Observational studies in epidemiology (MOOSE 
group). Journal of American Medical Association 2000;283:2008-12. 
 (47)  Kang TW, Jeon YJ, Jang E, Kim HJ, Kim JH, Park JL, et al. Copy number 
variations (CNVs) identified in Korean individuals. BMC Genomics 
2008;9:492. 
 (48)  ACOG Committee Opinion No. 446: array comparative genomic 
hybridization in prenatal diagnosis. Obstetrics and Gynecology 2009 
Nov;114(5):1161-3. 
    (49) S.C.Hillman, D.J.McMullan, G. Hall, F.S. Togneri, N. James, E.J Maher, C.H. 
Meller, D. Williams,   R.J. Wapner,  E.R. Maher and M.D.Kilby. Use of 
Prenatal chromosomal microarray use: a prospective cohort of fetuses and a 
systematic review and meta-analysis. Ultrasound in Obstetrics and 
Gynaecology 2013 Jun;41(6):610-20 
 (50)  Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, A 
working group of the american college of medical genetics ACMG laboratory 
quality assurance commitee. American College of Medical Genetics 
standards and guidelines for interpretation and reporting of postnatal 
constitutional copy number variation. Genetics in Medicine 2011 
Jul;13(7):680-5. 
 (51)  Lee CN, Lin SY, Lin CH, Shih JC, Lin TH, Su YN. Clinical utility of array 
comparative genomic hybridisation for prenatal diagnosis: a cohort study of 
3171 pregnancies. British Journal of Obsterics and Gynaecology 2012  
Apr;119(5):614-25 
 (52)  Fiorentino F, Caiazzo F, Napolitano S, Spizzichino L, Bono S, Sessa M, et 
al. Introducing array comparative genomic hybridization into routine prenatal 
diagnosis practice: a prospective study on over 1000 consecutive clinical 
cases. Prenatal Diagnosis 2011 Dec;31(13):1270-82. 
 (53)  D'Amours G, Kibar Z, Mathonnet G, Fetni R, Tihy F, Desilets V, et al. Whole-
genome array CGH identifies pathogenic copy number variations in fetuses 
with major malformations and a normal karyotype. Clinical Genetics 2012 
Feb;81(2):128-41. 
 (54)  Hillman SC, McMullan D.J., Silcock L, Maher E, Kilby MD. How does altering 
the resolution of Chromosomal Microarray Analysis in the prenatal setting 
affect the rates of pathological and uncertain findings? Journal of Maternal, 
Fetal and Neonatal Medicine 2013; Aug 19 (e-pub ahead of print) 
279 
 
 
 (55)  Connacher AA, Forsyth CC, Stewart WK. Orofaciodigital syndrome type I 
associated with polycystic kidneys and agenesis of the corpus callosum. 
Journal of Medical Genetics 1987 Feb;24(2):116-8. 
 (56)  Flynn M, Zou YS, Milunsky A. Whole gene duplication of the PQBP1 gene in 
syndrome resembling Renpenning. American Journal of Medical Genetics 
Part A 2011 Jan;155A(1):141-4. 
 (57)  Palumbo O, Palumbo P, Palladino T, Stallone R, Miroballo M, Piemontese 
MR, et al. An emerging phenotype of interstitial 15q25.2 microdeletions: 
clinical report and review. American Journal of Medical Genetics Part A 2012 
Dec;158A(12):3182-9. 
 (58)  Wat MJ, Enciso VB, Wiszniewski W, Resnick T, Bader P, Roeder ER, et al. 
Recurrent microdeletions of 15q25.2 are associated with increased risk of 
congenital diaphragmatic hernia, cognitive deficits and possibly Diamond--
Blackfan anaemia. Journal of Medical Genetics 2010 Nov;47(11):777-81. 
 (59)  Tissier-Seta JP, Mucchielli ML, Mark M, Mattei MG, Goridis C, Brunet JF. 
Barx1, a new mouse homeodomain transcription factor expressed in cranio-
facial ectomesenchyme and the stomach. Mechanisms of Development 
1995 May;51(1):3-15. 
 (60)  Freathy RM, Mook-Kanamori DO, Sovio U, Prokopenko I, Timpson NJ, Berry 
DJ, et al. Variants in ADCY5 and near CCNL1 are associated with fetal 
growth and birth weight. Nature Genetics 2010 May;42(5):430-5. 
 (61)  Villard L, Bonino MC, Abidi F, Ragusa A, Belougne J, Lossi AM, et al. 
Evaluation of a mutation screening strategy for sporadic cases of ATR-X 
syndrome. Journal of Medical Genetics 1999 Mar;36(3):183-6. 
 (62)  Cantagrel V, Lossi AM, Boulanger S, Depetris D, Mattei MG, Gecz J, et al. 
Disruption of a new X linked gene highly expressed in brain in a family with 
two mentally retarded males. Journal of Medical Genetics 2004 
Oct;41(10):736-42. 
 (63)  Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RC, Steel CM, et al. 
Definition and refinement of a region of loss of heterozygosity at 11q23.3-
q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer 
Research 1996 Mar 1;56(5):950-4. 
 (64)  Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A 
genome-wide association study of type 2 diabetes in Finns detects multiple 
susceptibility variants. Science 2007 Jun 1;316(5829):1341-5. 
 (65)  Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. 
Chromosomal microarray versus karyotyping for prenatal diagnosis. New 
England Journal Medicine 2012 Dec 6;367(23):2175-84. 
280 
 
 
 (66)  Bernhardt BA, Soucier D, Hanson K, Savage MS, Jackson L, Wapner RJ. 
Women's experiences receiving abnormal prenatal chromosomal microarray 
testing results. Genetics in Medicine 2013 Feb;15(2):139-45. 
 (67)  Glasziou P, Irwig l, Rain C, Colditz G. In PDQ evidence-based principles and 
practice. Hamilton Canade: 1999. 
 (68)  Shaffer LG, Dabell MP, Fisher AJ, Coppinger J, Bandholz AM, Ellison JW, et 
al. Experience with microarray-based comparative genomic hybridization for 
prenatal diagnosis in over 5000 pregnancies. Prenatal Diagnosis 2012 Aug 
2;1-10. 
 (69)  Fiorentino F, Napoletano S, Caiazzo F, Sessa M, Bono S, Spizzichino L, et 
al. Chromosomal microarray analysis as a first-line test in pregnancies with a 
priori low risk for the detection of submicroscopic chromosomal 
abnormalities. European Journal of Human Genetics 2013 Jul;21(7):725-30 . 
 (70)  Breman A, Pursley AN, Hixson P, Bi W, Ward P, Bacino CA, et al. Prenatal 
chromosomal microarray analysis in a diagnostic laboratory; experience with 
>1000 cases and review of the literature. Prenatal Diagnosis 2012 
Apr;32(4):351-61. 
 (71)  Schmid M, Stary S, Blaicher W, Gollinger M, Husslein P, Streubel B. 
Prenatal genetic diagnosis using microarray analysis in fetuses with 
congenital heart defects. Prenatal Diagnosis 2012 Apr;32(4):376-82. 
 (72)  Maya I, Davidov B, Gershovitz L, Zalzstein Y, Taub E, Coppinger J, et al. 
Diagnostic utility of array-based comparative genomic hybridization (aCGH) 
in a prenatal setting. Prenatal Diagnosis 2010 Dec;30(12-13):1131-7. 
 (73)  Faas BH, van dB, I, Kooper AJ, Pfundt R, Hehir-Kwa JY, Smits AP, et al. 
Identification of clinically significant, submicroscopic chromosome alterations 
and UPD in fetuses with ultrasound anomalies using genome-wide 250k 
SNP array analysis. Journal of Medical Genetics 2010 Sep;47(9):586-94. 
 (74)  Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, et al. Clinical 
implementation of whole-genome array CGH as a first-tier test in 5080 pre 
and postnatal cases. Molecular Cytogenetics 2011;4:12. 
 (75)  Evangelidou P, Sismani C, Ioannides M, Christodoulou C, Koumbaris G, 
Kallikas I, et al. Clinical application of whole-genome array CGH during 
prenatal diagnosis: Study of 25 selected pregnancies with abnormal 
ultrasound findings or apparently balanced structural aberrations. Molecular 
Cytogenetics 2010;3:24. 
 (76)  Valduga M, Philippe C, Bach SP, Thiebaugeorges O, Miton A, Beri M, et al. 
A retrospective study by oligonucleotide array-CGH analysis in 50 fetuses 
with multiple malformations. Prenatal Diagnosis 2010 Apr;30(4):333-41. 
281 
 
 
 (77)  Leung TY, Vogel I, Lau TK, Chong W, Hyett JA, Petersen OB, et al. 
Identification of submicroscopic chromosomal aberrations in fetuses with 
increased nuchal translucency and apparently normal karyotype. Ultrasound 
in Obstetrics and Gynecology 2011 Sep;38(3):314-9. 
 (78)  Srebniak MI, Boter M, Oudesluijs GO, Cohen-Overbeek T, Govaerts LC, 
Diderich KE, et al. Genomic SNP array as a gold standard for prenatal 
diagnosis of foetal ultrasound abnormalities. Molecular Cytogenetics 2012 
Mar 13;5(1):14. 
 (79)  Armengol L, Nevado J, Serra-Juhe C, Plaja A, Mediano C, Garcia-Santiago 
FA, et al. Clinical utility of chromosomal microarray analysis in invasive 
prenatal diagnosis. Human Genetics 2012 Mar;131(3):513-23. 
 (80)  Park JH, Woo JH, Shim SH, Yang SJ, Choi YM, Yang KS, et al. Application 
of a target array comparative genomic hybridization to prenatal diagnosis. 
BMC Medical Genetics 2010;11:102. 
 (81)  Bundey S, Alam H. A five-year prospective study of the health of children in 
different ethnic groups, with particular reference to the effect of inbreeding. 
European Journal of Human Genetics 1993;1(3):206-19. 
 (82)  Bundey S, Alam H, Kaur A, Mir S, Lancashire RJ. Race, consanguinity and 
social features in Birmingham babies: a basis for prospective study. Journal 
of Epidemiology and Community Health 1990 Jun;44(2):130-5. 
 (83)  Novelli A, Grati FR, Ballarati L, Bernardini L, Bizzoco D, Camurri L, et al. 
Microarray application in prenatal diagnosis: a position statement from the 
cytogenetics working group of the Italian Society of Human Genetics (SIGU), 
November 2011. Ultrasound in Obstetrics and Gynecology 2012 
Apr;39(4):384-8 . 
 (84)  Doolittle ND. Advances in the neurosciences and implications for nursing 
care. Journal of Neuroscience and Nursing 1991 Aug;23(4):207-10. 
 (85)  Hunt LM, Voogd KB, Castaneda Heide. The routine and the traumatic in 
prenatal genetic diagnosis: does clinical information inform patient decision-
making? Patient education and counseling 2005;56:302-12. 
 (86)  Scully JL, Porz R, Rehmann-Sutter C. 'You don't make genetic test decisions 
from one day to the next'--using time to preserve moral space. Bioethics 
2007 May;21(4):208-17. 
 (87)  McCoyd JL. Discrepant feeling rules and unscripted emotion work: women 
coping with termination for fetal anomaly. American Journal of 
Orthopsychiatry 2009 Oct;79(4):441-51. 
 (88)  Mishler EG, Norwood N. The discouse of medicine: Dialects of medical 
interviews. Ablex; 1984. 
282 
 
 
 (89)  Hunt LM, Arar NH. An analytical framework for contrasting patient and 
provider views of the process of chronic disease management. Medical 
Anthropology Quarterly 2001 Sep;15(3):347-67. 
 (90)  Bernhardt BA, Geller G, Doksum T, Larson SM, Roter D, Holtzman NA. 
Prenatal genetic testing: content of discussions between obstetric providers 
and pregnant women. Obstetrics in Gynecology 1998 May;91(5 Pt 1):648-
55. 
 (91)  Nusbaum R, Grubs RE, Losee JE, Weidman C, Ford MD, Marazita ML. A 
qualitative description of receiving a diagnosis of clefting in the prenatal or 
postnatal period. Journal of Genetic Counselling 2008 Aug;17(4):336-50. 
 (92)  Hillman SC, skelton J, Quinlan-Jones E, Wilson A, Kilby MD. "If it helps..." 
The use of Microarray technology in Prenatal Testing:  
  Patient and Partners Reflections. American Journal of Medical Genetics Part 
A 2013; 161(A)7:1619-27 
 (93)  Quinlan Jones E. "To have a little bit of hope is like being thrown a life line" 
participation in an interventional trial requiring an invasive procedure during 
pregnancy: influences on womens decision making Birmingham City 
University; 2011. 
 (94)  Ritchie J, Spencer L. Applied policy research Chapter 9. Analyzing 
qualitative data.London: Routledge; 1994. p. 177-94. 
 (95)  Srivastava A, Thomson SB. Framework Analysis: A Qualitative Methodology 
for Applied Policy Research. Journal of Administration and Governance 
2009;4(2):72-9. 
 (96)  Harpel TS. Fear of the unknown:ultrasound and anxiety about fetal health. 
Health: An interdisciplinary journal for the social study of health illness and 
medicine 2008;12(3):295-312. 
 (97)  Van der Zalm JE, Byrne PJ. Seeing baby: women's experience of prenatal 
ultrasound examination and unexpected fetal diagnosis. Journal of 
Perinatology 2006 Jul;26(7):403-8. 
 (98)  Statham H, Solomou W, Chitty L. Prenatal diagnosis of fetal abnormality: 
psychological effects on women in low-risk pregnancies. Baillieres Best 
Practice Research in Clinical Obstetrics and Gynaecology 2000 
Aug;14(4):731-47. 
 (99)  Vetro A, Bouman K, Hastings R, McMullan DJ, Vermeesch JR, Miller K, et 
al. The introduction of arrays in prenatal diagnosis: A special challenge. 
Human Mutation 2012 Jun;33(6):923-9. 
 (100)  Aune I, Moller A. 'I want a choice, but I don't want to decide'--a qualitative 
study of pregnant women's experiences regarding early ultrasound risk 
assessment for chromosomal anomalies. Midwifery 2012 Feb;28(1):14-23. 
283 
 
 
 (101)  McCoyd JL. Pregnancy interrupted: loss of a desired pregnancy after 
diagnosis of fetal anomaly. Journal of Psychosomatic Obstetrics and 
Gynaecology 2007 Mar;28(1):37-48. 
 (102)  Pieters JJ, Kooper AJ, Eggink AJ, Verhaak CM, Otten BJ, Braat DD, et al. 
Parents' perspectives on the unforeseen finding of a fetal sex chromosomal 
aneuploidy. Prenatal Diagnosis 2011 Mar;31(3):286-92. 
 (103)  Shuster E. Microarray genetic screening: a prenatal roadblock for life? 
Lancet 2007 Feb 10;369(9560):526-9. 
 (104)  Reiff M, Bernhardt BA, Mulchandani S, Soucier D, Cornell D, Pyeritz RE, et 
al. "What does it mean?": uncertainties in understanding results of 
chromosomal microarray testing. Genetics in Medicine 2012 Feb;14(2):250-
8. 
 (105)  Hillman SC, Barton P, Roberts T, Maher E, McMullan D.J., Kilby MD. 
Chromosomal microarray for prenatal detection of chromosome anomalies in 
fetal ultrasound anomalies: an economic evaluation. Fetal Diagnosis and 
Therapy (pending amendments). 
 (106)  Morris S, Devlin N, Parkin D. Economic analysis in health Care. John Wiley 
and sons; 2007. 
 (107)  Ballif BC, Rorem EA, Sundin K, Lincicum M, Gaskin S, Coppinger J, et al. 
Detection of low-level mosaicism by array CGH in routine diagnostic 
specimens. American Journal of Medical Genetics Part A 2006 Dec 
15;140(24):2757-67. 
 (108)  Curtis L. Unit costs of Health and social Care 2011.  Personal social services 
research unit, University of Kent; 2011.  
 (109)  Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: 
an audit of NICE current practice and a review of its use and value in 
decision-making. Health Technology Assessment 2009 Jun;13(29):iii, ix-61. 
 (110)  Ekberg M. Maximising the benefits and minimising the risks associated with 
prenatal testing. Health, Risk and Society 2007;9(1):67-81. 
 (111)  Wertz DC. Ethical and legal implications of the new genetics: issues for 
discussion. Social Science in Medicine 1992 Aug;35(4):495-505. 
 (112)  Rapp R. Refusing prenatal diagnosis: the meanings of bioscience in a 
multicultural world. Science Technology and Human Values 1998;23(1):45-
70. 
 (113)  Ackmann EA. Prenatal testing gone awry: the birth of a conflict of ethics and 
liability. Indiana Health and Law Review 2005;2(1):199-224. 
284 
 
 
 (114)  Dondorp W, Sikkema-Raddatz B, de Die-Smulders C, de WG. Arrays in 
postnatal and prenatal diagnosis: An exploration of the ethics of consent. 
Human Mutation 2012 Mar 6. 
 (115)  Elias S, Annas GJ. Generic consent for genetic screening. New England 
Journal of Medicine 1994 Jun 2;330(22):1611-3. 
 (116)  Holtzman NA, Murphy PD, Watson MS, Barr PA. Predictive genetic testing: 
from basic research to clinical practice. Science 1997 Oct 24;278(5338):602-
5. 
 (117)  Grody WW. Ethical issues raised by genetic testing with oligonucleotide 
microarrays. Molecular Biotechnology 2003 Feb;23(2):127-38. 
 (118)  Darilek S, Ward P, Pursley A, Plunkett K, Furman P, Magoulas P, et al. Pre- 
and postnatal genetic testing by array-comparative genomic hybridization: 
genetic counseling perspectives. Genetics in Medicine 2008 Jan;10(1):13-8. 
 (119)  Marteau TM, Drake H. Attributions for disability: the influence of genetic 
screening. Social Science in Medicine 1995 Apr;40(8):1127-32. 
 (120)  Garcia E, Timmermans DR, van LE. Parental duties and prenatal screening: 
Does an offer of prenatal screening lead women to believe that they are 
morally compelled to test? Midwifery 2012 Dec;28(6):e837-43. 
 (121)  Lippman A, Wilfond BS. Twice-told tales: stories about genetic disorders. 
American Journal of  Human Genetics part A 1992 Oct;51(4):936-7. 
 (122)  Jameton A. Dilemmas of moral distress:moral responsibility and nursing 
practice. Clinical issues perinatal womens health nursing 1993;4:542-51. 
 (123)  McGillivray G, Rosenfeld JA, McKinlay Gardner RJ, Gillam LH. Genetic 
counselling and ethical issues with chromosome microarray analysis in 
prenatal testing. Prenatal Diagnosis 2012 Apr;32(4):389-95. 
 (124)  Davis DS. Genetic dilemmas and the child's right to an open future. Hastings 
Central Rep 1997 Mar;27(2):7-15. 
 (125)  Feinberg J. The child's right to an open future. In: Whose Child? Children's 
rights, Parental authority and state power. Aiken W, La Follette H 1980. p. 
124-53. 
 (126)  Wilfond B, Ross LF. From genetics to genomics: ethics, policy, and parental 
decision-making. Journal Pediatric Psychology 2009 Jul;34(6):639-47. 
 (127)  Archard D. The moral and political status of children. Public Policy Research 
2006;13(1):6-12. 
 (128)  Shendure J, Ji H. Next-generation DNA sequencing. Nature Biotechnology 
2008 Oct;26(10):1135-45. 
285 
 
 
 (129)  Metzker ML. Sequencing technologies - the next generation. Nature Review 
in Genetics 2010 Jan;11(1):31-46. 
 (130)  Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, 
Gildersleeve HI, et al. Exome sequencing identifies MLL2 mutations as a 
cause of Kabuki syndrome. Nature Genetics 2010 Sep;42(9):790-3. 
 (131)  Talkowski ME, Ordulu Z, Pillalamarri V, Benson CB, Blumenthal I, Connolly 
S, et al. Clinical diagnosis by whole-genome sequencing of a prenatal 
sample. New England Journal Medicine 2012 Dec 6;367(23):2226-32. 
 (132)  Hatzaki A, Sifakis S, Apostolopoulou D, Bouzarelou D, Konstantinidou A, 
Kappou D, et al. FGFR3 related skeletal dysplasias diagnosed prenatally by 
ultrasonography and molecular analysis: presentation of 17 cases. American 
Journal of Medical Genetics Part A 2011 Oct;155A(10):2426-35. 
 (133)  Nagendran S, Richards AJ, McNinch A, Sandford RN, Snead MP. Somatic 
mosaicism and the phenotypic expression of COL2A1 mutations. American 
Journal of Medical Genetics Part A 2012 May;158A(5):1204-7. 
 (134)  Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. 
Presence of fetal DNA in maternal plasma and serum. Lancet 1997 Aug 
16;350(9076):485-7. 
 (135)  Costa JM, Benachi A, Gautier E, Jouannic JM, Ernault P, Dumez Y. First-
trimester fetal sex determination in maternal serum using real-time PCR. 
Prenatal Diagnosis 2001 Dec;21(12):1070-4. 
 (136)  Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of 
fetal blood group phenotypes: current practice and future prospects. Prenatal 
Diagnosis 2009 Feb;29(2):101-7. 
 (137)  Norbury G, Norbury CJ. Non-invasive prenatal diagnosis of single gene 
disorders: how close are we? Seminars in Fetal and Neonatal Medicine 2008 
Apr;13(2):76-83. 
 (138)  Chitty LS, Griffin DR, Meaney C, Barrett A, Khalil A, Pajkrt E, et al. New aids 
for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic 
features, charts of fetal size and molecular confirmation using cell-free fetal 
DNA in maternal plasma. Ultrasound in Obstetrics and Gynecology 2011 
Mar;37(3):283-9. 
 (139)  Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE, et al. 
Noninvasive whole-genome sequencing of a human fetus. Science 
Translational Medicine 2012 Jun 6;4(137):137ra76. 
 (140)  Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et 
al. The STRING database in 2011: functional interaction networks of 
proteins, globally integrated and scored. Nucleic Acids Research 2011 
Jan;39(Database issue):D561-D568. 
286 
 
 
(141) Newton HJ, Cox NJ. The Stata Journal 2008 8 (1) pp. 3–28  
(142) Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams KR, Kyzas PA, et 
al. Prognosis research strategy (PROGRESS) 2: Prognostic factor research. 
PLoS Med 2013 (in-press, early view on-line). 
(143) Deeks JJ, Higgins JPT, Altman DG: Chapter 9: Analysing data and 
undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of 
Interventions Version 501 (updated September 2008; Available from 
www.cochrane-handbook.org). Edited by Higgins JPT, Green S: The Cochrane 
Collaboration 2008 
(144) Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected 
by a simple, graphical test. British Medical Journal 1997; 315: 629-634. 
 
 
  
 
